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Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder, characterised 
by core symptoms of communication deficits, difficulties with social interaction, and 
restricted and repetitive behaviours. Affected people have difficulties in the ability to 
understand verbal and non-verbal social or emotional cues, as well as have repetitive 
patterns of behaviours or interests 1. First described by a “basic desire for aloneness 
and sameness” and distinct from schizophrenia by Leo Kanner in 1943 2, ASD has gone 
from being little-known outside the field of psychiatry to diagnosed in as many as 1 in 54 
children 3 and 1 in 45 adults 4 in the USA today. Nowadays, ASD is known to affect people 
of all geographies and ethnic, cultural and racial backgrounds 3–6. It can be diagnosed in 
children as young as 18 months old, yet is typically diagnosed at age 3-4 years in developed 
countries 3,7. Approximately three to four times as many boys are diagnosed than girls 8.
The underlying causes of ASD are poorly understood. Rather than having one specific 
cause, ASD likely reflects a group of distinct disorders influenced strongly by genetics 
and possibly by environmental factors 9–13. Today, diagnoses are made based on clinical 
symptoms; however, large family and sibling studies estimate that between 64-91% of 
effects are heritable 9,11,13. Indeed, the concordance rate for ASD diagnoses is around 
98% in monozygotic (identical) twins and 53% in dizygotic twins 13. The rates are lower 
in non-twin siblings, but still far higher than in the general population 14. Despite this 
evidence, no specific genomic variant of large effect is currently known to be implicated 
in more than 1% of cases 11,15. Such alterations are also not exclusively implicated in ASD 
opposed to other neurological disorders such as intellectual disability (ID), bipolar, or 
epilepsy, pointing towards overlapping genetic aetiology 11,16–18. Children with separate 
rare genetic syndromes such as Rett’s syndrome or Fragile X are at much higher risk of 
also being diagnosed with ASD or at least displaying some of the symptoms 11. Increased 
maternal and paternal age have also been associated with increased risk 19–22. Estimates 
for effects of environmental influences are much lower and tend to point the risk toward 
non-shared environments over shared environments (i.e. effects experienced by some 
but not all children in the same family) 9,10,13,23. Examples include maternal exposure to 
sodium valproate 24, depression 25,26 or infection 27 during pregnancy, increased maternal 
body mass index 28, season of birth 29, long or short intervals between pregnancies 30, 
caesarean delivery 31 and low birth weight 32,33. Evidence for causal relationships between 
autism and these environmental factors are generally amiss.
The variation in underlying ASD aetiology is likely what gives rise to the variation in its 
presentation. The manifestation and severity of symptoms vary with age 11 and different 
developmental trajectories have been observed in the natural history of disease 34,35. 
Some people with ASD will have severe language impairment throughout life, while 
others will develop abilities to read and speak fluently. Some autistic adults are able to 
live independently in the community whereas others require family or institutional help 
545324-L-bw-Houghton
Processed on: 28-12-2020 PDF page: 11
11
Introduction
to perform daily activities 15,36. Recent estimates are that around one-third of autistic 
children have comorbid ID, defined as having an intelligence quotient (IQ) of 70 points or 
less 3. The proportion of patients diagnosed with ID has been decreasing in recent years 
as the prevalence of ASD has risen 37. Other associated symptoms of autism – which also 
occur in some but not all cases – include obsessions, self-injury, irritability, aggression, and 
under-reactivity to sensory stimuli 1,3,15. Psychiatric and neurological conditions such as 
attention deficit/hyperactivity disorder (ADHD), anxiety, depression, epilepsy and bipolar 
disorder are also more commonly diagnosed in children and adults with autism than in 
the general population 38–42.
In 2013, to represent the wide range of known severities and symptoms, the American 
Psychiatric Association (APA) added the term “autism spectrum disorders” to the fifth 
edition of their Diagnostic and Statistical Manual of Mental Disorders (DSM-V) 1. This 
definition replaced the previously established subtypes of autism including autistic 
disorder, Asperger syndrome, childhood disintegrative disorder (CDD) and pervasive 
developmental disorder not otherwise specified (PDD-NOS) and was intended to make 
diagnoses more straightforward 15. While the underlying causes of autism may play some 
role in the increasing prevalence, other cited factors are greater awareness, less societal 
stigma and an expansion of the diagnostic criteria (not just in DSM-V but previously too) 43,44. 
A number of diagnostic instruments are available to aid a professional diagnosis of ASD, 
including the Autism Diagnostic Observation Schedule (ADOS) 45, the Autism Diagnostic 
Interview-Revised (ADI-R) 46 and the Childhood Autism Rating Scale (CARS) 47.
Treatment landscape in ASD
According to the American Academy of Pediatrics (AAP) the purposes of treatment 
in children with ASD should be to minimise core and associated ASD impairments, to 
maximise daily living skills for independence, and to relieve the impact of problem 
behaviours 11. Goals are similar across the whole age range in ASD, including adults, but 
should be tailored dependent on verbal fluency, comorbidities and individual preferences 
and challenges 48.
Drug treatments
There are currently no pharmacological treatment options for the core symptoms of 
ASD. In the USA, the only medications approved for associated symptoms - of irritability 
and aggression - are the atypical antipsychotics risperidone (since 2006 in children aged 
5-16 years) and aripiprazole (since 2009 in children aged 6-17 years). Evidence leading 
to the approvals granted by the Food and Drug Administration (FDA) primarily came 
from randomised placebo-controlled trials, each with a double blind phase lasting only 
8-weeks 49–52 and a primary endpoint of the Aberrant Behaviour Checklist Irritability-
subscale (ABC-I) 53. In Europe, based on the same data, the European Medicines Agency 
1
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(EMA) granted risperidone market authorisation for “persistent aggression in conduct 
disorder in children” on the basis that it demonstrated efficacy in an associated, rather 
than a broad, set of ASD symptoms 54. Although the EMA acknowledges aripiprazole 
demonstrated statistical superiority over placebo in randomised controlled trials (RCTs), 
the drug is not approved in ASD, as according to their review, the potential benefits of 
treatment did not outweigh risks 55. The EMA summary of product characteristics for 
aripiprazole documents that the clinical relevance of the ABC-I has not been established 
and that there were concerns over weight gain and reductions in serum prolactin levels 
under treatment 55.
Risperidone and aripiprazole have been recommended in clinical guidelines for treatment 
of aggression or self-injurious behaviours, in order to facilitate daily living, or to allow 
better adherence to non-drug therapies 11,15,56. For example, the American Academy of 
Child and Adolescent Psychiatry (AACAP) recommend these treatments may be used 
but only with irritability symptoms 56. The AAP recommend antipsychotics only when 
other behavioural factors and interventions have first been assessed, modified, and these 
modifications have not addressed concerns 11. Similarly, despite there being no marketing 
authorisation in Europe, the UK National Institute for Health and Care Excellence (NICE) 
also recommends antipsychotic medications for children with behavioural challenges but 
only when non-drug treatments have not helped: but the antipsychotics should be started 
by a paediatrician or psychiatrist 57.
Generally, it is acknowledged that other pharmacological treatments may be required 
to manage common comorbidities in ASD, but it is emphasised these treatments are 
not for ASD itself 15,58. Comorbid neurological disorders should be managed in a way 
similar to if the patient did not have ASD 15,57. These include for example, melatonin for 
sleep disturbances, stimulants for ADHD or selective serotonin reuptake inhibitors 
(SSRIs) for anxiety disorder or depression 58. In the USA, psychotropic medications are 
extensively used to treat comorbid psychiatric comorbidities or other symptoms of ASD 
59. A recent systematic review reported median psychotropic drug use estimates of 42% 
in children and 62% in adults in ASD 60. The systematic review also pointed to some clear 
gaps in the literature however. Firstly, the vast majority of studies only focused on North 
America and used data from over a decade ago. Furthermore, there are limited studies 
in the adult population and studies generally do not have non-ASD comparator groups 
to contextualise results.
Safety concerns
ADHD is the most common comorbidity in autism 40. As such, drugs used for the treatment 
of ADHD, such as stimulants (e.g. amphetamine, methylphenidate, lisdexamfetamine) and 
atomoxetine are used frequently in ASD (around 14-19% in children) 60. Studied over many 
years, these drugs have demonstrated efficacy in the short-term management of ADHD 
symptoms 61 but have consistently shown medication-induced increases in blood pressure 
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and heart rate 62. These findings, coupled with case reports 63, have raised concerns over 
the potential increased risk of more serious cardiovascular (SCV) events such as stroke, 
myocardial infarction (MI), and cardiac arrhythmias 64. A handful of observational studies 
in large samples have been conducted, but on data from over a decade ago, with limited 
statistical power due to rarity of outcomes, and have provided inconsistent results 65–70. 
Furthermore, children with ASD may be at increased risk of SCV events due to frequent 
use of concurrent medications, but until now, this subgroup has not been studied.
Antipsychotics are also commonly used by children and adolescents with ASD (around 
17%) 60 and are known to be associated with important adverse effects such as weight 
gain, somnolence/sedation, and extrapyramidal disorders 49–52. They are also commonly 
used among elderly dementia patients, and have been associated with increased bone 
fracture risk in this population 71,72. Fractures are a leading cause of emergency room 
admission in children 73 and the impact can be considerable, leading to reduction in daily 
functioning and exercise, lost days of schooling and increased chances of recurrent 
fractures in adulthood 74,75. The relationship between antipsychotics and bone fractures 
may be due to an increased risk of accidents or falling 76, or due to a negative impact on 
bone mineral density (BMD) 77,78. The relationship between antipsychotics and fracture 
risk has not been well studied in children. However, as risperidone and aripiprazole are 
commonly used in ASD and have slightly different pharmacological profiles 79, this setting 
can offer a unique opportunity to understand possible mechanisms and inform relevant 
clinical decisions about which treatment to prescribe.
Non-drug treatments
The mainstay of currently recommended treatments for ASD are non-pharmacological 
in nature, and include behavioural and social-communication based therapies 11,56,58. 
Emphasis is placed on early, intensive and individualised interventions, including speech, 
communication and adaptive skills training as needed, and parental involvement is 
encouraged 11,56. Social and daily living skills training can be offered for both children and 
adults, either in groups or individually 58.
In a study across 18 European countries, 91% of children with ASD received at least one 
type of non-drug intervention by age 7 years, although there was wide variation in the 
types of treatments reported, perhaps due to variation in services offered by schools and 
respective national health systems 80. Historical uptake of non-drug treatments is also high 
in the USA, with up to 77% current use 81. However, there are concerns that children in 
more rural settings have access to fewer services 82. Additionally, healthcare expenditures 
have previously been higher for ASD children with public versus private health insurance, 
suggesting public insurance is an advantage for accessing services 83. Most states have 
introduced mandates requiring private insurance plans cover autism services 44,84, but 
there has been little systematic research into current non-drug treatment patterns in the 
USA, or into understanding other barriers to receiving care.
1
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Having reliable treatment utilisation estimates is important for a variety of reasons. They 
can be used to quantify disease burden, inform healthcare resource and training plans, 
measure the scale of certain risks (e.g. adverse events) and to aid planning for further 
research (such as defining eligibility criteria for new clinical trials). Other uses include 
identifying deviations from treatment guidelines or spotting differences in treatment 
approaches between countries, regions or healthcare plans. This can lead to additional 
understanding of underlying causes of deviations from guidelines, or if one healthcare 
system can learn from the other 85.
Assessing treatment effectiveness
Finding new, safe and effective pharmacological interventions in ASD is an area of intense 
research. A recent search for “active” and “recruiting” phase 2 or 3 clinical trials in autism 
or ASD via the ClinicalTrials.gov website 86 yielded 45 studies: 13 of which are industry 
sponsored. Novel drug mechanisms under investigation mainly involve neurobiological 
targets such as neurotransmitters: GABA and glutamate; or neuropeptides: oxytocin and 
vasopressin 87,88. Other trials are on repurposed drugs from other disease areas, such as 
propranolol (a beta blocker) 89 and bumetanide (a loop diuretic) 90.
Unfortunately, there is little consensus on the most appropriate tools for measuring 
efficacy of treatments of ASD in clinical trials 87. Some measures were developed 
and tested according to older and more narrow definitions of autism (e.g. Behavioral 
Summarized Evaluation Scale (BSE) 91 and Real Life Rating Scale (RLRS) 92) or focus 
on specific symptoms only (e.g. Social Responsiveness Scale (SRS) 93 and Repetitive 
Behaviours Scale-Revised (RBS-R) 94). Furthermore, interview-administered measures 
such as the Vineland Adaptive Behavior Scales (VABS) 95,96, often require trained personal 
to administer, making them expensive and time-consuming. Reliable measures for real 
world monitoring of ASD symptoms beyond the timeframe and setting of clinical trials 
are also lacking.
In summary, the treatment landscape in ASD is complex. Many research questions remain 
unanswered with regards to levels of treatment utilisation, safety profiles of commonly 
used medications and a lack of appropriate tools for assessing treatment effectiveness.
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Real world data (RWD) can be broadly classified as any data collected outside the realm 
of strictly controlled settings like RCTs. Often cited advantages are that RWD can be 
collected more efficiently and cheaply, leading to opportunities to access data from large 
numbers of people 97. Additional advantages of RWD make this data more intrinsically 
valuable for certain research questions too.
Firstly, clinical trials often have strict inclusion criteria that restricts the eligibility of 
participants. For example, eligibility can be restricted to a certain age range, or to patients 
without other health conditions than the one being studied. Therefore, RCT study entry 
criteria may be unrepresentative of all patients likely to receive treatment in a real life 
setting. Given ASD is a lifelong disorder and many patients have comorbidities, this can be 
quite an issue for ASD studies. Furthermore, the way patients access and use treatments 
in RCTs is different to real life practice by design. Hence, the effects of socio-economic 
factors like family income, geography or insurance type on the ability to even access 
treatment is only possible to study by using RWD. Adherence to medications in real life 
practice is also known to be lower than in clinical trials, and especially so in psychiatric 
diseases or in patients with cognitive disabilities 98,99.
Secondly, it is not always possible to ascertain good estimates of potential adverse drug 
effects in small cohorts or in short periods of follow-up afforded by RCTs. The statistical 
logic of primary study outcomes is often not applied to adverse events. Consider rare 
adverse events mentioned above like serious cardiovascular events, which only occur in 
approximately 1 per 30,000 patient years for children with neurodevelopmental disorders 
65,70 or effects that are only biologically plausible after longer periods of drug exposure, 
such as reduced BMD leading to fractures. Studying these potential effects of treatment 
is simply not possible over the short timeframe of most clinical trials.
Finally, it is of interest to study the effectiveness of different interventions under real 
life conditions and over longer periods of use. By examining RWD from a large body of 
patients being exposed to a treatment for longer periods of time, both adverse events and 
expected (or even unexpected) benefits can be appreciated. Patient or caregiver-reported 
assessments can offer a quicker and cheaper option to abovementioned tools often used 
in clinical trials, which may need trained personal or a longer duration to administer. They 
may also be administered remotely, for example on a computer or mobile phone. Hence, 
provided they are validated, they can offer a more sustainable opportunity to evaluate 
treatment effectiveness over longer periods, and outside controlled clinical trial settings. 
Another advantage of using such tools in a real world setting is that they may also provide 
more rapid feedback to patients, caregivers and physicians, in order to effectively find 
optimal treatment strategies on the individual level 88.
1
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Some research questions can be answered using RWD that already exist. Such databases 
typically come into being via data entry on the individual level, but without much 
forethought of the research questions that data could address at an aggregate, population 
level. Examples of such databases are electronic medical records (EMRs) and medical 
insurance claims databases.
Clinical Practice Research Datalink
EMR data are routinely collected by doctors or other healthcare professionals to keep 
record of their patients’ medical history. One of the largest and most well established 
EMRs worldwide is the Clinical Practice Research Datalink (CPRD) database from the UK. 
The data are captured in the primary care setting by general practitioners (GP), who are 
seen as the “gatekeepers” to access other non-emergency care provided by the National 
Health Service (NHS) 100. As such, GPs play a key role in the management of services 
for people with ASD and the CPRD data contains patient demographics, consultations, 
diagnoses and prescriptions from primary care, as well as key referrals to, and diagnoses 
from secondary care 15,100,101. The number of patients included in the database has changed 
over time, but includes 14 million currently active patients as of 2020 102. The data are 
representative of the UK population in terms of age, sex and ethnicity 100. ASD diagnoses 
recorded in the CPRD are reliable and can be used with confidence 103. The data have been 
used in over 2,500 peer-reviewed publications 102, including to demonstrate the lack of 
association between autism and the measles-mumps-rubella (MMR) vaccination 104.
MarketScan insurance claims database
Medical insurance claims provide an alternative source of real world data. The IBM 
MarketScan ® databases 105 cover de-identified patient-level health data from private 
and publically insured populations from the USA. Information recorded comprise billed 
episodes of care from all settings, including retail, mail order and specialty pharmacy 
prescriptions. The MarketScan “commercial” dataset is representative of employees and 
dependents of mid to large sized companies, with company-sponsored private medical 
insurance. This can include dependants with ASD. The MarketScan Medicaid dataset 
covers the Medicaid public insurance program from around 10-12 states. Medicaid is a 
state-run health insurance for people of lower income families or with certain qualifying 
disabilities, including ASD. Each MarketScan database covers several million enrolees 
per year, and the data have been used in over 2,000 peer-reviewed publications 105.
Primary data collection and the SPARK study
Because EMR and claims data are not primarily collected for the purposes of medical 
research, they can lack important information. Such data includes detailed clinical 
characteristics, treatments received outside of the service network, societal or 
economic determinants of health, and concepts such as patient or caregiver opinions 
and preferences. In some circumstances, additional information may need to be gathered 
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proactively and systematically via a primary data collection study. Registry studies and 
surveys are primary data collection methods which are typically low-interventional in 
nature. They are hence cheaper to conduct than clinical trials yet maintain the advantages 
of representing real life clinical practice.
Simons Foundation Powering Autism Research for Knowledge (SPARK) is a USA based 
online research initiative for individuals with ASD and their family members, who have 
consented to providing information and medical samples to further autism research 106. 
Established in 2016 by the Simons Foundation Autism Research Initiative (SFARI), almost 
60,000 individuals with ASD enrolled by the end of 2018 107 and recruitment continues 
today. Whole exome sequencing studies identifying additional ASD risk genes are starting 
to be published from this data 108. Other examples of research based on the cohort 
include understanding medical profiles of ASD 107, beliefs in vaccines as a cause of autism 
109 and the study of coordination disorders in ASD 110. SFARI facilitates the opportunity 
for external researchers to collect additional information from SPARK participants via 
electronic surveys. This is only provided if the data is later returned and made linkable 
to other data from the same cohort in order to aid additional research. In this sense, the 
database allows cross-sectional and longitudinal assessment of the cohort.
Objectives and outline of this thesis
This thesis comprises a collection of studies to address various abovementioned 
knowledge gaps regarding the utilisation and outcomes of treatment in ASD. The goals can 
be grouped into the following three categories: treatment utilisation patterns, treatment 
safety, and validation of a new caregiver-reported measure of ASD symptom severity. 
Details of the thesis outline and sub-goals of each chapter are outlined in Figure 1.1.
1
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Objectives and outline of this thesis  
This thesis comprises a collection of studies to address various abovementioned knowledge gaps 
regarding the utilisation and outcomes of treatment in ASD. The goals can be grouped into the 
following three categories: treatment utilisation patterns, treatment safety, and validation of a new 
caregiver-reported measure of ASD symptom severity. Details of the thesis outline and sub-goals of 
each chapter are outlined in Figure 1.1.  
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ADHD=attention deficit hyperactive disorder; ASD=autism spectrum disorder 
 
Chapter 2 focuses on the production of up to date estimates of drug and non-drug treatment use in 
ASD. We extend the current literature by studying psychotropic drug use in the adult ASD population 
as well as children. Furthermore, we estimate treatment use in the USA and the UK, assess predictors 
of treatment use, and make comparisons to reference groups without ASD to contextualise our 
findings. For non-drug treatments, we evaluate the prevalence, intensity, setting and barriers to care 
ADHD=attention deficit hyperactive disorder; ASD=autism spectrum disorder
Chapter 2 focuses on the production of up to date estimates of drug and non-drug 
treatment use in ASD. We extend the current literature by studying psychotropic drug 
use in the adult ASD population as well s c ild n. Furthermore, we estimate treatment 
use in the USA and the UK, assess predictors of treatment use, and make comparisons to 
reference groups without ASD to contextualise our findings. For non-drug treatments, 
we evaluate the prevalence, intensity, setting and barriers to care for different treatment 
types in the USA, and test if geography or insurance type is associated with treatment 
use.
Chapter 3 explores safety concerns of commonly used drug treatments in children with 
ASD. Firstly, we quantify the risk of serious cardiovascular events in ASD and ADHD and 
assess if these events are associated with ADHD medication use. Secondly, we compare 
the risk of bone fractures head-to-head between risperidone and aripiprazole: two of the 
most commonly used antipsychotic treatments in ASD, but with differing pharmacological 
profiles.
Chapter 4 is dedicated to the psychometric validation of a new caregiver reported 
assessment for the severity of ASD symptoms in children.
Chapter 5 is a summary and critical reflection on the main body of this thesis. It includes 
a summary of the main findings, a critical evaluation of epidemiological methods used and 
considerations for future research and implications.
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This study investigated psychotropic medication usage in two large cohorts of people 
with autism spectrum disorder (ASD) throughout the calendar year 2014. The cohorts 
referred to individuals with commercial (employer-sponsored) and Medicaid insurance 
in the United States. We aimed to understand prescribing patterns of such medications 
across a wide age-range and in the presence/absence of other clinical and non-clinical 
characteristics, including psychiatric comorbidities. We described the prevalence 
and length of prescriptions by age, psychiatric comorbidity and overall. We also fitted 
multivariable logistic regression models to describe the relationship between treatments 
and subject characteristics simultaneously. Eighty percent of the identified population 
was male, although gender did not impact the odds of receiving medication. Medication 
use was strongly associated with age, increasing most rapidly before adulthood; generally 
plateauing thereafter. All psychiatric comorbidities studied also individually increased 
the chances of medication use, with epilepsy and ADHD having the highest associations 
in both the commercial (odds ratio (OR) > 7) and Medicaid (OR around 12) cohorts. 
Those in non-capitated insurance plans, in foster care and white individuals also had 
increased odds of prescriptions. Overall, slightly more Medicaid enrolees received any 
psychotropic treatment (commercial: 64%, Medicaid: 69%). Nonetheless in both cohorts, 
a large proportion of individuals received treatment even without a diagnosis of any other 
psychiatric comorbidity (commercial: 31%, Medicaid: 33%). In summary, this report 
sheds new light on the latest patterns of psychiatric comorbidity profile and psycho-
pharmacological treatment patterns in ASD.
Lay summary
This study identified a large number of children and adults in the US with autism spectrum 
disorder (autism) from employer-sponsored and government funded (Medicaid) health 
insurance data. Psychotropic medications were used by over two thirds of people, and 
four in ten people received two medications at the same time. The chances of receiving 
medication increased for individuals with other psychiatric conditions (e.g. ADHD), and 
also increased with age.
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Introduction
The personal, family and public health impact of autism spectrum disorder (ASD) is 
considerable. The latest reported prevalence estimates of ASD in the United States 
(US) were 2.24% 1, 1.46% 2, and 2% 3 in the National Health Interview Survey, Autism 
and Developmental Disabilities Monitoring Network, and National Survey of Children’s 
Health, respectively. Estimates also suggest that the prevalence of ASD has been 
increasing over the last two decades 4–6.
ASD has a documented impact on affected individuals and their families, for example 
individuals with an ASD diagnosis experience increased mortality compared with the general 
population 7. Other psychiatric conditions are more commonly diagnosed in individuals with 
ASD than in typically developing individuals, in both adult and paediatric populations 8–11. 
For example, in one of the largest studies, Abdallah et al 11 found that 73% of individuals with 
ASD had at least one other psychiatric diagnosis, with the most common being attention 
deficit hyperactivity disorder (ADHD, 7.9%), and depression (6.8%). In another study, 71% 
of children with ASD had at least one other DSM-IV psychiatric comorbidity diagnosis, with 
social anxiety disorder, ADHD and oppositional defiant disorder being the most common 8. 
Children with ASD incur six-fold higher medical costs than children without ASD and costs 
have been found to increase in the presence of another neurodevelopmental disorder (e.g. 
children with intellectual disability have much higher costs than children with ASD alone) 12.
Pharmacological treatment options for ASD are currently limited. Only two drugs have 
been approved in the US by the Food and Drug Administration (FDA) for the treatment of 
ASD: risperidone in 2006 and aripiprazole in 2009. Both drugs are atypical antipsychotics 
and are approved for the treatment of irritability associated with ASD. Neither targets 
the core symptoms of ASD and both are associated with important adverse events, such 
as tardive dyskinesia, weight gain and sedation. Psychotropic medications are extensively 
used to treat comorbid psychiatric morbidities, to improve ASD-associated symptoms, 
and off-label (non-evidence-based) to treat ASD’s core symptoms 13. For example, in 
a Medicaid dataset of children and adolescents with ASD, Schubart et al 14 found that 
approximately 65% of individuals received at least one psychotropic medication and that 
psychotropic prescribing had increased over 2000 to 2003.
Earlier studies of ASD treatment patterns in claims used datasets from more than a 
decade ago, limited their analyses to either commercial or Medicaid insured individuals, 
and/or mostly focused on one age group (mainly children and adolescents). We wished to 
better understand psychiatric comorbidities, to describe recent patterns in psychotropic 
and antiepileptic medication prescribing in people with ASD of all ages, and to identify 
characteristics associated with use of these prescription medications. For this, we analysed 
two populations in the US: one of people with ASD insured via commercial providers and 
another insured via the government’s Medicaid program.
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Data sources and study population
This study used US administrative insurance claims data from the Truven Health 
MarketScan® Commercial Database (abbreviated as “commercial”) and the Truven 
Health MarketScan Multi-State Medicaid Database (abbreviated as “Medicaid”). The 
commercial database contains data from active employees, early retirees, Consolidated 
Omnibus Budget Reconciliation Act (COBRA) continuees, and dependents insured by 
employer-sponsored plans, while the Medicaid database contains data from government 
funded health insurance enrolees, who typically qualify due to low income or disability. 
The commercial database covers all states in the US and the Medicaid database covers 
approximately 10-12 states. The data provider cannot disclose which exactly states these 
are, but assure they are geographically distributed across the US. Both datasets include 
insurance claims across the continuum of care (e.g. inpatients, outpatient, outpatient 
pharmacy, carve-out behavioural healthcare etc.). Research using the MarketScan data 
has been widely published in peer-reviewed medical and health services journals 15 and 
these data are fully anonymised and comply with the US Health Insurance Portability and 
Accountability Act (HIPAA). The commercial dataset is representative of employees and 
dependents (mainly children in the case of this study) of mid to large sized companies, with 
company-sponsored medical insurance. The Medicaid dataset is representative of lower 
income families and persons with certain disabilities.
The study period was the calendar year 2014. Enrolees were eligible for the analysis 
if they had at least two claims for ASD (International Classification of Diseases, Ninth 
Revision (ICD-9) codes 299.0x, 299.8x, 299.9x), of which at least one had to be recorded 
in 2014 (sample size: commercial: 87,297, Medicaid: 74,744). Requiring at least two codes 
has been shown to be appropriate in claims analysis to identify ASD 16. Enrolees below 
the age of 3 were excluded given diagnostic uncertainties 17, as were people with any 
Rett’s syndrome claim 18,16. Finally, all participants were required to have full medical and 
drug coverage for the whole of 2014, as well as in November and December of 2013 
in order to capture drugs dispensed in 2013 with enough quantity supplied to last into 
2014. This resulted in two ASD cohorts of 46,943 commercially-insured and 46,696 
Medicaid-insured subjects.
Definition of study variables
Prescription records (mail-order or card program prescription drug claim) for the 
following psychotropic medication classes were collected: stimulants, antidepressants, 
antipsychotics/tranquilizers, hypotensive agents, anticonvulsants and anxiolytics/
sedatives/ hypnotics. Psychiatric comorbidities (medical claims) of interest were: attention 
deficit hyperactivity disorder (ADHD), anxiety disorder, bipolar disorder, conduct disorder, 
depression, epilepsy, intellectual disability, schizophrenia and sleep disturbances. Drug 
classes were identified using medication classes from the Truven Health Red Book and 
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comorbidities using ICD-9 codes (see online supplementary material for full code lists; 
https://doi.org/10.1002/aur.1848). We defined psychotropic polypharmacy as having 
a days-supply for at least two drugs in different medication classes overlapping by 30 
consecutive days or more.
Demographic variables available in both datasets were age, sex and insurance plan type. 
We grouped the plan types based on whether they contained capitation or not. Geographic 
region was available for the commercially insured cohort only, and race was available for 
Medicaid only. Also in Medicaid only, we extracted information from the “basis of eligibility” 
information to derive whether an individual was in foster care, given its association with 
psychotropic medication use in ASD 19. ASD subtype was defined by the subjects’ most 
frequent ICD-9 code during 2014 (299.0x=autistic disorder, 299.8x=other specified 
pervasive developmental disorders, 299.9x=unspecified pervasive developmental disorder).
Data Analysis
Each cohort was analysed separately. We described all demographic variables by absolute 
number and percentage, stratifying age (in years) into the following groups: 3-4, 5-11, 
12-17, 18-24, 25-49 and ≥50. In bivariate analyses, we described the percentage of subjects 
with different comorbidities and psychotropic medications by age group and overall. The 
number of days on different treatments in 2014 (maximum 365 days) was described by 
means and standard deviations. The prevalence of each medication was also reported 
within subgroups of subjects where each of the psychiatric comorbidities was observed.
To identify characteristics associated with psychotropic prescribing patterns, we fitted 
multivariable logistic regression models for the outcomes “any psychotropic medication” and 
“psychotropic polypharmacy” separately. An odds ratio (OR) greater than one indicates an 
increased likelihood of the variable to be associated with psychotropic medication use. We 
included all psychiatric comorbidities, insurance type and demographic variables as covariates. 
Covariate reduction techniques and interactions were not applied. We assessed model fit using 
adjusted r-squared values for generalised linear models, the area under the curve (AUC) scores, 
and both Pearson and deviance residuals 20. The Hosmer and Lemeshow statistic for goodness-
of-fit was not employed, as the probability of rejecting an appropriate model increases with 
sample size, and is actually unsuitable in sample sizes greater than 25,000; like in this case 21.
Results
In both cohorts, people with ASD were four times more likely to be male and more than 
two thirds were between the age of 5 and 17 years (Table 2.1.1). Autistic disorder (ICD-9 
299.0x) was the predominant ASD diagnosis code. The commercially insured sample was 
geographically balanced across the US. The most frequent psychiatric comorbidity was ADHD 
(around 40%), followed by anxiety disorder (commercial) or intellectual disability (Medicaid). 
2
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Male 37,775 (80.47) 37,116 (79.48)
Female 9,168 (19.53) 9,580 (20.52)
Age (years)[n/%]
3-4 2,959 (6.30) 3,440 (7.37)
5-11 17,420 (37.11) 19,527 (41.82)
12-17 15,086 (32.14) 12,954 (27.74)
18-24 8,370 (17.83) 6,716 (14.38)
25-49 2,722 (5.80) 3,807 (8.15)
≥50 386 (0.82) 252 (0.54)
Geographic region [n/%]
Northeast 11,508 (24.51) N/A
North Central 10,909 (23.24) N/A
South 13,660 (29.10) N/A
West 9,171 (19.54) N/A
Unknown 1,695 (3.61) N/A
Race [n/%]
White N/A 23,404 (50.12)
Black N/A 8,792 (18.83)
Hispanic N/A 1,909 (4.09)
Other N/A 12,591 (26.96)
Most prevalent ASD diagnosis [n/%]
Autistic disorder 30,588 (65.16) 35,554 (76.14)
Other specified pervasive developmental disorder 13,952 (29.72) 9,567 (20.49)
Unspecified pervasive developmental disorder 2,403 (5.12) 1,575 (3.37)
Insurance plan type (grouped) [n/%]
Capitated Plan 6,015 (12.81) 17,276 (37.00)
Non-Capitated Plan 40,432 (86.13) 29,404 (62.97)
Missing/Unknown 496 (1.06) 16 (0.03)
Selected psychiatric comorbidities [n/%]
ADHD 17,756 (37.82) 18,905 (40.49)
Anxiety disorder 11,614 (24.74) 6,526 (13.98)
Bipolar disorder 2,298 (4.90) 3,718 (7.96)
Conduct disorder 5,547 (11.82) 9,031 (19.34)
Depression 4,764 (10.15) 4,290 (9.19)
Epilepsy 3,335 (7.10) 5,023 (10.76)
Intellectual disability 2,362 (5.03) 10,910 (23.36)
Schizophrenia 514 (1.09) 1,070 (2.29)
Sleep disturbances 2,688 (5.73) 4,400 (9.42)
None 17,299 (36.85) 13,403 (28.70)
Selected psychotropic medications by class [n/%]
Anticonvulsants 7,968 (16.97) 11,550 (24.73)
Antidepressant 15,636 (33.31) 13,380 (28.65)
Antipsychotics/Tranquilizer 11,801 (25.14) 16,138 (34.56)
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Table 2.1.1: Description of ASD cohorts in commercial and Medicaid claims (cont.) 
Characteristic ASD Cohort
Commercial Medicaid
Selected psychotropic medications by class [n/%]
Anxiolytics/Sedatives/Hypnotics 5,961 (12.70) 8,256 (17.68)
Hypotensive agents 9,312 (19.84) 14,626 (31.32)
Stimulants 14,051 (29.93) 14,924 (31.96)
None 17,043 (36.31) 14,494 (31.04)
Basis of eligibility is foster care [n/%]
Yes N/A 1,342 (2.87)
No N/A 45,354 (97.13)
ASD=Autism Spectrum Disorder, ADHD=Attention Deficit Hyperactivity Disorder. N/A=Not Applicable.
Having none of the selected psychiatric comorbidities was more common in the 
commercial cohort (37%) than Medicaid (29%). The largest difference in comorbidity 
profiles between the databases was that Medicaid had a far larger proportion of people 
with intellectual disability across all age groups (commercial: 5%, Medicaid: 23%; see Table 
2.1.2a and 2.1.2b).
Thirty-six percent of individuals in the commercial cohort were not receiving any 
psychotropic medication, compared to 31% in Medicaid. Antidepressants (33%) and 
stimulants (30%) were the most commonly prescribed drug classes in the commercial 
cohort. Antidepressant usage was lower (29%) and stimulant usage was similar (32%) in 
the Medicaid cohort. Medicaid had a markedly higher proportion of individuals prescribed 
with each of the other four drug classes, with antipsychotics/tranquilizer (35%) being the 
most common.
In the commercial-claims cohort, 77% in the 3-4 years age group had an ASD diagnosis 
only, without other psychiatric comorbidities; this proportion was only 53% in Medicaid 
(Table 2.1.2a and 2.1.2b). Furthermore, in both cohorts, the frequencies of different 
comorbidities increased with age, at least until adulthood. In commercial claims, 
psychotropic medication use in children aged 3-4 years was below 5% for each of the 
six classes investigated (Table 2.1.2a). In all children in this age group, only 11% were 
prescribed a psychotropic medication; however, during adolescence (12-17 years), this 
proportion increased to 76%. In the Medicaid data, 25% of children in the 3-4 years age 
group were prescribed at least one psychotropic medication (Table 2.1.2b). The most 
commonly prescribed medication in this group was α2 adrenergic agonists (clonidine and 
guanfacine, 14%). The proportion of Medicaid adolescents with at least one psychiatric 
medication was 80%. In both cohorts, most drug classes studied, except Anxiolytics/
Sedatives/Hypnotics, were taken for more than seven months of the year. Anticonvulsants 
and antipsychotics/tranquilizers were associated with the highest number of days treated; 
taken about two-thirds of the year on average. Generally, the number of days treated 
increased with age, and increased more profoundly for antipsychotics/tranquilizers.
2
545324-L-bw-Houghton






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Processed on: 28-12-2020 PDF page: 37
37


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Processed on: 28-12-2020 PDF page: 38
38
Chapter 2.1
Table 2.1.3 summarises the results of the logistic regressions. In the commercial cohort, 
age was associated with receiving any psychotropic medication and with polypharmacy, 
with the highest odds at age 18-24 years (OR 21 for any medication, OR 38 for 
polypharmacy). This pattern was also observed in Medicaid, but with the highest odds in 
the age group 25-49 years (OR 12 for any medication, OR 20 for polypharmacy). In both 
cohorts, gender was not associated with prescribing. All psychiatric comorbidities were 
associated with prescribing, with epilepsy and ADHD having the highest associations 
in both the commercial (OR > 7) and Medicaid (OR around 12) cohorts. Patients with 
schizophrenia were more likely to have received psychotropic medication if they were 
covered by Medicaid compared to individuals covered by commercial insurance. In 
both cohorts, participating in a capitated plan decreased the likelihood of prescribing. 
In Medicaid, white individuals and those in foster care also had increased odds of 
psychotropic prescriptions. All four models had good predictive ability (AUCs between 
0.79 and 0.88). Residual checking and adjusted r-squared values (between 0.32 and 0.50) 
indicated that the models fitted the data well in general terms.
In both cohorts, people with ASD were most likely to receive polypharmacy if they had 
a concomitant diagnosis code of bipolar disorder or schizophrenia (Figure 2.1.1). Over 
30% of participants received medication in the absence of a coded psychiatric condition 
other than ASD; one sixth in this group had polypharmacy prescribing. Overall, however, 
medications were most frequently prescribed in conjunction with the indicated psychiatric 
condition (Figure 2.1.2).
Finally, Figure 2.1.3 shows the mean number of overlapping psychotropic treatments as a 
function of age for the commercial and Medicaid cohorts. The number of concomitant drug 
classes increased from an early age, plateauing during adolescence. In older individuals, 
and especially in the commercial cohort, a small reduction in the number of overlapping 
drug classes was observed, although the number of subjects at older ages is small, making 
estimates less certain.
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ASD=Autism Spectrum Disorder, ADHD= Attention Deficit Hyperactivity Disorder, Int. Dis= Intellectual Disability, No 








ASD=Autism Spectrum Disorder, ADHD= Attention Deficit Hyperactivity Disorder, Int. Dis= Intellectual Disability, No 
Comorb=No Comorbidity, Schiz= Schizophrenia. 
 
ASD Autis  Spec rum Disorder, ADHD= Attention Deficit Hyperactivity Disorder, Int. Dis= Intellectual 
Disability, No Comorb=No Comorbidity, Schiz= Schizophrenia.
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Figure 2.1.2: Cross-tabulation of psychiatric comorbidities with classes of psychotropic medications 
 
 
Percentages are calculated with psychiatric comorbidity as the denominators. Legend provided to help find associations. ASD=A
Disorder, Depress=Depression, Int. Dis= Intellectual Disability, No Comorb=No Comorbidity, Schiz= Schizophrenia. 
  
Percentages are calculated with psychiatric comorbidity as the denominators. Legend provided to 
help find associations. ASD=Autism Spectrum Disorder, ADHD= Attention Deficit Hyperactivity 
Disorder, Depress=Depression, Int. Dis= Intellectual Disability, No Comorb=No Comorbidity, 
Schiz= Schizophrenia.
Figure 2.1.3: Number of overlapping psychotropic medications classes prescribed by year of age
32 
 
Figure 2.1.3: Number of overlapping psychotropic medications classes prescribed by year of age  
 
 
Individual observations are scattered slightly around the exact coordinate, such that they do not overlap. Age given in years.  
 
 
Individual observations are scattered slightly around the exact coordinate, such that they do not overlap. 
Age given in years.
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Discussion
We found that psychiatric comorbidities and psychotropic medication use are common 
in individuals with ASD in the US and, further, that psychotropic medications were 
prescribed in individuals with ASD without coded comorbid psychiatric conditions, 
potentially suggesting their use to treat symptoms of ASD. If so, the high prescribing 
rates may indicate a high symptom burden and large unmet medical need, as ASD is a 
non-labelled indication for almost all drug classes studied. Our regression models also 
identified characteristics associated with psychotropic prescribing, such as age, psychiatric 
comorbidities, and type of insurance plan.
Overall, the pattern of results from the commercial and Medicaid cohorts were similar. 
However, compared to the commercial cohort, a larger proportion of subjects in the 
Medicaid cohort had psychiatric comorbidity, used psychotropic medication, and had 
polypharmacy. This is consistent with the findings by Wang et al 22 that Medicaid-covered 
individuals had higher total healthcare, ASD-specific, and psychotropic medication 
costs. This could be due to the different enrolment criteria in commercial and Medicaid 
insurance. Individuals with severe ASD are more likely to fulfil disability criteria in Medicaid 
waiver programs, which allow individuals to receive support in ASD treatment through 
Medicaid regardless of family income. This may have contributed to the larger proportion 
of intellectually disabled individuals in the Medicaid cohort. Another potential reason is 
that commercial insurance plans may not reimburse certain treatments for ASD, resulting 
in lower observed prescription rate in the database. We also found that non-capitated 
insurance plans were associated with psychotropic treatment. This could be due to the 
requirement for capitated plans to keep expenditure under a certain budget. It could also 
be because those who enrol in non-capitated plans are generally in more genuine need 
of treatment.
Our findings are largely consistent with earlier studies of ASD treatment patterns in 
claims, although this current study uses more recent data and has a larger and broader 
sample than previous work in data more than a decade old. Similar to the overall 
prescribing rate we found, Schubart et al 14 found that 65% of children and adolescents 
used psychotropic medication in a Medicaid analysis of years 2000-2003. In a similar age 
group in calendar year 2001 and also in Medicaid, Mandell et al 19 found that 56% used 
any psychotropic medication, with neuroleptics, antidepressants, and stimulants most 
frequently prescribed. They also showed that age and several psychiatric comorbidities 
were associated with psychotropic medication use in this age group, although they did 
not consider anticonvulsants in the study. Oswald and Sonenklar 17 found increasing 
psychotropic medication use from 5 years and older in a study of people with ASD younger 
than 21 years using commercial claims for the year 2002, and Spencer et al 18 reported 
that 64% of children and adolescents with ASD were using at least one psychotropic 
medication using commercial claims for the years 2001-2009. Also in commercial claims 
2
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but for an adult ASD population only, Vohra et al 23 showed that annually, around 85% of 
subjects were prescribed a psychotropic medication, between years 2000-2008.
Other studies on medication use in subjects with ASD have surveyed parents, with 
generally inferior sample size. For example, Martin et al 24 investigated 109 subjects 
of whom 55% were taking at least one psychotropic medication and 29%, at least two 
concomitantly. About a third took antidepressants and one-fifth took stimulants. In 
two-thirds of individuals with ASD, anxiety-related symptoms were the main reason for 
prescribing. As in our study, Aman et al 4 showed that psychotropic medication use was 
associated with age. In a web-based survey Rosenberg et al 25 with over 5,000 parents of 
children with ASD in the US (conducted in 2008), 35% used at least one psychotropic 
medication; this figure is considerably lower than ours and previous studies have found. 
This may be attributable to the way the cohort was selected and to the extent that parents 
were able to correctly provide prescription drug information. Also using parent reported 
information from 2007-2011 in the Autism Treatment Network (ATN) registry, Coury et 
al 26 estimated that 27% of individuals with ASD aged 2-17 years (N=2,853) took one or 
more psychotropic medication. The study results agreed with ours in the respect that 
age and presence of psychiatric comorbidities increased the likelihood of medication. 
Finally, in a narrower age range of 13-17 years, Frazier et al 27 also showed that an ADHD 
diagnosis in addition to ASD increased the frequency of psychotropic medication to 58%, 
from 34% for those with ASD alone. In this case, the parent reported data was captured 
for 890 subjects via telephone interview and email questionnaire, in 2001.
In another study in the UK, electronic clinical records of children in secondary care 
between 2008 and 2013 were abstracted (n=3,482). Only about 10% received 
antipsychotics, which is substantially lower than that observed in the US. The use of other 
psychotropic medications was not reported in this publication 28.
Our analysis extended this previous work in several ways. Firstly, it analysed up-to-date 
data using two contemporary cohorts and presented the commercially and Medicaid-
covered populations side by side. Secondly, we included a broader range of psychotropic 
medications than previous studies and also analysed a wider age range, which gave results 
on treatment patterns in both children and adults with ASD. In fact, the cohorts had 
over 10,000 adult ASD participants in each, which allowed an analysis of how psychiatric 
comorbidities and prescribing patterns continued into adulthood and beyond. Another 
strength of using claims data is our large sample size and general representativeness 
of both privately and publicly insured individuals. The data are recorded by physicians, 
minimising issues such as recall and selection bias present in surveys.
Our study has some limitations. Diagnosis of ASD or any of the psychiatric comorbidities 
was based on ICD codes used for reimbursement purposes. The study would also have 
benefited from having more granular geographical information to understand differences 
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at state level. Also, reasons for prescribing psychotropic medications cannot be assessed. 
Claims data do not contain any details on the severity of ASD or the predominant 
symptoms. Lastly, some people with ASD may have eligibility in both commercial insurance 
and Medicaid. However, the prescription rates should not be meaningfully affected, as 
reimbursement will only be provided by one of the coverage means. Given the nature of 
the data, we could not assess whether concomitant psychiatric diagnoses were coded to 
allow for reimbursed prescription medicines for ASD, e.g. for symptomatic treatment, 
or whether individuals with ASD suffer from other psychiatric comorbidities with need 
for medication. Only detailed psychiatric assessments would be able to provide those 
insights.
In conclusion, psychotropic medication use and polypharmacy was frequent in this study 
of commercially and Medicaid insured people with ASD. This is concerning, considering the 
paucity of evidence supporting psychotropic medications in individuals with ASD. Long-
term effects of psychotropic medications, particularly for developing brains in children, are 
not well understood, but preclinical evidence provides reason for concern 29. Overall, this 
study highlights a need for evidence-based standards of care for psychotropic medication 
use in ASD, preferably through controlled trials, to assess long-term effectiveness and 
safety in individuals with different combinations of psychiatric comorbidities
2
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Psychiatric comorbidities and use of psychotropic medications are common among 
patients with autism spectrum disorder (ASD). However, most previous research used 
data from the United States (US) and few studies have compared medication use in ASD 
to control groups, making contextualisation of results difficult. In the United Kingdom 
(UK), general practitioners play a key role in the management of ASD. We conducted a 
retrospective, cross‐sectional study over calendar year 2015, using primary care data 
from the UK. We identified a prevalent cohort of ASD cases (n=10,856) and matched 
control groups of (a) general population (n=21,712) and (b) attention deficit hyperactivity 
disorder (ADHD; n=7,058) on age, sex and region. We described psychiatric comorbidities, 
psychotropic medications, and healthcare utilisation in all three cohorts. Within the ASD 
cohort, we used multivariable logistic regression models to explore associations between 
patient characteristics and the outcomes of: any psychotropic medication, polypharmacy, 
and number of primary care visits. We used conditional logistic regression to compare 
the ASD and control groups. Psychiatric comorbidities were recorded for 41.5% of ASD 
patients; 32.3% received psychotropic medication and 9.8% received polypharmacy. 
Increased age and all psychiatric comorbidities (except conduct disorder) were associated 
with treatment use. Males were less likely to receive a treatment than females [odds ratio 
and 95% confidence interval (OR) 0.74 (0.66–0.83)]. ASD patients were more likely to 
take psychotropic medications than the general population [OR 4.91 (4.46–5.40)], but less 
likely compared to ADHD patients [OR 0.40 (0.37–0.44)]. Overall, rates of medication 
use in the UK were lower than those previously reported in the US.
Lay summary
We used electronic medical records from the UK to describe the amount of psychiatric 
comorbidities, psychotropic medication use and healthcare resource use in ASD. Around 
one in three people with ASD were prescribed a psychotropic medication, which was 
more than the general population, but less than for those with ADHD. Increased age, 
psychiatric comorbidities and female gender were all independently associated with 
psychotropic medication use. Rates of medication use in the UK were lower than those 
previously reported in the US.
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Introduction
Autism spectrum disorder (ASD) is a group of neurobiological disorders of brain 
development; they are characterised by impairments in social communication and social 
interaction, as well as the presence of restricted, repetitive interests, behaviours and 
activities 1. According to Buescher’s report 2, ASD leads to a huge burden to individual 
patients and the entire family at both a financial and emotional level and is associated 
with society burden across health, education and social systems. ASD has been reported 
across all ethnic, racial and socio-economic groups 3, with a median reported prevalence 
rate of approximately 0.62% worldwide 4. The increasing prevalence of autism has been 
reported globally 5.
There are currently no approved pharmacological treatments for the core symptoms 
of ASD. Nonetheless previous observational studies have highlighted the high rates of 
psychotropic medication use in the autistic population 6–10. These high observed rates are 
thought to be partly due to the co-occurrence of other mental disorders with ASD 11,12, 
but perhaps also due to a lack of available specific pharmacological treatment options. 
For example, a prior study in the United States (US) showed that one-third of people with 
ASD aged 3 to 65 years were prescribed a psychotropic medication, even when they did 
not have other psychiatric conditions 13.
The majority of studies which have examined psychotropic medication use in ASD have 
been set in the US. Such studies in the United Kingdom (UK) have generally been limited 
to smaller sample sizes, less recent data and only to specific drugs classes 14–16. Moreover, 
few studies have compared medication use in ASD to control groups; especially not to 
other neurodevelopmental conditions. The absence of comparisons to such control groups 
makes contextualisation of results more difficult.
We aimed to conduct a more contemporary study in the UK, with a large number of 
ASD patients, and compare their pharmacological treatment patterns to two control 
cohorts -- namely, a general population and a cohort with attention deficit hyperactivity 
disorder (ADHD). ADHD was deemed an appropriate comparison due to it being another 
neurodevelopmental condition, affecting a similar age range in onset and also having a 
higher prevalence in males 17. We also assessed healthcare resource utilisation in terms 
of general practitioner (GP) visits and referrals to secondary care. The rationale was to 
provide a more complete picture of treatment provided for ASD in primary care.
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This study used data from the Clinical Practice Research Datalink (CPRD) database from 
the UK. The CPRD data is electronically and routinely captured in the primary care setting 
by GPs, who are seen as the “gatekeepers” for all non-emergency health matters. Over 
98% of the UK population is registered with a GP 18, and 7% of whom are registered at a 
practice which uses software feeding into the CPRD database. The data includes patient 
demographics, consultations, diagnoses and prescriptions from primary care, as well as 
key referrals to, and diagnoses from secondary care. It is representative in terms of age 
and sex 19. A recent study suggested that ASD diagnoses recorded in the CPRD are reliable 
and can be used with confidence 20.
Study design and populations
This was a retrospective, year-long, cohort study set in the calendar year 2015. The study 
follow-up time was exactly one year for all participants. As such, an inclusion criterion for 
all patients was continued registration at the same GP practice throughout the whole 
calendar year. In order to assess baseline characteristics and if prescriptions during 2015 
were new or repeated, all subjects were also required to be enrolled during the calendar 
year 2014. Both the subject and practice level data had to meet the CPRD derived “up 
to standard” and “patient acceptability” quality criteria throughout 2014 and 2015.
We defined an ASD cohort and two control cohorts of interest. Patients were identified for 
the ASD cohort if they had at least one diagnosis code for ASD recorded at any time before 
1st January 2015. This meant the cohort selected was a prevalent ASD cohort. Given 
diagnostic uncertainties, individuals were excluded from the ASD cohort if they were 
below the age of 3 years 7, or had a record for Rett’s syndrome at any time in their file 9,21.
The control cohorts were: (a) a cohort of people without ASD (“general controls”), and 
(b) cohort of people with ADHD (“ADHD controls”). All patients without any record of 
ASD in their patient file were considered as potential general controls. All patients with 
an ADHD record prior to 1st January 2015, and without record of ASD in their whole 
patient file were considered as potential ADHD controls. Exact matching was performed 
randomly and without replacement so that individuals in both control cohorts matched 
individual ASD cases on year of birth, sex and region of GP practice. Matching each of the 
comparator cohorts was initially intended with a 2:1 ratio, with the pre-specified option 
of matching 1:1 if necessitated by available sample size.
Definition of study variables
The key outcome variables included in the analysis were definitions of comorbid 
conditions (attention deficit hyperactivity disorder (ADHD), anxiety disorder, bipolar 
disorder, conduct disorder, depression, epilepsy, intellectual disability, schizophrenia, 
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sleep disturbances and obsessive compulsive disorder (OCD)), classes of psychotropic 
medications (stimulants/atomoxetine, antidepressants, antipsychotics/tranquilizers, 
hypotensive agents, anticonvulsants and anxiolytics/sedatives/hypnotics), polypharmacy, 
and resource utilisation.
Each of the comorbidities was considered either absent or present based on whether 
an associated code was recorded prior to or during the study period (any time prior to 
31st December 2015). Each of the psychotropic medications were considered absent 
or present based on whether there was a prescription recorded within the study 
period (any time during calendar year 2015). Polypharmacy was defined in accordance 
with previous research 6,9,13 as having a days-supply for at least two drugs in different 
psychotropic medication classes overlapping by 30 consecutive days or more throughout 
2015. Additionally, patients with any psychotropic medication prescribed in the study 
period (calendar year 2015) were split into two categories as follows: (a) “new users” and 
(b) “continuing users”, based on if they had been prescribed at least one psychotropic 
medication of interest within one year prior to first psychotropic medication in 2015 or 
not. Finally for medications, the number of days on treatment per psychotropic drug class 
was calculated based on the quantity prescribed and the recommended numeric daily 
dose. When the daily dose was missing, we imputed the median daily dose per drug class 
among non-missing information. When a patient had two prescriptions from the same 
drug class with overlapping dates, we assumed that treatment supply left from the first 
prescription was not carried over.
Resource utilisation included the number of visits to primary care, and the number of 
recorded referrals to secondary care during 2015. The presence of referrals to secondary 
care is well captured in the database, but the specialty-type of secondary care is generally 
omitted. Hence, we summarised the most frequent specialties of secondary care, but a 
more detailed analysis was not possible.
Demographic variables available were age, sex and region. All comorbidities were 
identified based on Read codes, and drug codes were identified on the bases of the British 
National Formulary 22. A full list of codes used is available in the online supplementary 
material (https://doi.org/10.1002/aur.2040).
Data analysis
First we described the demographic characteristics of the ASD cohort and both control 
cohorts by absolute number and percentage, stratifying age into the following groups: 
3-4, 5-11, 12-17, 18-24, 25-49 and ≥50 years. We also grouped region to the country 
level: England, Scotland, Wales and Northern Ireland. In bivariate analyses, we described 
the percentage of subjects with different comorbidities, psychotropic medications and 
amount of resource use by age group.
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For the ASD cohort only, the number of days on different psychotropic medications 
in 2015 (maximum 365 days) was described by means and standard deviations. The 
prevalence of each medication was also reported within subgroups of subjects where each 
of the psychiatric comorbidities was observed. The prevalence and days on treatment with 
each medication, the prevalence of psychiatric comorbidity and frequency of resource use 
were also reported within the subgroups of new and continuing psychotropic medication 
users. Also in the ASD cohort only, we fitted separate multivariable logistic regression 
models for the outcomes “any psychotropic medication”, “psychotropic polypharmacy” 
and “greater than median number of GP visits”. We included presence/absence of each 
psychiatric comorbidity and demographic variables as covariates.
For a comparison of ASD patients with control groups, conditional logistic regression 
models - taking matching into account - were fitted for the same outcome variables as 
described above. Age, sex and region were adjusted for by exact matching, and we also 
adjusted for the presence or absence of any psychiatric comorbidity.
In pre-specified sensitivity analyses, we restricted all regression modelling to the age range 
5-24 years. The rationale for this was to see if results remained consistent in a population 
for whom we might expect fewer unobserved potential sources of bias associated with 
younger or older age (like uncertainty of diagnosis, other comorbid conditions and factors 
to do with family home). This is also the same upper age range as used by Murray et al 16, 
the prior study most similar to ours. We used R version 3.4.2 for all analyses.
Protocol and ethics approval
The protocol was submitted to and accepted by the Independent Scientific Advisory 
Committee (ISAC) of CPRD (reference: 17_103, available in the online supplementary 
material: https://doi.org/10.1002/aur.2040). The presented data are anonymised. Exact 
numbers in subgroups with five patients or fewer are not presented, in order to maintain 
a very low risk of patient identification. In minor deviation from the protocol and the 
ISAC submission, we added OCD to the investigated psychiatric comorbidities. Failure 
to account for this in the original protocol was due to oversight.
Results
Study populations
Figure 2.2.1 shows the attrition table for selection of the cohorts from the database. 
A total of 38,753 subjects were identified in CPRD with an ASD record. After applying 
the selection criteria (see methods), 10,856 subjects remained in the final ASD study 
cohort. As expected, a higher proportion of participants were male (80.7%). The mean 
(SD) age was 18.76 (11.86) years. The majority (62.0%) resided in England. It was possible 
to match cases with a 2:1 ratio for general controls (n=21,712) and the ADHD cohort was 
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matched 1:1 (n=7,058). Matching was performed on sex, age, and region, so for these 
characteristics all matched cohorts were perfectly balanced (see Table 2.2.1). The full 
ADHD cohort was remarkably similar to the full ASD cohort even before matching (see 
supplement S.2.2.1).
Figure 2.2.1: Attrition table for patients included in study cohorts
ADHD=attention deficit hyperactive disorder; ASD=autism spectrum disorder
Descriptive data
Forty-two percent of the ASD patients had at least one of the psychiatric comorbidities 
of interest; with the most frequent being sleep disturbances and ADHD, with 14.9% and 
13.8% respectively. About one third had at least one of the psychotropic medication 
classes prescribed (32.3%). The most frequently prescribed classes were anxiolytics/
sedatives/hypnotics (14.2%), followed by antidepressants (12.8%). Polypharmacy was 
observed in 9.8% of ASD patients. A sizeable proportion of patients (13.8%) received 
medication despite having none of the mental comorbidities. The vast majority of ASD 
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patients had at least one GP visit in calendar year 2015 (86.1%), and seven visits per 
year on average. About one-fifth of ASD patients had at least one referral to secondary 
care (18.9%). The specialties most commonly referred to were: paediatrics; ear, nose 
and throat; and child and adolescent psychiatry. Information on the specialty referred 
to was however seldom recorded in the database. Matching to the ADHD cohort did 
not qualitatively affect the distribution of mental comorbidities and psychotropic drug 
classes in the ASD cohort.
In the matched ADHD cohort, 28.8% had any of the selected mental comorbidities. 
Similarly to the ASD cohort, the most common was sleep disturbances (15.2%), followed by 
depression (10.2%). Almost half the ADHD patients had any psychotropic medication, and 
by far the most frequently prescribed were stimulants/atomoxetine (34.6%). Interactions 
with the health care system were similar to the ASD cohort (GP visits and referrals).
In the matched overall population, mental comorbidities were recorded in 11.9%, again 
with sleep disturbances and depression being most common (4.8% and 4.3%, respectively). 
Any psychotropic medication was used by 6.5%.
Detailed patterns in the ASD cohort
Table 2.2.2 describes the comorbidities and medications in ASD by age group. The 
presence of any mental comorbidity was increasingly recoded in the higher age groups, 
starting at 7.3% in the age group 3-4 years and reaching 76.2% in those at least 50 years. 
The same general pattern was observed for all individual comorbidities except ADHD, 
which peaked at 17.7% in the age group 12-17 years. The greatest increase in prevalence 
with age was for depression and anxiety disorder, primarily starting with age group 25-49 
years.
The use of any of the psychotropic drug classes steadily increased with age, with 10.9% in 
the youngest group to 68.2% in the oldest group. This pattern was mainly due to increased 
use of the classes of antidepressants, antipsychotics/tranquilizers and anxiolytics/
sedatives/hypnotics. Polypharmacy increased about 10 percentage points between age 
groups 18-24 years and 25-49 years (from 8.9% to 19.9%), and similar then again to the 
oldest age group (30.6%).
Patients newly starting a psychotropic medication in 2015 typically started with a single 
class of treatments (polypharmacy was 6.5% for new-users vs 34.8% for continuing users). 
New users were less often prescribed anticonvulsants, antipsychotic/tranquilizers and 
stimulants/atomoxetine, while the proportion of patients receiving antidepressants, 
anxiolytics/sedatives/hypnotics or hypotensives was similar to those having been on any 
of the classes before. Interactions with the health care system were remarkably similar 
between the two groups, although new-users had more referrals (31.2% vs 24.6%). Full 
details are presented in Table 2.2.3.
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Table 2.2.1: Baseline demographics, mental comorbidities and psychometric medication use 
of ASD patients and matched* control groups (ADHD and general population)
ASD vs general population 
comparison
(matched 2:1 ratio)











n 10,856 21,712 7,058 7,058
Male 8,760 (80.7) 17,520 (80.7) 5,736 (81.3) 5,736 (81.3)
Region
England 6,730 (62.0) 13,460 (62.0) 4,412 (62.5) 4,412 (62.5)
Northern Ireland 779 ( 7.2) 1,558 ( 7.2) 400 ( 5.7) 400 ( 5.7)
Scotland 1,864 (17.2) 3,728 (17.2) 1,167 (16.5) 1,167 (16.5)
Wales 1,483 (13.7) 2,966 (13.7) 1,079 (15.3) 1,079 (15.3)
Age (mean (SD))[years] 18.76 (11.86) 18.76 (11.86) 20.05 (9.91) 20.05 (9.91)
Age group (years)
3-4 110 ( 1.0) 220 ( 1.0) 1,082 (15.4) 
**
1,082 (15.4) 
**5-11 2,813 (25.9) 5,626 (25.9)
12-17 3,371 (31.1) 6,742 (31.1) 2,187 (31.0) 2,187 (31.0)
18-24 2,467 (22.7) 4,934 (22.7) 2,259 (32.0) 2,259 (32.0)
25-49 1,667 (15.4) 3,334 (15.4) 1,368 (19.4) 1,368 (19.4)
≥50 428 ( 3.9) 856 ( 3.9) 162 ( 2.3) 162 ( 2.3)
Mental comorbidity
ADHD 1,495 (13.8) 314 ( 1.4) 1,076 (15.2) 7,058 (100.0)
Anxiety 826 ( 7.6) 516 ( 2.4) 618 ( 8.8) 430 ( 6.1)
Bipolar disorder 83 ( 0.8) 20 ( 0.1) 57 ( 0.8) 33 ( 0.5)
Conduct disorder 46 ( 0.4) 16 ( 0.1) 37 ( 0.5) 78 ( 1.1)
Depression 919 ( 8.5) 923 ( 4.3) 679 ( 9.6) 722 ( 10.2)
Epilepsy 713 ( 6.6) 211 ( 1.0) 518 ( 7.3) 198 ( 2.8)
Intellectual disability 408 ( 3.8) 15 ( 0.1) 274 ( 3.9) 58 ( 0.8)
Schizophrenia 57 ( 0.5) 17 ( 0.1) 39 ( 0.6) 17 ( 0.2)
Sleep disturbances 1,620 (14.9) 1,035 ( 4.8) 1,099 (15.6) 1,075 ( 15.2)
OCD 267 ( 2.5) 54 ( 0.2) 202 ( 2.9) 65 ( 0.9)
Any 4,505 (41.5) 2,593 (11.9) 3,167 (44.9) 2,032 ( 28.8)
Psychotropic medication use
Anticonvulsants 770 ( 7.1) 251 ( 1.2) 541 ( 7.7) 220 ( 3.1)
Antidepressants 1,386 (12.8) 872 ( 4.0) 1,039 (14.7) 796 ( 11.3)
Antipsychotics/Tranquilizers 898 ( 8.3) 91 ( 0.4) 614 ( 8.7) 234 ( 3.3)
Anxiolytics/Sedatives/Hypnotics 1,540 (14.2) 415 ( 1.9) 941 (13.3) 966 ( 13.7)
Hypotensives 40 ( 0.4) 11 ( 0.1) 33 ( 0.5) 35 ( 0.5)
Stimulants/atomoxetine 713 ( 6.6) 159 ( 0.7) 470 ( 6.7) 2,445 ( 34.6)
Any 3,507 (32.3) 1,415 ( 6.5) 2,397 (34.0) 3,354 ( 47.5)
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Table 2.2.1: Baseline demographics, mental comorbidities and psychometric medication use 
of ASD patients and matched* control groups (ADHD and general population) (cont.) 
ASD vs general population 
comparison
(matched 2:1 ratio)











Drug classes used concurrently
Polypharmacy 1,059 (9.8) 152 (0.7) 709 (10.0) 802 (11.4)
Exactly 2 803 ( 7.4) 125 ( 0.6) 541 ( 7.7) 696 ( 9.9)
Exactly 3 229 ( 2.1) 25 ( 0.1) 150 ( 2.1) 88 ( 1.2)
Exactly 4 25 ( 0.2) 1 ( 0.0) 16 ( 0.2) 16 ( 0.2)
Exactly 5 2 ( 0.0) 1 ( 0.0) 2 ( 0.0) 2 ( 0.0)
GP consultation 9,346 (86.1) 15,720 (72.4) 5,928 (84.0) 6,211 ( 88.0)
GP consultations (mean (SD)) 6.93 (8.20) 3.69 (5.33) 6.68 (8.27) 7.05 (7.65)
Referral to secondary care 2,053 (18.9) 2,758 (12.7) 1,313 (18.6) 1,355 ( 19.2)
Referrals (mean (SD)) 0.27 (0.67) 0.17 (0.51) 0.27 (0.69) 0.28 (0.69)
ADHD=Attention Deficit Hyperactive Disorder, ASD=Autism Spectrum Disorder, OCD=Obsessive-
compulsive Disorder, SD=Standard Deviation.
*Cohorts are matched on age (exact, not grouped) at index (1st Jan 2015), gender and region (four 
regions). Data are n(%) for year 2015 unless stated otherwise. **Adjacent cells combined as patient count 
in 3-4 age group is <5.
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ADHD 111 ( 19.6) 729 ( 24.8)
Anxiety 72 ( 12.7) 445 ( 15.1)
Bipolar disorder < 5 (< 0.9)* 74 ( 2.5)
Conduct disorder < 5 (< 0.9)* 24 ( 0.8)
Depression 90 ( 15.9) 584 ( 19.9)
Epilepsy 27 ( 4.8) 561 ( 19.1)
Intellectual disability 12 ( 2.1) 283 ( 9.6)
Schizophrenia < 5 (< 0.9)* 38 ( 1.3)
Sleep disturbances 145 ( 25.6) 733 ( 24.9)
OCD 15 ( 2.6) 168 ( 5.7)
Any 343 ( 60.5) 2,290 ( 77.9)
Psychotropic medication use
Anticonvulsants 29 ( 5.1) 741 ( 25.2)
Antidepressants 232 ( 40.9) 1,154 ( 39.3)
Antipsychotics/Tranquilizers 53 ( 9.3) 845 ( 28.7)
Anxiolytics/Sedatives/Hypnotics 275 ( 48.5) 1,265 ( 43.0)
Hypotensives < 5 (< 0.9)* 36 ( 1.2)
Stimulants/atomoxetine 80 ( 14.1) 633 ( 21.5)
Any 567 (100.0) 2,940 (100.0)
Polypharmacy 37 ( 6.5) 1,022 ( 34.8)
Duration of psychotropic medication 
use (mean (SD))[days in 2015]**
Anticonvulsants 240.5 (115.8) 301.3 (99.0)
Antidepressants 219.4 (119.3) 262.7 (107.9)
Antipsychotics/Tranquilizers 192.8 (125.9) 298.1 (97.2)
Anxiolytics/Sedatives/Hypnotics 162.1 (133.3) 218.8 (135.9)
Hypotensives n/a * 260.1 (114.5)
Stimulants/atomoxetine 217.3 (120.5) 275.9 (94.8)
GP consultations 566 ( 99.8) 2885 ( 98.1)
GP consultations (mean (SD)) 11.87 (9.70) 12.01 (10.59)
Referrals to secondary care 177 ( 31.2) 723 ( 24.6)
Referrals (mean (SD)) 0.48 (0.87) 0.38 (0.84)
ADHD=attention deficit hyperactive disorder; ASD=autism spectrum disorder; OCD=obsessive–
compulsive disorder; SD=standard deviation; n/a, not applicable. *Not reportable as patient count <5.
**Adjusted to whole-year for new drug users, to allow comparison with continuing users.
Data are n(%) for year 2015 unless stated otherwise.
Regression analyses in ASD cohort
The multivariable logistic regression demonstrated - similarly to the descriptive analysis - that 
increasing age was associated with both any psychotropic medication use and polypharmacy 
in patients with ASD (Table 2.2.4). Male patients had lower odds of receiving any class 
of psychotropic medication [odds ratio and 95% confidence interval (OR) 0.74 (0.66-
0.83)] or two or more psychotropic medications at the same time [OR 0.80 (0.68-0.95)].
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Table 2.2.4: Association of psychotropic medication use and visits to GP with patient 
characteristics and comorbidities in ASD patients (multivariable logistic regression, GP visits 
dichotomised at median)
No medication  
vs any medication
No polypharmacy  
vs polypharmacy
<5 GP visits  
vs ≥5 GP visits




















































































































































* n/a: not applicable as n = 0. Model diagnostics for “any drug”: McFaddon R‐squared=0.22; Nagelkerke 
R‐squared=0.34; area under curve (AUC) = 0.81. Model diagnostics for “polypharmacy”: McFaddon 
R‐squared=0.19; Nagelkerke R‐squared=0.24; AUC=0.80. Model diagnostics for visits to GP: McFaddon 
R‐squared=0.08; Nagelkerke R‐squared=0.15; AUC=0.76. ADHD=attention deficit hyperactive disorder; 
ASD= autism spectrum disorder; OCD=obsessive–compulsive disorder. Ref=Reference group
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All types of mental comorbidities except conduct disorder increased the odds of receiving 
any psychotropic medication. Subjects with epilepsy [OR 12.76 (10.36-15.81)] and bipolar 
disorder [OR 8.68 (4.13-20.64)] were the most likely to receive medication. Epilepsy [OR 
5.09 (4.18-6.19)] and bipolar disorder [OR 5.51 (3.33-9.16)] were also the comorbidities 
most strongly associated with polypharmacy. Similarly to any psychotropic medication, 
there was no association between conduct disorder and polypharmacy. Again, all other 
types of mental comorbidities increased the odds of polypharmacy, although schizophrenia 
was only directionally related and not statistically significant.
Apart from conduct disorder, all comorbidities were significantly associated with the 
intensity of GP consultations. Male ASD patients were also much more likely to have a 
low intensity of GP interactions [OR 0.54 (0.49-0.60)]. The 3-4 years age group had by 
far the highest frequency of GP consultations, followed by those over 50 and then those 
aged 5-11 years. The proportion of ASD patients with high GP visits frequency was rather 
similar in all age groups between 12 and 49 years.
ASD patients in England were least likely to receive psychotropic medications, and ASD 
patients in Scotland were least likely to have a high frequency of GP visits. In sensitivity 
analyses, the above findings were very similar when repeated in the analysis population 
with age range 5-24 years.
Comparisons of ASD cohort to control cohorts
Compared to an age-, gender-, and region-matched cohort from the general population, 
and adjusting for comorbidities, ASD was associated with a substantially increased 
likelihood of receiving any psychotropic medication [OR 4.91 (4.46-5.40)], or 
polypharmacy [OR 9.60 (7.72-11.93)]. ASD patients also had twice the odds of a high 
intensity of GP visits [OR 2.08 (1.97-2.21)].
In comparison to the matched cohort with ADHD and adjusting for comorbidities 
however, the odds were about halved for all three outcomes (any psychotropic medication 
use: OR 0.40 (0.37-0.44); polypharmacy: OR 0.60 (0.52-0.68); and GP visit intensity: 
OR 0.61 (0.57-0.66)). Mainly this was attributable to the higher frequency of stimulant/
atomoxetine prescriptions (6.7% in ASD vs 34.6% in ADHD).
Table 2.2.5 demonstrates that in crude analyses (without adjusting for comorbidities), 
these associations were directionally the same and also statistically significant. Once more, 
in sensitivity analyses, these results remained very similar when restricting the age of all 
cohorts to range from 5-24 years.
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Table 2.2.5: Conditional logistic regressions in matched groups: control groups versus ASD 
patients








































Each cell represents a different model. Odds ratios are for ASD compared to control groups as 
reference.
* Crude comparison of cohorts which are already matched for age, gender and region
**Also adjusted for presence of any psychiatric comorbidity (yes/no).
ADHD=attention deficit hyperactive disorder; ASD=autism spectrum disorder.
Discussion
This study shows that ASD patients in the UK have a high psychiatric comorbidity burden 
and substantial use of psychotropic medications. Findings are largely consistent with the 
most comparable previous study set in primary care in the UK, in which Murray et al 16 
explored pharmacological treatments in ASD using The Health Improvement Network 
(THIN) database, between 1992 and 2008. Murray’s sample was about half the size of 
the sample in this present study and only included people with ASD up until age 24 years. 
Thirty-seven percent of ASD participants in Murray’s study had a psychiatric comorbidity 
compared to 41.5% in the present study, and rates of any psychotropic medication use 
were 29.0% and 32.3% respectively. Overall this provides reassurance that the data used 
reflects practice across the UK and that findings can be reproduced. Our study extended 
the work by Murray et al, by providing more recent data, expanding the age range studied 
and most notably, making comparisons to control cohorts.
A major finding of ours was that females with ASD were far more likely to receive 
psychotropic medications than males, even when controlling for specific comorbidities. 
This could be additional support to the growing evidence that ASD is underdiagnosed 
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in females 23–25. In a recent meta-analysis, Loomes et al 26 concluded that the true male 
to female ratio in ASD is closer to 3:1, rather than 4:1, which we observed in this study. 
It follows, if diagnosed females generally have more severe symptoms, reasonably we 
would expect those females to be in need of more care and more treatment. White et al 
27, for example, reported that females with ASD face more difficulties with activities of 
daily living than their male counterparts. Also consistent with this finding was that female 
gender in our study was associated with more GP visits. Murray et al 16 also observed 
higher psychotropic treatment rates in females with ASD in the UK. A multitude of other 
gender related, but unmeasured symptoms, such as functional social behaviour, aggression 
or self-injurious tendencies might also play a role in the choice of whether to initiate 
psychotropic treatment or not 28–30.
We also extended previous work by showing that psychotropic medications are far more 
likely to be given to people with ASD than the general population, even when controlling 
for psychiatric comorbidities. This suggests that prescriptions of psychotropic medications 
are sometimes actually targeted at ASD itself; highlighting an unmet medical need in 
ASD targeted medication. Indeed, 14% of participants in this study were prescribed 
psychotropic medication despite having no records of corresponding psychiatric 
comorbidities. An alternative explanation for some, but likely not all of this discrepancy, 
is that some diagnoses recorded in secondary and specialist care may not have been 
manually entered into the CPRD by the GP. The rate of psychotropic treatment in ADHD 
was higher than in ASD, but this was driven by the use of stimulants/atomoxetine, which 
are approved in ADHD, while no medication is currently approved in the UK to treat 
ASD.
Another novel finding was that anti-depressants and anxiolytics/sedatives/hypnotics are 
the most common psychotropic medications initially prescribed to people with ASD. Other 
psychotropic medication classes are typically added later. A general point however, is that the 
reason for prescription is not recorded in CPRD, nor are medications bought over-the-counter.
Comparison to non-UK setting
Previous findings in the US are systematically different in that the rate of psychotropic 
medication use is much higher, about double as high in fact. In 2014, psychotropic 
medication use among ASD patients was 64% in a database of privately insured individuals 
and 69% covered by Medicaid 13. Other studies set in the US had largely similar numbers, 
for example Mandell et al with 56% 6, Schubart et al with 65% 8, and Spencer et al with 64% 
9. Contrasts from the latter three studies to the UK are even more significant given they 
included only children and adolescents, yet a consistent finding throughout has been that 
greater age is among the strongest predictors for treatment.
Sizeable (n > 1000) European studies have been conducted by Dalsgaard et al 31 and 
Bachmann et al 32 in Finland (n=1,577) and Germany (n=1,124), respectively. Bachmann 
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et al reported an annual psychotropic prevalence rate of 33% in Germany, while Dalsgaard 
et al only studied medications for ADHD, but recorded an annual prevalence rate of 
16%. Like this study, Dalsgaard et al also unsurprisingly confirmed, that such medications 
(methylphenidate, dexamphetamine and atomoxetine) were more commonly prescribed 
in ADHD verses ASD. Both studies again limited analyses to children and adolescents. 
Nevertheless, these results are more in-line with our findings, confirming that psychotropic 
medication in ASD is more limited in Europe than in the US. Both studies were also 
included in a systematic review by Jobski et al 33, who reported a crude median overall 
psychotropic medication rate of 45.7%: higher than our estimate for the UK. The review 
included participants from Europe, the Middle East, and South Africa, but overwhelmingly 
from North America (37/47 studies and approximately 94% of participants were from the 
US or Canada). This demonstrates the need for studies like the present one to investigate 
ASD populations outside the US.
The proportion of ASD patients with a record of another mental condition is also markedly 
higher in the US than in the UK. Houghton et al 13 estimated that 63% with commercial 
insurance in the US and 71% in Medicaid had one or more mental comorbidities compared 
with only 42% in our current study. Lower recorded rates of comorbidity in the UK could 
partly be due to the fact that CPRD is an electronic medical record (EMR) database, where 
medical history is stored and is retrievable by GPs after only entering the information 
once. This is in contrast to insurance claims data, where diagnosis codes are supplied 
at each consultation for reimbursement purposes, thus potentially inflating the rate of 
comorbidities. We took measures to account for this where possible, by using all prior 
diagnoses in CPRD, rather than only using the diagnoses appearing during the study 
period like typically done in previous ASD claims data analyses 6,10,13.
Finally, results from this study also suggest that GPs in the UK play an important role in 
the overall care of people with ASD, because the ratio of visits to primary care verses 
secondary care is very high. Almost all participants in our study had a consultation with 
the GP during the one year study period. This is in line with the findings of Unigwe et al 
34, whose survey of GPs reported that they play a “key role” in the management of ASD, 
despite approximately 40% “never having received formal training” and being “divided 
about the remit of the GP” in ASD-care. This could call for more guidance about ASD to 
be given to GPs in the UK.
Limitations and possible extensions
There are several limitations to the present study. Firstly, there are no standardised 
definitions of diseases in CPRD (i.e. Read code lists for diseases, including ASD). Thus, 
inconsistent definitions may hamper comparability between different studies. Wherever 
possible we used existing code lists from other published CPRD studies for ASD and the 
other mental comorbidities of interest. Secondly, as mentioned, not all diagnoses made 
in secondary care are guaranteed to be reported to the GP and entered in the CPRD.
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Warranting further research is the need to quantify the types and frequencies of non-
drug therapies available for and accessed by those with ASD. This would provide an even 
more well-rounded understanding of ASD care and allow further comparisons between 
different countries. For example, Salomone et al 35 identified a lower rate of early childhood 
interventions in the UK compared to other European countries (except Ireland).
Conclusion
This study demonstrates prescription of psychotropic medications to people with ASD 
and a high mental comorbidity burden. GPs play an important role in ASD care in the UK, 
as evidenced by the high consultation rate observed. The rate of psychotropic medication 
use in the UK however, is distinctly lower than in the US.
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Northern Ireland 517 ( 6.3)
Scotland 1,339 (16.3)
Wales 1,379 (16.8)








≥50 278 ( 3.4)
Abbreviations: ADHD, attention deficit hyperactive disorder; SD, standard deviation;
* Adjacent cells have been merged together because count <5 in at least one of the cells.
Data are n(%) unless stated otherwise.
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Children with autism receive different types of non-drug treatments. We aimed to 
describe caregiver-reported pattern of care and its variability by geography and healthcare 
coverage in a US-wide sample of children aged 3-17 years. We recruited caregivers from 
the Simons Foundation Powering Autism Research for Knowledge (SPARK) cohort. Two 
online questionnaires (non-drug treatment, Autism Impact Measure) were completed in 
September/October 2017. Primary outcome measures were caregiver-reported types and 
intensities of treatments (behavioural, developmental/relationship, speech and language 
(SLT), occupational, psychological, “other”; parent/caregiver training) in the previous 12 
months. Main explanatory variables were geography and type of healthcare coverage. 
We investigated associations between the type/intensity of treatments and geography 
(metropolitan/nonmetropolitan) or coverage (Medicaid vs privately insured by employer) 
using regression analysis. Caregivers (n=5,122) were mainly mothers (92.1%) with mean 
(SD) age of 39.0 (7.3) years. Children had mean (SD) age 9.1 (3.9) years and were mostly 
males (80.0%). Almost all children received at least one intervention (96.0%). Eighty 
percent received SLT or occupational therapy, while 52.0% received both. Behavioural 
therapy and SLT were significantly more frequent and more intense in metropolitan than 
in nonmetropolitan areas. No consistently significant associations were seen between 
healthcare coverage and frequency or intensity of interventions. At least one barrier such 
as “waiting list” and “no coverage” was reported by 44.8%. In conclusion, in children sampled 
from SPARK, we observed differences between metropolitan and nonmetropolitan areas, 
while we did not find significant differences between those privately insured versus Medicaid.
Lay summary
The American Academy of Child and Adolescent Psychiatry recommends the use 
of multiple treatment modalities in autism spectrum disorder (ASD). We wanted to 
understand what types of treatment children (aged 3–17 years) with ASD receive in the 
United States, how and where the treatments take place and for how long. We invited 
caregivers from Simons Foundation Powering Autism Research for Knowledge (“SPARK”; 
https://sparkforautism.org/) to complete the study questions online. Participants reported 
on utilisation of conventional, non-drug treatments for ASD, including behavioural 
interventions, developmental/relationship interventions, speech and language therapy 
(SLT), occupational therapy, psychological therapy, and parent/caregiver training. People 
that completed the study (n=5,122) were primarily mothers of the child with ASD (92%); 
most of the children were boys (80%). The ASD care for the child was mostly coordinated 
by the mother. Almost all children received at least some type of non-drug therapies 
(96%), most often SLT and/or occupational therapy, mainly provided in school. Behavioural 
therapy was most often received in public school in rural areas, while at home in urban 
areas. We saw less use of behavioural therapy and SLT in rural areas, but overall comparable 
use between children covered by Medicaid and those covered by private insurance. 
Almost half the caregivers reported at least one barrier to treatment, such as “waiting 
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list” and “no coverage.” More than half said that their child benefited “much” or “very 
much” from the therapies received. While overall non-drug treatment rates for children 
with ASD were high in the United States in our study, differences existed depending on 
where the family lives; not only regarding the type of therapy, but also where it takes place.
Introduction
Autism spectrum disorder (ASD) is a family of neurodevelopmental disorders characterised 
by repetitive or stereotyped behaviours and deficits in social interactions. An estimated 
11.9 in 1,000 children in the United States (US) have ASD 1. The American Academy of 
Child and Adolescent Psychiatry recommends the use of multiple treatment modalities 
in ASD 2. Conventional non-drug treatments, including behavioural interventions, speech 
and language therapy (SLT), and occupational therapy (OT), are utilised across paediatric 
age groups and administered in diverse settings (e.g. home, school, and specialty clinics/
offices) 3. Previous studies reporting on the pattern of care received by children with ASD 
either relied on a network of centres or providers 4, utilised subsections of existing US 
surveys 5, used claims analysis 6, or investigated certain age groups 7,8.
Prior research has raised concerns that children in more rural settings have access to 
fewer services 9, as well as that the type of healthcare coverage may dictate utilisation 
of services, specifically that Medicaid provided for more interventions than commercial 
plans 10. Therefore, the goal of our study was to describe the caregiver-reported pattern 
of non-drug ASD treatment and its variation by geographic region and type of healthcare 
coverage across the US in children aged 3-17 years. Our study recruited caregivers from 
the Simons Foundation Powering Autism Research for Knowledge (SPARK) cohort, a 
US-based online research cohort with individuals and families who have consented to 
providing information and medical samples to further autism research 11.
Methods
Online surveys for non-drug therapy and for the Autism Impact Measure (AIM; to 
assess frequency and impact of ASD symptoms 12,13) were sent to caregivers (i.e. parents 
and guardians/legally authorised representatives) in the SPARK cohort between 13th 
September and 22nd October 2017. Invitations were sent in four batches, first inviting 
potentially eligible caregivers (i.e. have children with ASD registered in SPARK in required 
age range) that had most recently joined SPARK. Participants and their oldest ASD 
dependent aged 3-17 years (hereafter “children with ASD”) had to have been living in the 
same household, with the caregiver as the main person supporting this child for at least 
the preceding 12 months. SPARK currently provides information in English and requires 
for inclusion that participants be able to read and understand English.
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The research protocol was approved by an institutional review board (Western IRB) and 
participants consented online. Upon completion of both surveys, participants received a 
$20 online shop voucher via email.
The primary outcome measures were the types and intensities of non-drug treatments 
in the preceding 12 months as reported by the caregiver, categorised into seven 
groups (child-directed: behavioural, developmental and/or relationship-based, SLT, OT, 
psychological, and “other”; and parent/caregiver training). This categorisation was similar 
to a study by Salomone et al 14 in order to allow comparisons, with the only difference 
being that we separated out psychological interventions from the “other” category. The 
main explanatory variables were geography of residence and healthcare coverage type. 
Geography was defined by a six-level urban-rural classification scheme based on US state 
and county (i.e. six-level metropolitan statistical area (MSA) 15). For the analysis of the 
association between geography and outcomes, we collapsed this to two levels (i.e. two-
level MSA), nonmetropolitan and metropolitan, indicating “rural” and “urban” as per the 
classification scheme. Healthcare coverage types were categorised into mutually exclusive 
groups: those with only Medicaid (“Medicaid-only”), those with only private insurance 
provided by an employer (“private insurance-only”), one other type of coverage, more 
than one, and uninsured. Barriers (adapted from a previous study 16), caregiver’s role in 
access to and perceived benefits of non-drug treatments, demographic characteristics of 
caregivers and children with ASD, and AIM scores were also analysed.
Statistical Methods
Data were summarised descriptively. Types and intensities of non-drug treatments were 
also stratified by geography, healthcare coverage type, and age group.
To model the associations between explanatory variables (geography, type of healthcare 
coverage) and outcomes, we identified covariates needed for adjustment using directed 
acyclic graphs 17 (see supplement S.2.3.1 and online supplementary material: https://doi.
org/10.1002/aur.2070), followed by propensity score methodology (inverse probability 
weighting) to create balance in the covariates, and finally applied regression modelling 
(logistic for treatment types; negative binomial for intensities). Populations did not 
sufficiently overlap to allow modelling the association between all four categories of 
insurance simultaneously, using multinomial logistic regression to derive propensity 
scores (i.e. Medicaid, private provided by employer, one type of coverage from the other 
categories, more than one coverage type). We therefore present only a comparison 
between private via employer versus Medicaid.
An intervention was counted as “absent” if a response of “don’t know” was given. For 
present treatments, missing intensity values were set to 0.5 hr/week. These imputations 
were necessary <5% of the time as the data were generally very well populated. For AIM, 
no total or domain scores were calculated if >20% of items had missing responses.
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We justified the sample size target of 5,000 based on the following: if 85% of children 
received at least one non-drug treatment and up to 16 strata analysed, a precision of 
0.85 (95% confidence interval [CI]: 0.81-0.89) could be achieved, which was considered 
adequate. R version 3.3.2 was used for all analyses.
Results
Invitations were emailed to 11,514 of 19,142 potentially eligible caregivers. The non-drug 
treatment survey was completed by 5,122 (44.5% of those invited), and the AIM by 5,001 
(43.4%; see supplement S.2.3.2). The study was closed online when the targeted sample 
size had been reached.
Characteristics of caregivers and children with ASD
The majority (92.1%) of the caregivers were mothers, with a mean age of 39.0 years and 
were mostly (76.5%) White/non-Hispanic (Table 2.3.1). Two-thirds had a higher education 
(completed college or higher) and most (81.2%) lived in metropolitan areas. The children 
with ASD were predominantly (80.0%) male, with a mean age of 9.1 years, and mostly 
(68.5%) White/non-Hispanic. About two-thirds had been diagnosed before age 5 years. 
Almost all had at least some insurance coverage. Of those who reported having ever had 
an IQ test, 44.6% scored <100.
There were a few demographic differences between children enrolled in special-education 
schools (21.7% of the total) and the overall group; notably, mean age was lower, a lower 
proportion were of White/non-Hispanic ethnicity, a higher proportion had been diagnosed 
before 5 years, and had IQ test scores of 70 or below (see online supplementary material: 
https://doi.org/10.1002/aur.2070).
The mean (SD) total AIM score was 220.8 (54.1); possible score range: 82–410, with 
higher scores indicating higher symptom frequency/impact. Mean (SD) [possible range] 
domain scores were: Repetitive Behavior, 41.1 (13.8) [16–80]; Communication, 30.6 (11.9) 
[12–60]; Atypical Behavior, 34.7 (10.1) [12–60]; Social Reciprocity 27.1 (7.4) [10–50]; and 
Peer Interaction, 22.9 (7.1) [8–40].
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Legal guardian 55 (1.1)
Other 34 (0.7)
Married/living with partner 4101 (80.1)
Completed college or higher 3259 (63.6)
Employment
Working (full or part-time) 3024 (59.0)


























Less than $20,000 512 (10.0)
$20,000 - $34,999 696 (13.6)
$35,000 - $49,999 619 (12.1)
$50,000 - $74,999 904 (17.6)
$75,000 - $99,999 681 (13.3)
$100,000 - $124,999 577 (11.3)
$125,000 - $149,999 312 (6.1)
$150,000 or more 576 (11.2)
Missing 245 (4.8)
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Autism/Autistic Disorder 553 (10.8)
Asperger Syndrome 455 (8.9)
PDDNOS 289 (5.6)
Unknown/Missing 39 (0.8)















Only Medicaid 1564 (30.5)
Only private (via employer) 2083 (40.7)
One type of other coverage 418 (8.2)
More than one type 970 (18.9)
Insurance drug coverage 4672 (91.2)
Prescription drug use
Overall 2683 (52.4)
Drugs for autism 1718 (33.5)
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Drugs for autism 965 (18.8)
Has other medical problems 2348 (45.8)
Has other mental health or psychiatric problems 2424 (47.3)






Attending school with special education students only 1109 (21.7)
At least 60% of classroom time with typically-developing peers 2312 (45.1)
n=5122 is the number of caregiver respondents and ASD children (oldest eligible autistic child considered 
per respondent).
ASD: Autism Spectrum Disorder; IQ: intelligence quotient; PDDNOS: pervasive developmental disorder 
– not otherwise specified; SD: standard deviation.
*IQ test was previously completed by n=2305 (45.0%).
Types of treatments
As shown in Table 2.3.2, 96.0% of children received at least one type of non-drug 
treatment, the most common being SLT (71.4%). A higher proportion of children in 
metropolitan versus nonmetropolitan areas received behavioural therapy (57.2% vs 
46.4%) and SLT (72.3% vs 65.0%). There was a pattern toward lower utilisation across 
urbanisation categories from large central metro to noncore for behavioural therapy, SLT, 
and parent/caregiver training (see supplement S.2.3.3). Similar proportions of children 
covered by Medicaid-only and private insurance-only received at least one therapy (96.2% 
vs 95.4%), although children under Medicaid-only received OT more frequently (61.8% 
vs 55.7%) and “other” therapies less frequently (63.4% vs 69.9%). For most therapies, use 
decreased from the lowest age group to the highest age group.
Most caregivers reported therapy as ongoing (i.e. not having ended in the 12-month recall 
period; ranging from 61.0% for parent/caregiver training to 89.1% for SLT). Approximately 
42% reported four or more interventions. Children were most likely to receive SLT and OT 
concurrently, followed by parent/caregiver training and behavioural therapy (supplement 
S.2.3.4). The most common interventions used concurrently were behavioural-SLT-OT-other 
(7.1%) and SLT-OT-other (5.9%; see supplement S.2.3.5). In nonmetropolitan areas, behavioural 
therapy was not in the three most common concurrently used interventions, and developmental/
relationship-based and parental training not in any of the combinations occurring for >2% of 
the children. Overall, 52.0% received at least SLT and OT, while 79.5% received at least either.
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The median intensity of all treatments was 6.0 hr/week, with behavioural therapy being 
the most intense (4.0 hr/week; Table 2.3.3). Metropolitan areas reported higher intensity 
for “any” therapy, behavioral therapy, “other” therapy, and developmental/relationship-
based interventions (supplement S.2.3.6). A difference between Medicaid-only and 
private insurance-only patients was seen only for behavioral therapy (2.0 and 4.0 hr/
week, respectively) and “other” (supplement S.2.3.7). Although there was no consistent 
pattern overall across age groups, the two lowest (3–4 and 5–9 years) had the highest 
intensity for behavioural therapy (Table 2.3.3).
Setting of treatments
Non-drug therapies were more often given in individual rather than group sessions, 
with psychological interventions and OT having the highest individual-to-group ratios 
(IGRs: 3.27 and 2.93, respectively; Table 2.3.3). Children in nonmetropolitan areas 
were more likely to receive individual sessions than those in metropolitan areas, with 
notable differences seen for behavioural therapy, psychological interventions, OT, and 
SLT. Children under Medicaid-only more often received individual sessions than those 
under private insurance-only; with differences seen for OT, SLT, and behavioural therapy. 
There was a pattern of individual sessions from lowest in large central metro to highest 
in noncore (supplement S.2.3.8).
SLT and OT were more often provided in school (school/not in school ratio [SNR]: 1.79 
and 1.33, respectively), while behavioural therapy and psychological interventions were 
more frequently provided outside school (SNR: 0.64 and 0.40, respectively). There were 
no notable differences in SNR’s between metropolitan and nonmetropolitan areas. A small 
difference was seen between the Medicaid-only and private insurance-only patients for 
SLT.
The most common place of care was the home for behavioural interventions (45.0%); 
public school for developmental/relationship-based interventions (56.0%), SLT (76.5%), 
OT (63.6%) and “other” interventions (57.7%); and private therapist (57.8%) for 
psychological interventions (Table 2.3.4). Behavioural therapy was most often received 
in public school in nonmetropolitan areas (44.7%), but at home in metropolitan areas 
(46.3%).
Barriers to treatments
Overall, 44.8% reported at least one barrier to non-drug therapy. “Waiting list” (26.4%) 
was the most common provider-related barrier (Table 2.3.5), whereas “no coverage” 
(17.9%) and “cost” (16.7%) were the most common health-plan-related barriers 
(Table 2.3.6). Metropolitan areas reported a higher frequency of “waiting list” than 
nonmetropolitan areas, but a much lower frequency of “not available in area” (15.1% vs 
32.0%).
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Treatment patterns in children with autism in the United States
Caregiver’s role and perception
Table 2.3.7 lists the non-drug therapies in the “other” category. The most frequent 
therapies were social skills training (37.0%) and academic support (28.3%). The main care 
coordinator was the caregiver (81.9%). Three quarters reported that they were satisfied 
with the current level of care, and 58.2% reported that their child benefited “much” or 
“very much” from care.
Associations between treatments and geography/insurance
As shown in Table 2.3.8, the odds of receiving “any” treatment, behavioural therapy and SLT 
were significantly greater in metropolitan areas than in nonmetropolitan areas (odds ratios 
[OR]: 1.71, 1.54, and 1.41, respectively). No consistently (i.e., significant in both, the PS-
adjusted and double-adjusted analyses) significant associations were seen between type 
of insurance (Medicaid-only vs private insurance-only) and type of treatment received.
The intensity of “any” treatment was significantly greater in metropolitan areas than in 
nonmetropolitan areas (rate ratio [RR]: 1.35), based on the intensities of behavioural 
therapy, SLT, psychological and “other” interventions that were all significantly greater 
in metropolitan areas. The RRs for the intensity of any of the treatment options did 
not indicate a consistently significant difference between the two types of healthcare 
coverage, except for “other,” where the rates were lower for those with private insurance 
provided by employer. For results on the six-level MSA and other additional analyses, refer 
to the supplements S.2.3.9 to S.2.3.11.
Table 2.3.7: Non-drug ASD therapies in the “other” category
Type n %
Social skills training 1894 36.98
Academic support (for example reading, writing, and math tutor) 1450 28.31
Sensory integration 792 15.46
Physical therapy 739 14.43
Recreational* 715 13.96
Biomedical** 431 8.41
Animal-assisted activities and therapies*** 395 7.71
Other therapy not previously mentioned 395 7.71
Other therapy – but don’t know which 234 4.57
Fast Forward, APE 206 4.02
Structured Teaching (TEACCH) 177 3.46
SCERTS 152 2.97
AIT 78 1.52
The Built Environment 2 0.04
Percentages are based on the 3,471 children who received at least one “other” therapy.
AIT: auditory integration training/therapy; APE: Adaptive physical education; ASD: Autism Spectrum 
Disorder; SCERTS: Social Communication/Emotional Regulation/Transactional Support; TEACCH: 
Training and Education of Autistic and Related Communication Handicapped Children
*For example, specialised summer camp
**For example, biofeedback, special diets, vitamins
***For example, therapies including dogs, horses, dolphins
2
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Association with type of therapy: OR (95% CI)
Any 1.71 (1.17,2.45) 0.63 (0.34,1.17) 0.58 (0.32,1.06)
Behavioural 1.54 (1.30,1.83) 1.12 (0.78,1.62) 1.07 (0.78,1.47)
Developmental/ relationship 1.01 (0.83,1.23) 0.99 (0.65,1.52) 1.04 (0.73,1.50)
SLT 1.41 (1.17,1.69) 0.67 (0.44,1.03) 0.66 (0.45,0.97)
Occupational 1.15 (0.96,1.36) 0.80 (0.54,1.19) 0.77 (0.55,1.09)
Psychological 1.13 (0.93,1.37) 0.77 (0.55,1.09) 0.69 (0.49,0.97)
Other 1.19 (0.99,1.42) 0.86 (0.58,1.26) 0.86 (0.62,1.20)
Association with intensity of therapy: RR (95% CI)
Any 1.35 (1.23,1.48) 0.90 (0.75,1.07) 0.84 (0.72,0.97)
Behavioural 1.71 (1.45,2.01) 1.02 (0.81,1.27) 0.98 (0.78,1.24)
Developmental/ relationship 1.23 (0.95,1.57) 1.37 (0.93,2.01) 0.99 (0.70,1.39)
SLT 1.18 (1.06,1.31) 0.90 (0.70,1.17) 0.88 (0.72,1.07)
Occupational 1.04 (0.93,1.17) 0.83 (0.64,1.08) 0.83 (0.66,1.05)
Psychological 1.46 (1.19,1.79) 0.89 (0.60,1.32) 0.81 (0.56,1.17)
Other 1.19 (1.04,1.35) 0.66 (0.54,0.81) 0.65 (0.54,0.80)
CI: Confidence interval; OR: Odds Ratio; PS: propensity score; RR: Rate ratio; SLT: Speech and language 
therapy
Models for insurance were adjusted for below variables using propensity score inverse probability weighting 
(adjusted and double adjusted: see methods section). See supplement S.2.3.9 for trimmed results.
Variables for adjustment: AIM domain scores (continuous), child race/ethnicity (White/Hispanic, White/
Non-Hispanic, Non-White/Hispanic, Non-White/Non-Hispanic), child other medical problems (yes/no), 
child other mental health or psychiatric problems (yes/no), geography (nonmetropolitan/ metropolitan), 
household income (four strata, ≥$20,000 to ≤$99,999), marital status (married/living with partner 
yes/no), mother employment (work full time/part time yes/no), US state (excluded states with n<3 for 
Medicaid and private employer insurance).
Discussion
This study investigated the caregiver-reported pattern of non-drug therapy and the 
variability of care by geographic region and type of healthcare coverage, in children with ASD.
The cohort was largely representative of children with ASD in the US. Population 
weighted survey data, from the 2016 National Survey of Children’s Health 18, reported 
a similar male to female ratio (around 80% male), use of medications for autism (around 
1/3), age at diagnosis (around 1/3 beyond age 5 years), and insurance coverage (around 
98% with coverage). The sample of the 2016 survey included close to 70% White/non-
Hispanics, as in our study, while the population estimate was around 53%, indicating over-
representation of this group among the survey respondents.
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Salomone et al 14 who grouped therapies similarly, reported that 91% of respondents 
from 18 European countries used at least one non-drug therapy (vs 96% in our study). 
Behavioural therapy, SLT, and OT were reported at 32%, 64%, and 35%, although there 
was wide variation across countries. Our study reported higher rates (66% and 60%, 
91% and 81%, 76% and 72% for these therapies, for the age groups 3–4 years and 5–9 
years, respectively, corresponding best to the age range investigated by Salomone et al). 
Most children in our cohort received more than one non-drug therapy. Approximately 
one-quarter used three therapies concurrently and two-thirds used three or more in the 
past 12 months with the most common combination being behavioural-SLT-OT-other 
(7.1%). It is difficult to compare these rates with other studies as they either did not use 
similar groupings of non-drug treatments, included medications and other modalities (e.g. 
vitamin supplements) in their count of combinations, or did not report on combinations 
at all. Guideline-recommended intensity of treatment of 25 hr/week for children 19, was 
not achieved in our study. Even the most intense treatments have not reached this level 
(children aged 3–4 years, four or more different interventions, mean intensity 19.7 hr/
week).
SLT was the most frequently used therapy in our study and was predominantly provided 
at public schools. That SLT was the most frequent therapy agrees with previous findings 
in the US (from a 2012 survey of four Kaiser Permanente regions 4) and in Europe 14. Since 
communication deficits are a core symptom of ASD, the high rate of SLT is not surprising.
We classified geography based on state and county, defining six levels of urbanisation from 
most urban/highest density to most rural/lowest density 15. The difference in frequency 
of “any” treatment between metropolitan and nonmetropolitan areas (96.2% vs 93.7%, 
OR 1.71 [95% CI: 1.17, 2.45]), although significant, was less pronounced than might have 
been expected 9. This may be because the most frequently used therapies (SLT and OT) 
are mostly provided at public school, and are thus not dependent on infrastructure such 
as specialists’ offices. The intensity of “any” treatment was also significantly greater in 
metropolitan areas than in nonmetropolitan areas, mostly driven by significant differences 
in the intensity of behavioural therapy, SLT, psychological, and “other” interventions. 
Specifically, behavioural therapy was less often used in nonmetropolitan settings, and, 
where used, was much less intense. Given that public school was reported as the most 
frequent setting for this therapy in nonmetropolitan areas, its use as a platform for 
care delivery probably warrants further consideration. A previous study 9 additionally 
suggested telehealth programs to provide better access to behavioural therapy in remote 
areas. The level of urbanisation has an influence on the number of children diagnosed 
with ASD 20, also called “treated prevalence” 21. Hence, the true difference in unmet need 
between metropolitan and nonmetropolitan areas is likely underestimated in our study.
Historically, large differences have been reported for ASD-related services between 
children covered under Medicaid versus those under private insurance, such that 
2
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Medicaid spending was much higher 10,22. We were able to investigate the association 
between frequency/intensity and type of healthcare coverage in two mutually exclusive 
insurance groups, namely Medicaid-only and private employer-based-only. We made 
these groups as comparable as possible by focusing on a subgroup of children with 
similar characteristics and further adjusting for important confounders. No significant 
differences in the frequency or intensity of treatment was observed, with the exception 
that intensity for “other” interventions was lower in privately insured children. However, 
given that the sample size for this analysis was substantially smaller than for the analysis 
of association with geography, the results may also reflect limited statistical power, as 
point estimates mostly directionally favoured Medicaid, except for behavioural and 
developmental-relationship based therapies.
Our study has some limitations. The use of the SPARK cohort might have introduced 
selection bias toward caregivers with higher motivation and higher education. This is 
likely to have underestimated the difference between nonmetropolitan and metropolitan 
areas, given the known associations between area of residence and educational level 
and likelihood of seeking treatment 8. The possibility of recall bias cannot be ruled out 
as the study relied on caregiver-reported information over the previous year. However, 
as most of the treatments were still ongoing, this seems to be less of a concern. Our 
grouping of treatment options into categories may not be universally acceptable, 
although a very similar grouping has been used before 14, and caregivers may not have 
been able to clearly identify and distinguish the different treatment options. We also did 
not collect in the “other” category further details for the response option “other therapy 
not previously mentioned” which may include those considered complementary health 
approaches. Finally, as this was a cross-sectional study, it is not possible to conclude any 
causal relationships, particularly between geographic region and any type of healthcare 
coverage, although it is implied that the pattern of care is determined by geography of 
residence and type of coverage.
Strengths of this study lie in the recency of the data presented (2016 and 2017), and its 
collection from a large sample not linked to a specific provider or network of centres, and 
no reliance on claims data. Since most respondents reported themselves as the main care 
coordinator, the data are likely to be complete. The design of the survey also allowed us 
to capture important details including the setting of care. Finally, these data will be made 
available via SPARK, and will be linkable to other data collected from the same cohort.
While this study provides unprecedented detail on current non-drug therapy in ASD 
for children in the US, future research should investigate the effectiveness of those 
treatments in routine practice.
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S.2.3.1: Directed acyclic graph displaying the relationship between non-drug treatment, 
covariates, and key exposures (insurance type and geography)
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ASD: autism spectrum disorder 
  
ASD: autism spectrum disorder
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S.2.3.2: Participant flow
S.2.3.2: Participant flow 
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Y N Y Y N Y N 362 7.1
N N Y Y N Y N 302 5.9
N N Y Y N N N 243 4.7
Y N Y Y N Y Y 235 4.6
N N N N N N N 185 3.6
Y N Y Y N N N 180 3.5
N N Y N N Y N 153 3.0
Y Y Y Y N Y N 150 2.9
N N Y N N N N 146 2.9
Y Y Y Y N Y Y 143 2.8
N N N N N Y N 140 2.7
By geography: Metropolitan (n=588)
Y N Y Y N Y N 305 7.3
N N Y Y N Y N 225 5.4
Y N Y Y N Y Y 202 4.9
N N Y Y N N N 186 4.5
Y N Y Y N N N 152 3.7
N N N N N N N 142 3.4
N N Y N N Y N 126 3.0
Y Y Y Y N Y N 124 3.0
Y Y Y Y N Y Y 121 2.9
N N Y N N N N 112 2.7
N N N N N Y N 111 2.7
Y N Y Y Y Y Y 87 2.1
Y N Y Y Y Y N 86 2.1
By geography: Nonmetropolitan (n=4,158)
N N Y Y N Y N 47 8.0
N N Y Y N N N 41 7.0
N N N N N N N 35 6.0
Y N Y Y N Y N 31 5.3
N N Y N N N N 28 4.8
N N N N N Y N 23 3.9
N N Y N N Y N 19 3.2
Y N Y Y N N N 16 2.7
Y N Y N N Y N 14 2.4
Y N Y Y Y Y N 13 2.2
D/R: Developmental and/or relationship-based intervention; SLT: speech and language therapy; N: No; 
Y: Yes
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S.2.3.6: Intensity of treatment (hours/week) by metropolitan statistical area (MSA)
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Behavioral: Behavioural intervention; Develop: Developmental and/or relationship-based intervention; IntType: Intervention 
Type; MSA: Metropolitan Statistical Area; OT: Occupational Therapy; Other: Other intervention; Parent: Parent/Caregiver 
training; Psych: Psychological intervention; SLT: Speech and language therapy 
  
Behavioral: Behavioural intervention; Develop: Developmental and/or relationship-based intervention; 
IntType: Intervention Type; MSA: Metropolitan Statistical Area; OT: Occupational Therapy; Other: Other 
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S.2.3.7: Intensity of treatment (hours/week) by insurance type
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S.2.3.7: Intensity of treatment (hours/week) by insurance type 
 
 
Behavioral: Behavioural intervention; Develop: Developmental and/or relationship-based intervention; IntType: Intervention 
Type; OT: Occupational Therapy; Other: Other intervention; Parent: Parent/Caregiver training; Psych: Psychological 




Behavioral: Behavioural intervention; Develop: Developmental and/or relationship-ba ed intervention; 
IntType: Intervention Type; OT: Occupational Therapy; Other: Other intervention; Parent: Parent/
Caregiver training; Psych: Psychological intervention; SLT: Speech and language therapy
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S.2.3.9: Association of caregiver-reported type and intensity of non-drug therapy with 
insurance (PS trimmed analyses)
Non-drug therapy type
Insurance
(Only private via employer vs only Medicaid)
N=1,625*
PS-adjusted Double-adjusted
Association with type of therapy OR (95% CI)
Any 0.57 (0.31,1.04) 0.53 (0.28,0.99)
Behavioural 0.84 (0.64,1.10) 0.84 (0.63,1.13)
Developmental/ relationship 1.27 (0.94,1.72) 1.32 (0.95,1.83)
SLT 0.91 (0.68,1.21) 0.90 (0.64,1.28)
Occupational 0.86 (0.66,1.14) 0.85 (0.62,1.16)
Psychological 0.80 (0.61,1.07) 0.77 (0.55,1.06)
Other 0.89 (0.67,1.18) 0.85 (0.62,1.17)
Association with intensity of therapy RR (95% CI)
Any 0.94 (0.80,1.11) 0.89 (0.77,1.03)
Behavioural 1.04 (0.84,1.28) 0.98 (0.78,1.22)
Developmental/ relationship 1.49 (1.03,2.17) 1.21 (0.86,1.71)
SLT 0.94 (0.74,1.21) 0.90 (0.76,1.08)
Occupational 0.86 (0.68,1.08) 0.89 (0.72,1.10)
Psychological 0.95 (0.66,1.38) 0.92 (0.63,1.33)
Other 0.71 (0.58,0.86) 0.69 (0.56,0.85)
CI: Confidence interval; OR: Odds Ratio; PS: propensity score; RR: Rate ratio; SLT: Speech and language 
therapy
Models were adjusted for below variables using propensity score inverse probability weighting (adjusted 
and double adjusted: see methods section)
Variables for adjustment: AIM domain scores (continuous), child race/ethnicity (White/Hispanic, White/
Non-Hispanic, Non-White/Hispanic, Non-White/Non-Hispanic), child other medical problems (yes/no), 
child other mental health or psychiatric problems (yes/no), geography (nonmetropolitan/ metropolitan), 
household income (four strata, ≥$20,000 to ≤$99,999), marital status (married/living with partner yes/
no), mother employment (work full time/part time yes/no; excluded fathers), US state (excluded states 
with n<3 for Medicaid and private employer insurance).
* 7 participants trimmed (2 from only Medicaid group, 5 from only private via employer group)
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Psychostimulants and atomoxetine have been shown to increase blood pressure, heart 
rate, and QT interval in children and adolescents; however, based on current literature, 
it is unclear if these “attention-deficit/hyperactivity disorder (ADHD) medications” are 
also associated with serious cardiovascular (SCV) events. We addressed this question 
in commonly exposed groups of children and adolescents with either ADHD or autism 
spectrum disorder (ASD). Using commercial (years 2000-2016) and Medicaid (years 
2012-2016) administrative claims data from the United States (US), we conducted two 
case-control studies, nested within respective cohorts of ADHD and ASD children 
aged 3-18 years. We defined cases by a composite outcome of stroke, myocardial 
infarction, or serious cardiac arrhythmia. For each case, we matched ten controls on 
age, sex, and insurance type. We conducted conditional logistic regression models to 
test associations between SCV outcomes and a primary exposure definition of current 
ADHD medication use. Additionally, we controlled for resource use, cardiovascular and 
psychiatric comorbidities, and use of medications in a variety of sensitivity analyses. We 
identified 2,240,774 children for the ADHD cohort and 326,221 children for the ASD 
cohort. For ADHD, 33.9% of cases (63 of 186) versus 32.2% of controls (598 of 1860) 
were exposed, which yielded an odds ratio and 95% confidence interval (OR) of 1.08 
(0.78-1.49). For ASD, 12.5% of cases (6 of 48) versus 22.1% of controls (106 of 480) 
were exposed [OR 0.49 (0.20-1.20)]. Covariate-adjusted results and results for individual 
outcomes and other exposure definitions were consistent with no increased risk of SCV 
events. Using large US claims data, we found no evidence of increased SCV risk in children 
and adolescents with ADHD or ASD exposed to ADHD medications.
Lay summary
ADHD medications have been shown to increase blood pressure and heart rate in children. 
Using historical insurance claims data, we tested if these drugs were also related with 
increased risks of serious cardiovascular events like stroke or heart attack, in children with 
ADHD and ASD. We found this not to be the case. There were no significant differences 
in ADHD medication use between patients who did or did not have a serious event.
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Introduction
Prescription stimulants such as methylphenidate and non-stimulants such as atomoxetine 
are labelled for the treatment of attention-deficit/hyperactivity disorder (ADHD) in from 
age approximately 6 and above years, and are also commonly used in medical practice for 
the management of non-core symptoms of autism spectrum disorder (ASD) 1. In the US 
and in Europe, there has been a trend toward higher prescription rates of these drugs 
(hereon referred to as “ADHD medications”) for both children and adults over the past 
two decades, nevertheless, use remains most common in middle childhood and not all 
ADHD diagnosed individuals are prescribed ADHD medications 2–7.
Despite evidence for short-term effectiveness 8, both placebo-controlled and open-label 
extension trials have repeatedly shown ADHD medication-induced increases in mean blood 
pressure, heart rate, and QT interval in children, adolescents, and adults 9–11. Although 
these increases were described as relatively minor, their existence has raised concern to 
what degree ADHD medication could influence the likelihood of serious cardiovascular 
(SCV) events such as stroke, myocardial infarction (MI), and cardiac arrhythmia, especially 
in people with underlying heart problems 11. Furthermore, ADHD medications have been 
linked to sudden cardiac death in case reports and currently carry a US Food and Drug 
Administration (FDA) class-specific warning regarding these potential increased risks 12–14.
A limited number of observational studies have generally found no increased risk of SCV 
events with ADHD medication use, but results have not been consistent 14. The majority of 
such studies were conducted on data from over a decade ago and due to the low absolute 
numbers of SCV events, the ability to rule out such an association has been limited 15,16. 
To the best of our knowledge, no studies have specifically studied this question in the 
growing subgroup of exposed children with ASD, who frequently use other psychotropic 
co-medications such as antidepressants or antipsychotics 17, which may further increase 
heart rate, QT interval, and consequently the risk of SCV events.
Given the uncertainty described above, which surrounds the relationship between SCV 
events and ADHD medications, plus the increasing number of children and adolescences 
with ADHD and ASD that are exposed, our study aimed to quantify this risk, in large 
cohorts, representative of these populations.
Methods
Study design and data
This was a retrospective, nested case-control study using the Truven Health MarketScan 
administrative insurance claims database. At the time of analysis, the full database 
contained billed records of care on 184 million commercially insured and 19 million 
3
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Medicaid insured individuals between calendar years 2000-2016 (with at least some 
coverage from each US state) and 2012-2016 (10-12 states), respectively.
Cohort selection and follow-up
From within the whole MarketScan database, we defined two main cohorts of interest: 
individuals with (a) ADHD (but not ASD) and (b) individuals with ASD (with or without ADHD). 
Eligibility requirements were: two or more claims for ASD or ADHD respectively; age between 
3 and 18 years; and individuals were excluded from the ASD cohort if they ever had any claim 
for Rett’s syndrome, to avoid possibly misdiagnosed cases 17–19. To avoid overlap between the 
two cohorts, individuals with ASD claims were removed from the ADHD cohort, but not vice 
versa. This decision was made because previous studies have shown over 1 in 3 autistic people 
have an ADHD comorbidity versus a lower proportion (around 1 in 8) of the ADHD population 
with comorbid ASD 20,21. We also excluded individuals with any previous SCV event of interest 
prior to diagnosis and start of follow up. Individuals in both cohorts were followed from first 
ASD diagnosis claim (minimum age of 3 years) until first SCV event, the end of database 
enrolment, or end of calendar year marking their 18th birthday, whichever occurred first.
Outcomes and case/control selection
From within each of the two cohorts, we conducted a nested case-control study. Cases 
were identified by the first inpatient primary diagnosis claim for any of the three secondary 
SCV outcomes, namely: (1) stroke, (2) MI, and (3) serious cardiac arrhythmia (SCA). SCA 
included cardiac arrest, complete atrioventricular block, and ventricular tachycardia, 
ventricular fibrillations or flutter. Definitions were based upon previously published studies 
and systematic reviews which show high positive predictive values (PPV >85%) 15,22–27. For 
each case we defined the index date as the date of the composite (first) event.
For each case, 10 controls were matched, randomly and without replacement, using 
the risk set sampling technique 28. Matching was based on age, sex, insurance type, and 
calendar time, so controls were assigned the same index date as their case. Finally, both 
cases and controls were required to have at least 30-days continuous enrolment in the 
database, directly prior to the index date. This was needed in order to establish baseline 
risk factors and to observe exposures.
Exposure definitions
Based on dispense date and days-supply, the primary exposure variable was defined as 
currently versus not-currently exposed to any ADHD medication on the index date. As 
per previous studies 15,23, current use was deemed to be the most etiologically relevant 
exposure as the half-life of stimulants/atomoxetine is short (hours opposed to days).
Statistical analysis
After matching, we used conditional logistic regression to perform the crude (matched) 
analysis. Beyond the crude analysis, a causal diagram was used to identify other covariates 
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to be included in a minimal adjustment set (see supplement S.3.1.1 and Greenland 
et al 29 and Textor et al 30 for diagram theory). We refer to this set as adjustment set 1, 
which included the concepts of underlying cardiovascular risk and healthcare resource 
use (HCRU). We defined underlying cardiovascular risk by taking prior record of the 
following comorbidities into account: congenital circulatory system disorders, congestive 
heart failure (CHF), essential hypertension, disorders of lipid metabolism, peripheral 
artery disease, asthma, chronic obstructive pulmonary disease (COPD), diabetes, and 
obesity 15,23. We approximated HCRU via presence/absence of a visit to the emergency 
department, cardiology specialist, behavioural therapist, inpatient visit for any reason, 
and the total number of medical claims pro-rated to the past year. When deriving these 
variables, we ignored data during the month prior to index, in order to avoid over-
adjustment bias by using data potentially collected post exposure. The total number of 
medical claims in the past year was pro-rated for individuals with less than 12 months 
prior follow up. Covariate adjustment was made by selecting a weighted subset of the 
controls that had characteristics most similar to the cases. To achieve optimal covariate 
balance between cases and controls, weights were assigned by a generalised boosted 
model algorithm 31, before unmatched logistic regression was applied to test the exposure-
outcome association.
Sensitivity analyses
We conducted two sets of sensitivity analyses and a post-hoc subgroup analysis. In the 
first sensitivity analysis, we adjusted exposure definitions to within 90-days and “ever use” 
prior to index. In the second sensitivity analysis, we additionally controlled for an expanded 
set of other covariates. Adjustment set 2 included all covariates from adjustment set 1 
as well as severe medical comorbidities, common psychiatric comorbidities, psychotropic 
medications, and beta-blocker use. Psychotropic and beta-blocker medication use were 
based on prescriptions in the 6-months prior to index. These covariates were selected a 
priori using potential confounders and clinical assumptions from the literature (but not 
using causal diagrams like adjustment set 1). Additionally, we adjusted for both adjustment 
sets via adjusted conditional logistic regression to test if model specification had an impact 
on findings.
Lastly, in a post-hoc subgroup analysis, we excluded cases and controls with either 
congenital circulatory system disorders, congestive heart failure, or any cardiology 
specialty visit in the past year (and their matched pairs). We also repeated crude and 
weighted analysis by individual endpoints (stroke, MI, SCA). Throughout, results were 
deemed statistically significant or not based upon 95% confidence intervals.
3
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A total of 2,240,774 children and adolescents were identified for the ADHD cohort 
and 326,221 were identified for the ASD cohort (Table 3.1.1). The ADHD cohort had 
1,531,687 (68.4%) males and the mean (standard deviation; SD) age at first ADHD claim 
was 11.1 (3.7) years. This cohort had 186 composite SCV events over a mean (SD) 2.66 
(2.11) years of at-risk time, resulting in an incidence rate (95% confidence interval; CI) of 
3.12 (2.70-3.60) per 100,000 person years. The ASD cohort had 262,434 (80.4%) males 
and the mean (SD) age at first ASD claim was 9.3 (4.4) years. This cohort had 48 composite 
SCV events over a mean (SD) 2.62 (2.14) years of at-risk time, resulting in an incidence 
rate (95% CI) of 5.62 (4.23-7.45) per 100,000 person years. The most common specific 
event in both cohorts was stroke, and MI was the rarest. See supplements S.3.1.2 and 
S.3.1.3 for full listings of events.
Table 3.1.1: Attrition table and selection of cohorts
ADHD ASD
At least 1 claim for ASD/ADHD at age at least 3 years 5,978,601 612,856
At least 2 claims for ASD/ADHD at age at least 3 years 4,428,572 452,851
Exclude individuals with claim for ASD (from ADHD 
cohort) and Rett’s syndrome (from ASD cohort)
4,211,082 451,832
Only include individuals enrolled for some time 
between ages 3-18 (inclusive) and first claim for ASD/
ADHD at age before 19 years
2,240,854 326,246
Exclude individuals with event of interest (stroke, 
myocardial infarction, serious cardia arrhythmia) prior 
to first ASD/ADHD diagnosis claim
2,240,774 326,221
Total SCV events 186 48
 Stroke 102 25
 Myocardial infarction 10 1
 Serious cardiac arrhythmia 75 22
Composite event was the main event of interest, defined as the first of individual events.
ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; SCV events = serious 
cardiovascular events.
Characteristics of cases and controls, selected from the ADHD and ASD cohorts based 
on the composite SCV endpoint, are presented in Table 3.1.2. We found 10 controls for 
each case as planned on the matching characteristics (age, sex, and insurance). Cases in 
both cohorts more often had underlying cardiovascular comorbidities and higher amounts 
of inpatient, emergency and cardiology resource use than controls. ADHD cases were on 
average slightly older at time of SCV event compared to ASD cases (mean 13.9 vs 12.5 
years) and received fewer psychotropic drugs. By design, none of the ADHD cases has 
comorbid ASD, but 9 (18%) of the ASD cases had comorbid ADHD.
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Demographics (initial matching criteria)
Female 53 ( 28.5) 530 ( 28.5) NA 10 ( 20.8) 100 ( 20.8) NA
Age in years (mean (SD)) 13.9 (3.4) 13.9 (3.4) NA 12.5 (4.4) 12.5 (4.4) NA
Age category in years NA NA
 3-4 0 (0.0) 0 (0.0) 4 ( 8.3) 40 ( 8.3)
 5-9 20 ( 10.8) 200 ( 10.8) 9 ( 18.8) 90 ( 18.8)
 10-14 78 ( 41.9) 780 ( 41.9) 15 ( 31.2) 150 ( 31.2)
 15-18 88 ( 47.3) 880 ( 47.3) 20 ( 41.7) 200 ( 41.7)
Medicaid 58 ( 31.2) 580 ( 31.2) NA 14 ( 29.2) 140 ( 29.2) NA
Capitated insurance 52 ( 28.0) 520 ( 28.0) NA 14 ( 29.2) 140 ( 29.2) NA
History of cardiovascular comorbidities
Congenital circulatory system 
disorders
29 ( 15.6) 20 ( 1.1) 0.544 9 ( 18.8) 11 ( 2.3) 0.557
Congestive heart failure 11 ( 5.9) 1 ( 0.1) 0.350 6 ( 12.5) 0 ( 0.0) 0.535
Essential hypertension 11 ( 5.9) 32 ( 1.7) 0.220 2 ( 4.2) 14 ( 2.9) 0.068
Disorders of lipid metabolism 5 ( 2.7) 30 ( 1.6) 0.074 2 ( 4.2) 9 ( 1.9) 0.134
Peripheral artery disease 3 ( 1.6) 1 ( 0.1) 0.172 1 ( 2.1) 0 ( 0.0) 0.206
Asthma 38 ( 20.4) 295 ( 15.9) 0.119 9 ( 18.8) 85 ( 17.7) 0.027
Chronic obstructive 
pulmonary disease
1 ( 0.5) 5 ( 0.3) 0.042 1 ( 2.1) 7 ( 1.5) 0.047
Diabetes 2 ( 1.1) 12 ( 0.6) 0.047 2 ( 4.2) 7 ( 1.5) 0.164
Overweight or obese 8 ( 4.3) 70 ( 3.8) 0.027 4 ( 8.3) 24 ( 5.0) 0.134
HCRU
1 or more emergency room visits 71 ( 38.2) 350 ( 18.8) 0.439 21 ( 43.8) 93 ( 19.4) 0.543
1 or more inpatient hospital visits 32 ( 17.2) 51 ( 2.7) 0.497 6 ( 12.5) 18 ( 3.8) 0.324
1 or more cardiology specialty visits 35 ( 18.8) 33 ( 1.8) 0.584 9 ( 18.8) 21 ( 4.4) 0.461
Received behaviour therapy 57 ( 30.6) 452 ( 24.3) 0.142 7 ( 14.6) 163 ( 34.0) 0.464
Days with any medical claim 
(mean (SD))
21.5 (31.6) 12.0 (22.4) 0.349 28.6 (39.3) 22.7 (33.7) 0.160
Psychiatric comorbidities
ADHD NA NA NA 9 ( 18.8) 191 ( 39.8) 0.475
Anxiety 31 ( 16.7) 231 ( 12.4) 0.121 10 ( 20.8) 107 ( 22.3) 0.035
Depression 31 ( 16.7) 215 ( 11.6) 0.147 5 ( 10.4) 54 ( 11.2) 0.027
Epilepsy 13 ( 7.0) 32 ( 1.7) 0.260 9 ( 18.8) 41 ( 8.5) 0.301
Sleep disturbances 13 ( 7.0) 95 ( 5.1) 0.079 6 ( 12.5) 31 ( 6.5) 0.207
Other serious medical conditions
Cancer 12 ( 6.5) 7 ( 0.4) 0.339 0 ( 0.0) 1 ( 0.2) 0.065
Renal disease 2 ( 1.1) 4 ( 0.2) 0.108 0 ( 0.0) 1 ( 0.2) 0.065
Liver disease 4 ( 2.2) 6 ( 0.3) 0.166 1 ( 2.1) 4 ( 0.8) 0.104
Human immunodeficiency virus 0 (0.0) 0 (0.0) NA 0 ( 0.0) 0 ( 0.0) NA
Psychotropic medications
Antidepressants 33 ( 17.7) 222 ( 11.9) 0.164 8 ( 16.7) 123 ( 25.6) 0.221
Antipsychotics 7 ( 3.8) 110 ( 5.9) 0.100 13 ( 27.1) 98 ( 20.4) 0.157
Anxiolytics/Sedatives/Hypnotics 4 ( 2.2) 38 ( 2.0) 0.008 6 ( 12.5) 14 ( 2.9) 0.365
Benzodiazepines 13 ( 7.0) 16 ( 0.9) 0.320 8 ( 16.7) 21 ( 4.4) 0.409
Beta-blockers 12 ( 6.5) 3 ( 0.2) 0.357 2 ( 4.2) 2 ( 0.4) 0.253
Results are n (%) unless stated otherwise. ADHD = attention-deficit/hyperactivity disorder; ASD = autism 
spectrum disorder; HCRU = healthcare resource use; NA = not applicable; SD = standard deviation; 
SMD = standardised mean difference between cases and controls
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Table 3.1.3 shows that for both ADHD and ASD, there was no increased risk of SCV 
events associated with ADHD medication use. For ADHD, the proportion of cases 
currently exposed was 33.9% (63 of 186 cases) versus 32.2% of controls (598 of 1,860 
controls). This translated to no association of ADHD medication use with SCV events in 
the crude analysis [odds ratio (OR) (95%CI) 1.08 (0.78-1.49)]. For ASD, the proportion 
of cases currently exposed was 12.5% (6 of 48 cases) versus 22.1% of controls (106 of 
480 controls). This also translated to no crude association of ADHD medication use with 
SCV events in the ASD cohort [OR (95%CI) 0.49 (0.20-1.20)].
Furthermore, based on the current exposure definition, and across both ADHD and ASD 
cohorts, all results statistically adjusted for covariates were consistent with these findings 
(Table 3.1.3). For weighted cohort characteristics, see supplements S.3.1.4 and S.3.1.5. 
After completely excluding individuals with underlying congenital circulatory system 
disorders, CHF, or recent cardiology visits, odds ratios were closer to a null association 
than in crude (and most adjusted) analyses.
Point estimates for associations between the outcomes and exposures were also stable 
(and without trend) regardless of the exposure definition used. Due to small sample sizes, 
some of the associated confidence intervals were wide, especially in the ASD cohort. 
There were no obvious differences in specific drugs or dosages used, between cases and 
controls nor ASD and ADHD (see supplement S.3.1.6). Finally, Table 3.1.4 demonstrates 
that crude and adjusted results based upon the individual outcomes (stroke, MI, SCA) 
were not materially different than those for the composite endpoint.
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Discussion
Results of this study indicate that there is no association between the use of ADHD 
medications and increased risk of SCV events in children and adolescents with ADHD and 
ASD. Strengths of our study lie in the large number of individuals observed (234 events 
in total vs 81 in the largest previous study with similar outcomes 15), representivity across 
all states of the US, and the objectivity of administrative claims data (e.g. no recall bias). 
Moreover, our results were stable across a series of sensitivity analyses, which adjusted 
for different covariates (demographics, resource use, comorbidities and concomitant 
treatment use) and used different statistical models. There was no increased risk found 
regardless of the timing of exposure, nor for any individual SCV events. Overall, in both 
cohorts, SCV events were extremely rare.
These findings are largely in line with former research. Indeed, seven of the nine previous 
studies included in a recent literature review also found no associations between 
stimulants and paediatric cardiovascular risk 14. This included three studies perhaps most 
comparable to ours, also based on US claims data and with similar outcome definitions 
15,16,32. Another study in claims data found no associations between current, former, or 
non-use of stimulants and cardiovascular-related hospitalisations and emergency room 
visits 33. The two studies with findings contrary to ours had different outcome definitions. 
Gould et al 34 took an unconventional approach in comparing cases of any unexpected 
deaths to victims of road traffic accidents, while Dalsgaard et al 35 analysed a cohort of 
children from Danish national data but used a much wider event definition that included 
any hospital contact for any cardiovascular reason. A study by Shin et al 36 found an 
increased association between methylphenidate use and arrhythmia among children and 
adolescents in Korea, but again, the definition of arrhythmia was also much wider and 
included less serious events. No consistent increased risks were found for MI, stroke, 
heart failure, or hypertension. These data, on the whole are consistent with a recent meta-
analysis of methylphenidate, atomoxetine, and/or placebo in controlled trials that showed 
a pre-post exposure elevation of systolic blood pressure and heart rate in children and 
adolescents, but no increase of serious cardiac adverse events 10. In general, these more 
minor cardiovascular effects during treatment with ADHD medications are thought to 
be manageable, although should not be underestimated 37. For consistency with above-
mentioned previous systematic reviews of ADHD medications on SCV events 13,14 as 
well as blood pressure and heart rate 9,10 we did not include guanfacine and clonidine 
as exposures in our analyses. However, given that these medications have been more 
recently been approved in some countries for treatment of ADHD, this could be an area 
for further research.
A novel aspect of our study is the contemporaneous nature of data used (up until the end 
of 2016). In contrast, the most recent data used by any of the studies included by the 
Zito and Burcu review 14 was from 2007, only one year after an FDA advisory committee 
3
545324-L-bw-Houghton
Processed on: 28-12-2020 PDF page: 116
116
Chapter 3.1
first advised for class-specific warning for stimulants and SCV risk to be introduced 12. 
Regardless of these policy statements or subsequent debate about limiting use in people 
with heart problems 38–40, inference from our study results remains the same compared 
to the majority of earlier observational studies: no association found between SCV events 
and ADHD medications. In any case, across both ADHD and ASD, cases were more likely 
to already have underlying serious cardiac conditions than controls, which may indicate 
the class wide warnings are not always followed.
The overall incidence rate of SCV events was extremely low. Our incidence rate estimate 
of 3.1/100,000 person years in the ADHD cohort is consistent with the rates observed 
in other cohorts that primarily comprised ADHD children and adolescents (3.1/100,000 
15 and 2.8/100,000 32). Underlying risk for the subgroup of children and adolescents with 
ASD in our study was slightly higher (5.6/100,000 person years), which may be partially 
explained by higher prevalence of other psychotropic drugs within this group 41. The lower 
point estimate for exposure-outcome relationship found in the ASD group may also be a 
consequence of their higher concurrent treatment use, with more caution exercised by 
prescribing doctors deciding if to suggest ADHD medication as an additional treatment, 
or not.
Designing this study presented different methodological considerations. Due to the 
expected rarity of events, we used a nested case-control study design to include as many 
events in the analyses as possible. However, this meant there was possibility of over-
adjustment via inclusion of post-exposure variables, and hence we emphasised results of 
the crude matched analyses. When we did adjust for covariates, we tried to mitigate the 
risk of over-adjustment by not counting medical diagnoses and HCRU variables within the 
month prior to index. Furthermore, as logistic regression adjustment for many covariates 
and small sample sizes is known to increase the chance of unstable results 42, we opted 
for a weighted analysis as our primary adjusted model. Attaching weights to observations 
from the control group, such that this group is more similar to the cases, is an extension 
of simple matching, with the same theoretical motivation. In matched cohort studies, 
propensity scores are commonly used to find suitable weights, but here we preferred 
the gradient boosted method because the algorithm directly assigns weights for optimum 
balance without need to model the propensity of group assignment in the first place. This 
has two advantages: firstly, that many covariates can be controlled for without considering 
the functional form of their relationships to each other and to group assignment 31, and 
secondly, that there are known difficulties in estimating propensity scores for case-control 
studies 43.
Other limitations of our study include the inability to confirm outcomes by linking claims 
data to medical records, or assessing medication adherence beyond prescription filing, 
however we expect such misclassifications to be few, non-differential between groups, 
and have little bearing on our results. The case-control design also limits interpretation 
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to the subgroup of ADHD and ASD children and adolescents reflective of those who 
experience SCV events. Confounding by contraindication means that cases with more 
severe underlying cardiac conditions and inpatient, emergency and cardiology resource 
use may actually have been least likely to receive ADHD medication, biasing results away 
from a positive association. Finally, despite controlling for many factors, it is possible that 
residual confounding remained, either through unobserved variables (e.g. diet/exercise) 
or limited detail in the database (e.g. severity of comorbid conditions). Such limitations are 
common to many epidemiological studies, but since the SCV event rate is low and ADHD 
medications are widely used, randomised studies to address this question are unpractical, 
and analysis of large-scale, real world observational data is meaningful and relevant.
In conclusion, in a large, contemporary insurance database, we found low rates of SCV 
events in children and adolescents with ADHD (3.1/100,000 person years) and ASD 
(5.6/100,000 person years). Furthermore, we found no evidence of an increased SCV 
risk when exposed to ADHD medications.
3
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S.3.1.1: Directed acyclic graph for the causal assumptions between exposure (ADHD 
medication), outcome (serious CV event), and possible confounders 
 
 
ADHD = attention-deficit/hyperactivity disorder. CV event = serious cardiovascular event.  
Underlying CV risk = risk from underlying comorbidities. 
HCRU = Healthcare resource utilisation, a proxy for general health status and propensity to use and claim for healthcare 
interactions. Insurance = commercial vs Medicaid and capitated vs fee-for-service plans. 
According to causal diagram theory and our diagram, the minimal efficient set of variables needed for adjustment was sex, 
age, insurance type, underlying CV risk, and healthcare resource utilisation (HCRU). While sex, age, and insurance type were 




ADHD = attention-deficit/hyperactivity disorder. CV event = serious cardiovascular event.
Underlying CV risk = risk from underlying comorbidities.
HCRU = He lthcare resource utilisat on, a proxy for general health status and propen ity to u e and 
claim for healthcare interactions. Insurance = commercial vs Medicaid and capitated vs fee-for-service 
plans.
According to causal diagram theory and our diagram, the minimal efficient set of variables needed for 
adjustment was sex, age, insurance type, underlying CV risk, and healthcare resource utilisation (HCRU). 
While sex, age, and insurance type were adjusted for by matching, underlying CV risk and HCRU were 
included in both covariate adjustments set 1 and set 2 (see methods).
545324-L-bw-Houghton
Processed on: 28-12-2020 PDF page: 121
121
ADHD Drugs and CV Safety in ADHD and ASD Children
S.3.1.2: Listing of serious cardiovascular events observed among cases in the ADHD cohort 
(n=186)
Stroke (n=102) n (%)
ICD-9-CM
431: Intracerebral hemorrhage 25 (13.4)
430: Subarachnoid hemorrhage 23 (12.4)
434.91: Cerebral artery occlusion, unspecified with cerebral infarction 19 (10.2)
434.11: Cerebral embolism with cerebral infarction 9 (4.8)
434.01: Cerebral thrombosis with cerebral infarction 3 (1.6)
433.11: Occlusion and stenosis of carotid artery with cerebral infarction 2 (1.1)




I61.1: Nontraumatic intracerebral hemorrhage in hemisphere, cortical 3 (1.6)
I63.8: Other cerebral infarction 3 (1.6)
I61.8: Other nontraumatic intracerebral hemorrhage 2 (1.1)
I63.9: Cerebral infarction, unspecified 2 (1.1)
I60.6: Nontraumatic subarachnoid hemorrhage from other intracranial arteries 1 (0.5)
I60.8: Other nontraumatic subarachnoid hemorrhage 1 (0.5)
I61.5: Nontraumatic intracerebral hemorrhage, intraventricular 1 (0.5)
I61.9: Nontraumatic intracerebral hemorrhage, unspecified 1 (0.5)
I63.10: Cerebral infarction due to embolism of unspecified precerebral artery 1 (0.5)
I633.11: Cerebral infarction due to thrombosis of right middle cerebral artery 1 (0.5)
I63.419: Cerebral infarction due to embolism of unspecified middle cerebral 
artery
1 (0.5)
I63.511: Cerebral infarction due to unspecified occlusion or stenosis of right 
middle cerebral artery
1 (0.5)
I63.512: Cerebral infarction due to unspecified occlusion or stenosis of left 
middle cerebral artery
1 (0.5)





410.71: Subendocardial infarction, initial episode of care 3 (1.6)
410.01: Acute myocardial infarction of anterolateral wall, initial episode of care 2 (1.1)
410.41: Acute myocardial infarction of other inferior wall, initial episode of care 2 (1.1)
410.11: Acute myocardial infarction of other anterior wall, initial episode of care 1 (0.5)
410.91: Acute myocardial infarction of unspecified site, initial episode of care 1 (0.5)
ICD-10-CM
I21.4: Non-ST elevation (NSTEMI) myocardial infarction 1 (0.5)
3
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S.3.1.2: Listing of serious cardiovascular events observed among cases in the ADHD cohort 
(n=186) (cont.) 
Serious cardiac arrhythmia (n=75)
ICD-9-CM
427.1: Paroxysmal ventricular tachycardia 35 (18.8)
426.0: Atrioventricular block, complete 10 (5.4)
427.41: Ventricular fibrillation 8 (4.3)
427.5: Cardiac arrest 8 (4.3)
427.42: Ventricular flutter 1 (0.5)
ICD-10-CM
I46.9: Cardiac arrest, cause unspecified 5 (2.7)
I47.2: Ventricular tachycardia 4 (2.2)
I44.2: Atrioventricular block, complete 2 (1.1)
I46.8: Cardiac arrest due to other underlying condition 1 (0.5)
I49.01: Ventricular fibrillation 1 (0.5)
n (%) are based on the n=186 composite events. One person had more than one event, namely a stroke 
(433.11) and serious cardiac arrhythmia (I47.2).ADHD = attention-deficit/hyperactivity disorder.
ICD-CM = International Classification of Diseases, Clinical Modification (version 9 and version 10 
used).
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S.3.1.3: Listing of serious cardiovascular events observed among cases in the ASD cohort 
(n=48)
Stroke (n=25) n (%)
ICD-9-CM
434.91: Cerebral artery occlusion, unspecified with cerebral infarction 8 (16.7)
431: Intracerebral hemorrhage 5 (10.4)
430: Subarachnoid hemorrhage 4 (8.3)
434.01: Cerebral thrombosis with cerebral infarction 1 (2.1)
434.11: Cerebral embolism with cerebral infarction 1 (2.1)
ICD-10-CM
I61.1: Nontraumatic intracerebral hemorrhage in hemisphere, cortical 1 (2.1)
I61.5: Nontraumatic intracerebral hemorrhage, intraventricular 1 (2.1)
I63.132: Cerebral infarction due to embolism of left carotid artery 1 (2.1)
I63.232: Cerebral infarction due to unspecified occlusion or stenosis of left carotid 
arteries
1 (2.1)
I63.49: Cerebral infarction due to embolism of other cerebral artery 1 (2.1)





410.41: Acute myocardial infarction of other inferior wall, initial episode of care 1 (2.1)
Serious cardiac arrhythmia (n=22)
ICD-9-CM
427.1: Paroxysmal ventricular tachycardia 8 (16.7)
427.5: Cardiac arrest 5 (10.4)
427.41: Ventricular fibrillation 3 (6.3)
I46.9: Cardiac arrest, cause unspecified 2 (4.2)
I47.2: Ventricular tachycardia 2 (4.2)
I44.2: Atrioventricular block, complete 1 (2.1)
I46.2: Cardiac arrest due to underlying cardiac condition 1 (2.1)
n (%) are based on the n=48 composite events. ASD = autism spectrum disorder.
ICD-CM = International Classification of Diseases, Clinical Modification (version 9 and version 10 used).
3
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S.3.1.6: Specific ADHD medications and mean doses currently prescribed to cases and controls 











 Currently exposed (n, %) 2 ( 1.1) 44 ( 2.4) 0 ( 0.0) 12 ( 2.5)
 Dose, mg/day (mean, SD) 60.00 (28.28) 45.84 (22.23) NA 55.14 (28.10)
Amphetamine
 Currently exposed (n, %) 17 (9.1) 138 (7.4) 1 ( 2.1) 15 ( 3.1)
 Dose, mg/day (mean, SD) 22.21 (16.00) 24.03 (13.85) 10.00 (NA) 19.29 (10.72)
Dexmethylphenidate
 Currently exposed (n, %) 7 ( 3.8) 59 ( 3.2) 3 ( 6.2) 11 ( 2.3)
 Dose, mg/day (mean, SD) 12.86 (4.88) 16.43 (9.89) 27.50 (17.68) 15.23 (8.25)
Lisdexamfetamine
 Currently exposed (n, %) 8 ( 4.3) 121 ( 6.5) 1 ( 2.1) 24 ( 5.0)
 Dose, mg/day (mean, SD) 41.25 (11.26) 41.73 (17.50) 30.00 (NA) 39.59 (19.88)
Methylphenidate
 Currently exposed (n, %) 28 (15.1) 232 (12.4) 1 (2.1) 44 (9.1)
 Dose, mg/day (mean, SD) 36.54 (18.67) 35.71 (18.69) 10.00 (NA) 34.55 (17.98)
Dextroamphetamine was the other stimulant prescribed; to 5 individuals with ADHD (1 case and 4 controls).
ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; NA = not applicable; 
SD = standard deviation.
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The Autism impact measure (AIM) is a caregiver-reported questionnaire assessing autism 
symptom frequency and impact in children, previously shown to have good test–retest 
reliability, convergent validity and structural validity. This study extended previous work 
by exploring the AIM’s ability to discriminate between “known-groups” of children, and 
estimating thresholds for clinically important responses. Data were collected online and 
electronically on computer and mobile devices; hence, it was also possible to confirm 
other psychometric properties of the AIM in this format. This study provides confirmatory 
and additional psychometric validation of the AIM. The AIM offers a valid, quick and 
inexpensive method for caregivers to report core symptoms of autism spectrum disorder 
(ASD) including communication deficits, difficulties with social interactions and repetitive 
behaviours.
Lay summary
The Autism impact measure (AIM) is a caregiver-reported questionnaire to assess autism 
symptom frequency and impact in children. This study showed the AIM is a valid tool, 
which can be quickly completed by caregivers on computer and mobile devices.
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Psychometric validation of the Autism Impact Measure (AIM)
Introduction
The Autism Impact Measure (AIM) is a caregiver-reported questionnaire, designed to 
be used in clinical trials and clinical practice to assess effectiveness of interventions in 
Autism Spectrum Disorders (ASD) 1,2. It consists of 41 items, and each is rated on a 5-point 
Likert-type scale for both frequency and impact. Caregiver-reported clinical outcome 
assessment measures such as the AIM may have some advantages over established 
interview-administered measures in that they are often less time consuming and do 
not need specifically trained personnel to administer. As a result, the AIM could also 
potentially serve as suitable tool for real world monitoring of ASD symptoms, embedded 
in more routine care or remote settings. Additional advantages of the AIM are that other 
commonly used scales have either been created for diagnostic purposes only (e.g. Autism 
Diagnostic Observational Scale: ADOS 3), were developed and tested according to older 
and more narrow definitions of ASD (e.g. Behavioral Summarized Evaluation Scale: BSE 4 
and Real Life Rating Scale: RLRS 5) or focus on non-core or not all core characteristics (e.g. 
Social responsiveness scale: SRS-2 6). The AIM, in contrast, has been shown to exhibit 5 
“theoretically and empirically meaningful” symptom domains, namely; Repetitive Behavior, 
Communication, Atypical Behavior, Social Reciprocity and Peer Interaction 2. The domain 
scores utilise only 29 of the 41 items, while the total score still builds on all items. Higher 
domain and total scores represent worse severity of ASD symptoms.
While the AIM has shown to have good test-retest reliability, cross-informant reliability 
and convergent validity with other scales 1,2, other important validation questions 
remain untested. Importantly, the ability of the AIM to detect differences between 
known subgroups of individuals with ASD has not been demonstrated. Known-group 
analysis is needed to demonstrate that a measure is sensitive and able to discriminate 
between subgroups previously established to have differences in severity. Furthermore, 
there has been no attempt to estimate magnitudes of such differences that constitute 
clinically meaningful changes. Successful validation of these two concepts is fundamental 
for confidence to use the AIM in any study wishing to demonstrate efficacy of a given 
intervention. Therefore, the primary objective of our study was to address these gaps in 
a large and representative sample. Also, because participants in our study completed the 
questionnaire electronically, rather than on paper, secondary objectives were to assess the 
time needed to complete the AIM and confirm other measures of psychometric validity 
in this format, including internal/external validity and confirmatory factor analysis.
Methods
Data Collection
Participants were invited to take part in our study via the Simons Foundation Powering 
Autism Research for Knowledge (SPARK) cohort. SPARK is an online community for 
4
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people with ASD and their families in the United States (US), who are interested in 
participating in ASD research 7. Families complete a battery of questionnaires on entry 
to the cohort, and third-party researchers (industry or academic) can recruit the same 
families to their studies thereafter. All data generated are anonymised and made linkable 
via unique identifiers. To be eligible for the current study, participants had to be the main 
caregiver living in the same household as a child with ASD, and were instructed to answer 
the AIM in relation to only the oldest child with ASD between 3-17 years. All data used 
for the study were provided by caregiver-report and were collected during September 
and October 2017 as part of a wider study on non-drug treatments and potential barriers 
to care. Details on recruitment and data collection have been published elsewhere 8. 
Informed consent was obtained from all individual participants included in the study. The 
study protocol was approved by Western IRB.
Analysis Populations
In total, 5,001 participants returned the AIM survey. As the current AIM scoring system 
does not mention methods for handling missing data, our main analysis population of 
interest was those 4,415 participants who completed all items. We qualitatively checked 
for differences in characteristics of those who did not complete all items however, as well 
as between those who took part on either a vertical or horizontal layout. In the horizontal 
layout, possible responses to each item were displayed “across” the screen. In the vertical 
layout the possible responses were displayed “down” the screen (i.e. underneath one 
another). The format deployed was based on the screen dimensions of the device used 
to complete the survey (e.g. vertical layout for most mobile phones and horizontal layout 
for laptops/computers).
A subgroup of respondents had also previously completed the Social Communication 
Questionnaire-Lifetime (SCQ) 9,10 and/or the Repetitive Behaviors Sale-Revised (RBS-R) 
11 as part of the SPARK procedures. We linked this data for convergent validity analysis 
so long as the age of the child differed by no more than 1 year between the time of AIM 
assessment and the time of SCQ/RBS-R (exact date of SCQ/RBS-R was unknown). Linked 
sample sizes available were 3,064 for the SCQ and 3,190 for the RBS-R. There was a 
significant overlap of 2,571 participants who completed all of AIM, SCQ and RBS-R.
Descriptive analysis
We calculated the mean and median score for all items in order to identify items with 
higher or lower than average impact and frequency and to assess response distributions. 
For the purposes of this descriptive analysis, we highlighted items with 50% or more of 
responses at the lowest or highest possible values as the cut-off value for which some 
items might be considered to show floor or ceiling characteristics, respectively. We also 
assessed missingness for each item and the time taken to complete the AIM. All descriptive 
analyses were also stratified by vertical/horizontal format.
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Internal consistency
To measure consistency of underlying concepts, Cronbach’s alpha 12 was calculated for 
each of the domain scores. We specified a threshold of ≥ 0.7 13 to identify domains with 
a good internal consistency. Similarly, we also calculated Cronbach’s alpha for total AIM 
score and total scores based on just frequency items or impact items in order to assess 
whether AIM items contributing to a specific score measured the same construct. We 
calculated inter-domain correlations using Spearman’s correlation coefficient.
Convergent validity
Pearson correlation coefficients were derived to assess the correlations between total 
SCQ and total AIM scores, as well as between the total SCQ and different domains of the 
AIM, and the domain scores of both. This approach was repeated for the RBS-R scores. 
For the SCQ, three domain scores were derived from item responses as per the SCQ 
scoring manual 10. The domains are Reciprocal Social Interaction, Communication and 
Repetition/Stereotyped Behavior. For RBS-R, factor analysis supports a total score, but 
also 2-, 3-, 4-, 5- and 6-factor solutions for domain-level scores, but this study utilised 
the 3-factor solution, which appears to have the most relevant conceptual structure 11: 
Stereotypy Restricted; Self-injurious; Compulsive, Ritualistic, Sameness.
We expected at least a moderate correlation (>0.3) between the total SCQ/RBS-R and 
total AIM scores, as well as between the total SCQ/RBS-R and each of the AIM domain 
scores. Those domains for which we hypothesised the highest correlations (>0.5) have 
been marked alongside the results for all domains in Table 4.1.3. Our hypotheses were 
based on domains which were conceptually related. Post-hoc, we recalculated correlations 
between SCQ and AIM communication domains within certain subgroups. The subgroups 
of interest were ASD individuals who were verbal or non-verbal only, as this limits the 
scoring range of the SCQ communication domain score, as well as those aged 4-5 years 
old, as this is the age range asked to focus on for half of the items of the SCQ: the other half 
have a lifetime perspective, e.g. “ever had” 10. In comparison, the RBS-R has no specified 
recall period and the AIM has a two-week recall period.
Factor analysis
We summed frequency and impact scores for each of the 29 items which are needed to 
create the 5 domain scores proposed by the scale developers 2. We then fitted a 5-factor 
solution on those 29 items with Varimax rotation. Finally, we compared items with highest 
loadings on each factor in our solution, with the domains proposed. The purpose of our 
factor analysis was only to confirm the five domains suggested by the developers rather 
than to explore other potential factor solutions.
4
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Based on previous literature and clinical knowledge, pre-specified “known-groups” were 
defined based on the following variables: (1) IQ score 14,15; (2) proportion of school-time 
spent with typically developing peers 16,17; (3) presence/absence of psychiatric comorbidity 
18; (4) received speech and language therapy (SLT) in the preceding 12-months (particularly 
relevant for communication domain); (5) caregiver reported overall health status of child 
(expected to be correlated with ASD severity if caregiver deems ASD symptoms relevant 
to overall health); (6) children who qualified for Medicaid despite family income greater 
than $75,000 per annum (to identify the subgroup who were Medicaid-eligible based 
on severity opposed to financial circumstance); (7) the number of non-drug therapies 
received for ASD in last 12 months 16,17; (8) medication prescribed for ASD (assuming 
prescriptions are made for individuals with more severe symptoms, on average); (9) verbal/
non-verbal ability (based on item 1 of the SCQ). More detailed definitions of these known-
groups are provided in Table 4.1.1.
We summarised mean and median scores within each level of each known-group and 
conducted analysis of variance (ANOVA) to see if those differences were statistically 
significant (p<0.05). We produced both crude and age-adjusted ANOVA results based 
on the total AIM scores, total frequency/impact scores and individual domain scores.
The range of possible scores for the total AIM was 82-410. For both frequency and impact 
domains the possible range was 41-205. For each of the domains, the possible ranges 
were: 16-80 for Repetitive Behavior; 12-60 for Communication; 12-60 for Atypical 
Behavior; 10-50 for Social Reciprocity; 8-40 for Peer Interaction.
Clinically important responder (CIR) estimates
As data were collected cross-sectionally we estimated clinically important responder (CIR) 
thresholds 19 for the total AIM scores and domain scores using distribution-based methods. 
Specifically the estimates were based on one-fifth and one-half of standard deviations 20,21. 
Prior to generating estimates, we rescaled the maximum range of total and domains scores 
to 0-100 points. This was done in order to make the magnitude of CIR estimates easier to 
compare across domains. For completeness we also presented CIR estimates based on raw 
scores, and we repeated the analysis by age and IQ strata to check for homoscedasticity.
Results
Cohorts and descriptive analysis
Figure 4.1.1 and Table 4.1.1 display the flow chart of key study groups and their 
characteristics, respectively. The majority of participants completed all items (n=4,415; 
88.3%). This “completers” group was used as the main analysis group. Around two-thirds 
of completers (66.4%) took part in the AIM in vertical layout.
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Figure 4.1.1: Flow chart of analysis populations
130 
 
                
IQ ≤70 390 3.30 - 8.25 3.10 - 7.76 3.91 - 9.78 4.40 - 11.01 4.67 - 11.68 4.41 - 11.03 3.41 - 8.52 
IQ 71 - 99 489 2.88 - 7.19 2.80 - 7.00 3.30 - 8.25 4.03 - 10.07 3.73 - 9.32 3.76 - 9.39 3.39 - 8.47 
IQ ≥100 670 2.92 - 7.29 2.88 - 7.19 3.30 - 8.26 4.09 - 10.22 3.11 - 7.78 4.00 - 10.01 3.29 - 8.21 
AIM: Autism Impact Measure. Estimates for clinically important responses (CIR) are 0.2 - 
change across the full range of possible scores.  








* One respondent had an unidentified screen size. AIM: Autism Impact Measure. 
For convergent validity: SCQ 
available (n=3,064) 
Submitted AIM (n=5,001) Vertical format [n=3,090 (61.8%)] * 
Horizontal format [n=1,910 (38.2%)] * 
Vertical format [n=2,933 (66.4%)] * 
Horizontal format [n=1,481 (33.5%)] * 
Main analysis population: completed all 
items (n=4,415)  
For convergent validity: RBS-R 
available (n=3,190)   
* One respondent had an unidentified screen size. AIM: Autism Impact Measure.
Respondents with complete AIM were mainly mothers (92.7%) with a mean (SD) age 
38.74 (7.20) years. All 50 states of the US were represented as well as some overseas 
territories. Children with ASD had a mean (SD) age of 9.01 (3.90) and were mainly male 
(79.9%). Almost a quarter of children (23.1%) attended full time special education school, 
while 45.2% spent between 60-100% of school time with typically developing peers. 
Of those with SCQ available, 83.5% were verbal (according to item 1 of the SCQ). The 
only qualitatively notable difference between caregivers who used the vertical instead of 
horizontal format was their slightly younger mean age (37.7 vs 40.8 years). Furthermore, 
there were no notable differences for completers, non-completers, and those which had 
SCQ and/or RBS-R data available for linkage.
The median time to complete the AIM was 7.08 minutes [IQR 5.53 - 9.82]. The mean time 
was just over one minute faster for completers on the horizontal format (median [IQR] 
6.28 minutes [4.90 - 8.63]) versus the vertical format (median [IQR] 7.47 minutes [5.97 
- 10.45]). A minority (4.1% in both vertical and horizontal format) took over one hour to 
complete all questions.
Item level analysis
Full item level analyses are summarised in supplement S.4.1.1. Responses to most items 
were approximately normally distributed. None of the items had a ceiling effect, but 5 had 
a floor effect which was defined by a median response of 1. Namely these items were: 
Q3 “lined things up” [impact only, repetitive behavior domain]: Q5 “used hand over hand” 
[frequency and impact; communication domain]: Q27 “used made-up or private language” 
[frequency and impact; communication domain].
Disregarding missing values, the item with highest (most severe) mean score (3.90) was 
Q38 “engaged in chit-chat [frequency; Social Reciprocity domain]. Furthermore, the top 
4
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5 highest scoring items were all frequency questions and only 3 of the top 20 highest 
scoring (mean ≥ 3.02) were impact questions. Only 2 of the 20 lowest scoring items (mean 
≤ 2.28) were frequency related. Mean scores for each item were not systematically higher 
or lower based on the vertical or horizontal layout.
Overall, there was very little missing data on an item-by-item basis. Some questions had 
as little as 10 missed responses from the whole sample (0.20%). Q36 “showed interest 
in others” [impact] was most frequently missed but still only for 76 participants (1.52%). 
All items were more often missing on the horizontal format, however with 2.46% being 
the highest rate of missing data in this layout (Q36 impact). In general, impact questions 
were more commonly missing than frequency questions.
Internal consistency
Cronbach alpha for the total AIM score was 0.96, which is well above the threshold 
of 0.7, which we pre-specified would identify scores with a good internal consistency. 
Frequency items and impact items also showed high internal consistency (0.96 and 0.95 
respectively), as did each of the individual domains (from 0.79 for Social Reciprocity to 
0.91 for Communication). The median (IQR) of all inter-item correlations was r=0.15 (0.22 
- 0.30) and only the correlation between frequency and impact scores for Q6 “problems 
with speech” was higher than 0.90. These results indicate little item redundancy.
All domains were positively and moderately inter-related according to Spearman’s rank 
coefficient (Table 4.1.2). The weakest relationship was between Repetitive Behavior and 
Social Reciprocity (0.39). The strongest relationship was between Repetitive Behavior 
and Atypical Behavior (0.67). Domain correlations were very similar with both Spearman 
and Pearson correlation methods, indicating that relationships between domain scores 
were linear.









Repetitive Behavior - 0.52 0.67 0.39 0.43
Communication - 0.45 0.54 0.48
Atypical Behavior - 0.51 0.58
Social Reciprocity - 0.63
AIM: Autism Impact Measure.
545324-L-bw-Houghton
Processed on: 28-12-2020 PDF page: 165
165
Psychometric validation of the Autism Impact Measure (AIM)
Convergent validity
The total AIM score showed good convergent validity with the total SCQ score (r=0.55, 
Table 4.1.3). Each individual AIM domain was also positively correlated (r≥0.34) with the 
total SCQ score. As hypothesised, the SCQ Reciprocal Social Interaction domain has 
highest correlations with the AIM Social Reciprocity (0.48) and Peer Interaction (0.45) 
domains. Also as expected, the SCQ Repetition/Stereotyped Behavior domain had the 
strongest relationship with AIM domains of Repetitive Behavior (0.48) and Atypical 
Behavior (0.34). None of the SCQ-AIM domain-domain relationships met the threshold 
of 0.5 however, and specifically against our expectations, the SCQ Communication domain 
was least correlated with the AIM Communication domain (0.18). In sensitivity analyses, 
this correlation was raised to 0.34 in verbal children and 0.25 in non-verbal children. 
When restricting to a 4 to 5 years old age-range, the correlation was 0.19.
The RBS-R total score had a strong positive correlation with the total AIM score (0.64). 
It also had good correlation (≥0.30) with all AIM domains, frequency and impact scores. 
Furthermore, for the RBS-R and AIM, all domain-domain correlations were positive, and 
were strongest (between 0.51 and 0.74) in the 4 pre-hypothesised cases. Results for both 
SCQ and RBS-R remained stable when restricting the analysis population to those children 
who were exactly the same age (in years) at the time of SCQ/RBS-R and AIM (opposed 
to within 1-year, as per main analyses; see supplement S.4.1.3).
Factor analysis
Table 4.1.4 provides a detailed comparison of the proposed factors 2 and factors found 
in our confirmatory analysis. The Communication domain was replicated perfectly in 
our data. The proposed six items for this domain all loaded highest on the third factor 
produced by our data and no other item loaded highest on this same factor. Other well 
pronounced and well reproduced latent concepts were Repetitive Behavior and Social 
Reciprocity. All items proposed for these domains loaded highest on factor 1 and factor 
2 in our data, respectively. The only additional item with highest loading on factor 2 
was Q32 “had positive response to approach”, which was supposed to be part of the 
Peer Interaction domain. Q32 also had a high loading on factor 4 however, and factor 4 
otherwise only had highest loadings of the other 3 of the 4 items representing the Peer 
Interaction domain. Hence, Peer Interaction was also well reproduced as a latent variable. 
Finally, 3 of the 6 items expected to load together to form the Atypical Behavior domain 
indeed did load together in a distinct fifth factor. The other three items however loaded 
highest on factor 1, showing some similarity with the Repetitive Behavior concept. The 
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For the patients who completed all items, the mean (median) total AIM score was 220.8 
(219). In general, frequency items received higher scores than impact items [119.9 (120) 
vs 100.9 (99)]. Mean and median scores for the five domains were; Repetitive Behavior: 
41.3 (40); Communication: 30.7 (28); Atypical Behavior: 34.8 (35); Social Reciprocity 27.1 
(27); Peer Interaction 22.9 (23). All of the above summary scores were approximately 
normally distributed.
Mean scores for total AIM, frequency, impact and all domains increased monotonically 
from high IQ to low IQ. These associations of low IQ and greater ASD severity were 
statistically significant in ANOVA analysis (p<0.01 in all domains). AIM scores were 
similar between those in full time special education and those who spent less than 30% of 
school-time with typically developing peers. Otherwise, AIM scores increased with higher 
proportion of special-education activity and all differences were statistically significant 
(p<0.01).
Other “known-groups” were binary-categorised. Both total AIM score (Figure 4.1.2) and 
impact score (supplement S.4.1.5) were able to differentiate between all pre-defined 
known-groups (p<0.01). All such associations were directionally as expected, with higher 
scores in the group expected to have more severe ASD. The largest difference in mean 
total AIM score was between verbal and non-verbal children (257 vs 214, respectively). 
The frequency score also differentiated between all known groups (p<0.01) except for 
those children with or without another psychiatric comorbidity (p=0.41, supplement 
S.4.1.4). Mean scores for the Communication (Figure 4.1.3) and Peer Interaction 
(supplement S.4.1.9) domains were significantly different (p<0.01) between levels of 
all 9 pre-defined known-groups. Repetitive Behavior, Social Reciprocity and Atypical 
Behavior domains significantly (p<0.01) distinguished between levels of 8, 8 and 7 of the 
9 known-groups respectively, too (see supplements S.4.1.6-S.4.1.8). None of the results 
for known-groups were altered by adjusting for age, i.e. p-values always remained stable 
(either ≥ 0.05, between 0.01 and 0.05, or <0.01). Results for a total AIM score based on 
only 29 items were very similar to those based on all 41 items.
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Figure 4.1.2: Mean Total AIM score by known-groups
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Fig re 4.1.2: Mean Tot l AIM score by known-g oups 
 
 
AIM: Autism Impact Measure. TD: typically developing peers, rx: prescription, SLT: Speech and language therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 



















































































































































































































AIM: Autism Impact Measure. TD: typically developi g peers, rx: presc iption, SLT: S ch and lang age 
therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 of SCQ. 
Significant differences observed across all known-groups (p<0.01 in both crude analysis and analyses 
adjusted for age). Higher scores represent higher symptom burden.
Figure 4.1.3: Mean AIM Communication domain score by known-groups
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igure 4.1.3: Mean AIM Communication domai  score by known-groups 
 
  
AIM: Autism Impact Measure. TD: typically developing peers, rx: prescription, SLT: Speech and language therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 































































































































































































AIM: Autism Impact Measure. TD: typically developing peers, rx: prescription, SLT: Speech and language 
therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 of SCQ. 
Significant differences observed across all known-groups (p<0.01 in both crude analysis and analyses 
adjusted for age). Higher scores represent higher symptom burden.
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Clinically important response estimates
For the total AIM score, the CIR estimate ranged from 3.30% to 8.25% (Table 4.1.5). This 
corresponded to a change of between 10.8 and 27.1 points on the raw scale (supplement 
S.4.1.2). The CIR estimate range for the frequency score was between 3.21% and 8.04% 
and between 3.74% and 9.34% for the impact score. Of the domains, Social Reciprocity 
had the least variability and hence the smallest estimates for the CIR (3.67% to 9.16%). 
All other domains had CIR estimates ranging between 4.20% and 4.96% at the lower end, 
and between 10.49% and 12.41% at the upper end.
The largest change in variability across strata was for the Communication domain and 
IQ level. CIR estimates decreased monotonically from low to high IQ (11.69% for IQ<70, 
7.78% for IQ>100; upper estimates). This corresponded to a 3.7 to 5.6 point difference 
on the raw scale (in which a maximum change of 48 points is possible). This example aside, 
the data had stable variance across IQ and age ranges, because estimates of variability 
were generally only slightly higher in the groups with smallest sample size (IQ <70 and 
age 15-17 years). Generally, variance was slightly smaller within children of similar IQ, 
rather than of similar age.
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To our knowledge, this study represents the largest fielding of the AIM to an ASD 
population to date. Our main findings were the estimates of thresholds of clinical 
importance and the ability of the AIM to separate known groups of children with ASD. 
We also believe our study represents the first investigations of these concepts for the 
AIM. Overall, the CIR for the total AIM score was estimated to be in the range of 3.30% 
to 8.25%, corresponding to 10.8-27.1 points of the full 82 to 410 score range. Total AIM 
scores and most domain scores were generally homogeneous across age and IQ strata, 
with the only marked exception being that there was more variation in communicative 
abilities of children with low IQ. Of 9 pre-defined known-groups, the AIM total score 
statistically differentiated all of them. Mean scores on each of the domains separated 
almost all known-groups too. Moreover, according to the lower bound for CIR estimates 
from above, the majority of these differences represented clinical meaningfulness. Even 
for the Communication domain, which had the largest CIR estimates relative to scale, 
the lower estimate (5.0%) was surpassed in all but one of the known-groups (yes/no to 
current prescription drug for ASD). The more stringent upper estimate of 12.4% was even 
achieved in 4 of the 9 known-groups. Namely these groups were: school time with typically 
developing peers, IQ strata, verbal ability and participation in SLT. In all, these results do 
provide some confidence that the AIM should be able to respond to symptom changes 
over time. However, it is uncertain whether any intervention (pharmacological or non-
pharmacological) could change such fundamental personal characteristics as represented 
by our known-groups. Likely our lower estimates for CIR are a most reasonable goal. A 
limitation of the CIR results is that only distribution-based estimates were generated 
due to a lack of follow-up data and an appropriate anchor, such as caregiver reported 
assessment of change. Therefore, further evaluation is required to test empirically the 
estimates generated.
Our sample, on the whole, was very similar to those used in previous AIM studies 1,2, in 
that respondents were mainly mothers of the child with ASD (around 90%), and families 
lived at various locations across the US. Children with ASD in each study were mainly 
male (between 80%-84%) and of similar age (between 2-14, 2-16, or 3-17 years). A key 
difference however, was that we fielded the AIM electronically, rather than on paper. We 
used this opportunity for secondary objectives of retesting other psychometric properties 
of the AIM in this format.
Importantly, there were no striking differences in the characteristics of participants 
or their responses, based on if they used the vertical or horizontal version of the 
questionnaire. Our data in the most part also confirmed the suitability of an underlying 
5-factor structure of the AIM proposed by Mazurek et al 2. Items proposed for the 
Repetitive Behavior, Communication, and Social Reciprocity domains all loaded highly 
and separately from each other. These first 3 domains accounted for almost 40% of the 
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variability in our data: impressive, given the heterogeneity of symptoms on the autism 
spectrum. In addition, the magnitude of variability explained by each of these domains 
was almost equal (11-15% each) and in line with the three core symptoms of ASD.
External convergent validity of the AIM total scores and most domain scores was also 
demonstrated. Specifically, both Repetitive Behavior and Atypical Behavior correlated 
highly (r>0.50) with the RBS-R domains of similar concepts. This is despite the RBS-R 
having no specific recall period, but the AIM having a two-week recall. Correspondence of 
the AIM to the SCQ total score was also high. Four out of 5 domain-domain relationships 
that were expected to generate the highest correlation coefficients did exactly that, 
albeit not to the extent hypothesised (r=0.34 to 0.48). Only the relationship between 
AIM Communication and SCQ Communication domains were at odds to the expected. 
The correlation was still positive but of modest magnitude (r=0.18). Sensitivity analysis 
in children aged 4-5 years – which is the age range asked to focus on for some items of 
the SCQ 10 - did not improve this (r=0.19). Nonetheless, the AIM Communication domain 
does represent a clear latent variable, given the perfect representation of this domain 
mentioned in factor-analysis results above. One explanation is that the AIM and SCQ 
Communication domains measure subtly different concepts. AIM Communication items 
mainly already assume verbal ability with some questions relating to concepts like made-
up languages, use of pronouns, and reciprocal communication. In contrast some SCQ items 
relating to communication are specifically omitted for non-verbal children 10. An alternative 
explanation is that the AIM directs caregivers to recall symptom severity over the last two 
weeks, whereas SCQ items have a lifetime perspective. A limitation of this study is that the 
SCQ and RBS-R surveys were not taken at the same time as the AIM, hence it is difficult 
to evaluate if non-concordance is due to differences in conceptual constructs or is due 
to actual differences in symptom severity at time of survey completion. Another more 
general limitation of the study is that all data are caregiver-reported and therefore some 
demographic and personal characteristics (e.g. IQ score) may be based on estimates only.
Future research and use of the AIM
Our CIR estimates above can be used to inform studies wishing to use the AIM in the near 
future. Better still would be to have repeated follow up in the same patients in order to 
also estimate CIR based on anchor based approaches 22,23. This is a possibility, as all data 
from this current study will be made available via SPARK.
Missing data was slightly more common in the horizontal layout and for impact questions 
but otherwise was seldom and unsystematic. The most commonly skipped item was 
only done so by 1.52% of respondents, but overall we had to exclude around 10% of 
the sample, as the developers currently offer no advice on dealing with missing data 1,2. 
Given our findings that missing item level data is infrequent, that the AIM has good internal 
consistency (a=0.96), and that most items are normally distributed, we recommend 
imputing missing items by multiple imputation (perhaps only excluding some observations 
4
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with missing data above a pre-defined threshold value of e.g. 20%). This approach has 
worked well for the AIM elsewhere 8.
Throughout our analysis, the Frequency and Impact summary scores also displayed 
good psychometric properties. This means that in addition to total and domain scores, 
future researchers could use the summed Frequency or Impact scores, depending on 
their specific question. In particular, the Frequency score might be more useful, because 
Impact may be more easily affected by other things than interventions, such as coping 
mechanisms built into everyday life. Furthermore, if an items frequency score is low, then 
the impact question may become redundant.
Electronically reported outcome measures have added benefits over paper-based 
measures. These include the avoidance of data entry errors, increased willingness of 
respondents to share sensitive information, and quicker access to this data for research 24. 
Electronic measures can also be completed remotely. A clear advantage of the AIM, is the 
limited time needed to complete it (median time: 7 minutes). This coupled with high overall 
participation rate in our study 8 demonstrates that caregivers are comfortable completing 
the AIM in such a way. This means that the AIM could potentially enable cheaper and 
low burden monitoring of severity changes as well as effectiveness of interventions in a 
real-world setting.
Conclusion
Our study provides estimates of thresholds of clinical importance for the AIM, as well 
as some indication that the AIM can distinguish between known groups of children 
with ASD. Our results also confirm the validity of the AIM based on other important 
psychometric properties. When administered electronically, the AIM offers a quick and 
relatively inexpensive method for caregivers to report core symptoms of children with 
ASD, including communication deficits, difficulties with social interactions and repetitive 
behaviours.
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Psychometric validation of the Autism Impact Measure (AIM)
S.4.1.4: Mean AIM Frequency score by known-groups
AIM: Autism Impact Measure. TD: typically developing peers, rx: prescription, SLT: Speech and language 
therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 of SCQ. 
Significant differences observed across all known-groups (p<0.01 in both crude analysis and analyses 
adjusted for age), except for mental comorbidity vs no mental comorbidity (p=0.41, adjusted p=0.42). 
Higher scores represent higher symptom burden.
S.4.1.5: Mean AIM Impact score by known-groups
AIM: Autism Impact Measure. TD: typically developing peers, rx: prescription, SLT: Speech and language 
therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 of SCQ. 
Significant differences observed across all known-groups (p<0.01 in both crude analysis and analyses 
adjusted for age). Higher scores represent higher symptom burden.
4
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Chapter 4.1
S.4.1.6: Mean AIM Repetitive Behavior score by known-groups
AIM: Autism Impact Measure. TD: typically developing peers, rx: prescription, SLT: Speech and language 
therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 of SCQ. 
Significant differences observed across all known-groups (p<0.01 in both crude analysis and analyses 
adjusted for age), except for High income Medicaid vs other (p=0.77, adjusted p=0.77). Higher scores 
represent higher symptom burden.
S.4.1.7: Mean AIM Atypical Behavior score by known-groups
AIM: Autism Impact Measure. TD: typically developing peers, rx: prescription, SLT: Speech and language 
therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 of SCQ. 
Significant differences observed across all known-groups (p<0.01 in both crude analysis and analyses 
adjusted for age), except for SLT vs no SLT (p=0.17, adjusted p=0.16) and high income Medicaid vs other 
(p=0.40, adjusted p=0.40). Higher scores represent higher symptom burden.
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Psychometric validation of the Autism Impact Measure (AIM)
S.4.1.8: Mean AIM Social Reciprocity score by known-groups
AIM: Autism Impact Measure. TD: typically developing peers, rx: prescription, SLT: Speech and language 
therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 of SCQ. 
Significant differences observed across all known-groups (p<0.01 in both crude analysis and analyses 
adjusted for age), except for mental comorbidity vs no mental comorbidity (p=0.97, adjusted p=0.98).
S.4.1.9: Mean AIM Peer Interaction score by known-groups
AIM: Autism Impact Measure. TD: typically developing peers, rx: prescription, SLT: Speech and language 
therapy in last 12 months, trt=treatments, verbal/non-verbal ability as assessed by item 1 of SCQ. 




Processed on: 28-12-2020 PDF page: 184
545324-L-bw-Houghton




Processed on: 28-12-2020 PDF page: 186
186
Chapter 5
This thesis explored utilisation and outcomes of treatment in ASD. Chapter 1 set out 
the background to this work, by characterising the current ASD treatment landscape 
and some important knowledge gaps. In Chapter 2, we provided up to date estimates 
for psychotropic drug (“drug”) and non-drug treatment use in ASD, expanding current 
literature in terms of age range studied (adults as well as children), geographies (USA 
and UK data), comparing to non-ASD comparator groups, and examining predictors of 
use. For non-drug treatments, we specifically assessed the association of geography and 
health insurance type with their uptake. In Chapter 3, we considered potential unintended 
effects of commonly used drugs in children with ASD: firstly, a possible relationship 
between ADHD medications and serious cardiovascular events (SCV), and secondly, a 
comparison of risperidone versus aripiprazole for differences in bone fracture risk, over 
the short and long term. In Chapter 4 we validated a new outcome measure for ASD 
symptom severity.
In this final chapter, we summarise and discuss the main findings, address important 
methodological considerations encountered, and reflect on main implications and 
recommendations for policy and future research.
Summary of findings in context
The aim of Chapter 2 was to describe the types and prevalence of drug and non-drug 
treatment use in ASD. For drug treatments, specific sub-goals were to extend previous 
literature by studying adults (as well as children), assess a non-USA cohort (UK as well 
as the USA) and to compare ASD to non-ASD groups. We also provided more up to date 
estimates than previous studies. For non-drug use, the novel aspect was to evaluate a USA 
cohort, as data was previously lacking in the area. We also explored possible predictors of 
treatments, and hypothesised specifically about the impact of geography (urbanisation 
level) and insurance type on uptake rates of non-drug treatments. Table 5.1 summarises the 
overall levels of treatment use found in this thesis, by country, insurance type and age group.
Drug treatment
The overall results demonstrated high levels of psychotropic treatment use in ASD, and 
especially so in the USA. Previous USA based claims-data studies in children found annual 
rates of any psychotropic treatment in the range of 56-65% 1–4, which encompasses 
our estimates of 59-65% in Chapter 2.1. A comparable study 5 in Medicaid adults with 
ASD found 85% use versus our estimate of 81%. Polypharmacy (defined as two or 
more treatments with 30 or more overlapping prescription days) in children with ASD 
was previously reported at 33-35% 3,4 versus our estimate of 31-40% (no comparable 
historical data in adults). In the USA, the main difference between this thesis and the 
previous studies is that the previous studies were based on data between 2000 and 2009, 
whereas our data were from 2014.
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Table 5.1: percentage of ASD patients receiving drug and non-drug treatments annually, by 



















2014 25 63 80 81 82 83 65 81 69
USA commercial
(Chapter 2.1)
2014 11 52 76 81 72 69 59 78 64
UK NHS
(Chapter 2.2)





2016/17 100* 97 93 - - - 96 - -
USA commercial
(Chapter 2.3)
2016/17 98 97 92 - - - 95 - -
Europe / [UK]
(Salomone et al) 9




Numbers in each cell represent the proportion of patients that received treatment annually from within 
each age group.
*Rounded; 206/207 received a non-drug treatment.
NHS=National Health Service. USA=United States of America, UK=United Kingdom.
Numbers for USA non-drug treatments are reported in different age groups in this table than in Chapter 
2.3 to aid comparisons to other chapters. Results from Salomone et al included for comparison purposes 
due to similar study design in Chapter 2.3 but only includes children aged 1-6 years; results are the mean 
score across 18 European countries [UK results in brackets].
In the UK, a previous study in ages up to 24 years found any psychotropic treatment 
use and polypharmacy at approximately 29% and 7% respectively, between 1999 
and 2008 6. In Chapter 2.2, for year 2015, we found 27% use for any drug and 7% for 
polypharmacy (weighted average across the same age range). The previous UK study 6 
defined polypharmacy as two or more treatments in a calendar year, whereas we defined 
polypharmacy as two or more treatments overlapping for at least 30 days. Another 
recently published UK study found 33% use across all age groups between 2009 and 
2016 7 which compares to our estimate of 32%.
Our results indicate little change in prevalence of exposure to psychotropic treatment 
use, in both the UK and the USA over recent years. A recent systematic review 8 reported 
median (not weighted mean) estimates of any psychotropic use at 42% in children and 62% 
in adults: but these were less useful for comparative purposes as they included a mix of 
countries (mainly North America), a mix of observation years (spanning over 30 years) 
and many smaller survey studies too.
5
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Our results demonstrated substantially more psychotropic treatment use in the USA than 
in the UK. For adults, the proportion of patients receiving treatment were around twice 
as high (44% vs 78-81%). For children, this ratio was even higher (24% vs 59-65%). In 
the UK, treatment rates increased gradually throughout childhood and adulthood years, 
with small increases in treated proportions at each increasing age group. In contrast, in 
the USA, peak treatment rates were already reached by teenage years (age group 12-17 
years), and plateaued thereafter. This demonstrates a tendency to use drug treatments 
earlier in life for people with ASD in the USA too.
There are various reasons why prescription rates in the UK may be lower than in the USA. 
Firstly, there are differences between countries in terms of approved treatments and 
guidelines. As summarised in Chapter 1, in the USA, the antipsychotics risperidone and 
aripiprazole are the only approved for medications for irritability and aggression in children 
with ASD, whereas in Europe there are no medications with specific mention of autism 
in the list of approved indications. In the UK specifically, treatment guidelines published 
by the National Institute for Health and Care Excellence (NICE) do reflect this, but 
nonetheless also recommend that antipsychotics be considered for managing “behaviour 
that challenges” in ASD children and adults when psychosocial interventions have not 
helped or cannot be adhered to 10,11. The guidelines also theoretically accommodate use of 
other medications frequently prescribed in the USA too, so long as they are for comorbid 
conditions and not ASD itself. For example, provided proper benefit-risk considerations, 
the selective serotonin re-uptake inhibitor (SSRI) fluoxetine can be recommended 
as part of first-line care for moderate to severe depression in children and adults 12,13. 
Stimulant medication can be recommended for ADHD if symptoms persist after making 
environmental modifications 14. NICE guidelines generally recommend psychotropic 
treatments are started by paediatric or psychiatry specialists however 10,11,14. Indeed, 
we found that people with ASD in the UK still received more drug treatments than the 
general non-ASD population (32% vs 7%) of similar age, sex and region. Of note however 
was that only 14% of UK ASD patients without a documented psychiatric comorbidity 
were prescribed a psychotropic drug. This compares to around one-third (31-33%) of 
USA patients with no documented psychiatric comorbidity that still received a drug 
prescription - despite similar guidance to only use psychotropic drugs for specific target 
symptoms or comorbidities in the USA 15. In summary, differences in approvals and 
guidelines likely play a role in differences between USA and UK prescribing rates, but do 
not explain differences entirely.
A second possible contributing factor is differences in healthcare systems. In the UK, 
most referrals for psychiatric services, like all other non-emergency care, are made via 
an initial consultation with the patient’s general practitioner (GP). This is a routine part 
of the “gatekeeper” role of GPs in the UK National Health Service (NHS). A recent survey 
among UK GPs however found widespread lack of clarity for referral pathways specific to 
ASD 16. They also reported a general lack of ASD training and were least confident about 
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knowing which medications to prescribe. The lack of knowledge about ASD in primary 
care is also perceived by caregivers and patients themselves, who report being less likely 
to even seek care due to poor experiences with non-specialists 17,18. In the USA, similar 
difficulties occur for ASD patients in the primary care setting 19–21, but not all patients 
necessarily need to consult a primary care physician before self-referral to specialists, 
especially those on non-capitated health plans (i.e. health plans that operate on a fee-
for-service basis; not with a flat fee for every patient covered). This corroborates the 
finding in Chapter 2.1 that an independent predictor of treatment use in the USA was 
being in a non-capitated health plan. While capitated plans can control healthcare costs, 
there is no clear evidence if they result in comparable outcomes 22. A related issue on the 
potential underreporting of psychotropic drugs in the CPRD database is discussed in the 
methodological considerations section of this chapter.
Thirdly, differences in physician and patient attitudes towards drug prescribing may play 
a role. There appears to have been little direct market research published on this topic, 
but there are other available indicators of similarities and differences between countries. 
First, the proportion of all ASD research funding committed to finding treatments has 
been comparable between the USA and UK in recent years (approximately 18% in the UK 
23 and 19% in the USA 24). Second, perceived-stigma and self-stigma around mental health 
has been declining in both countries 25–27 which makes help-seeking more likely 28. A third 
aspect is the ongoing debate reaching national newspapers in both countries concerning 
if autism really is a “disability” to be treated or a “difference” to be accepted 29–31. While 
the debate is mainly centred around the appropriate emphasis to be placed on finding a 
“cure” for autism, it is not unreasonable to imagine that public opinion on this topic could 
play a role in the decision to seek out or prescribe available treatments for non-core ASD 
symptoms and comorbidities too. Public and physician awareness campaigns to ensure 
appropriate use of antipsychotic medication have been launched in the USA 32,33. Since 
2016 in the UK, a national program to stop “over medication” of all psychotropic drugs 
to people with ASD or intellectual disabilities, has been supported by NHS England 34. 
Other differences include historically higher rates of psychotropic drug use in the USA, 
despite increases in recent years in Europe 35–37. And finally, direct to consumer advertising 
of prescription drugs in the USA has been shown to play a role in increased prescription 
rates for other psychiatric indications 38,39, whereas this practice is illegal in the UK, in line 
with patient and physician beliefs 40,41.
Other main findings were that in all age groups, the Medicaid cohort had slightly higher 
use of psychotropic drugs than patients with private insurance, perhaps reflecting a higher 
prevalence of comorbidities and severity of symptoms that made these individuals eligible 
for Medicaid in the first place. We also found that foster care and White race were associated 
with higher treatment rates. Conscious and unconscious biases that limit adequate 
diagnosis and treatment of other psychiatric conditions for Black and ethnic minority 
youth in the USA are well documented 42–45. In the UK, as per previous EMR studies 6,7, 
5
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females were more likely to be prescribed medications than males, but we found no 
difference between genders in the USA.
Non-drug treatments
In Chapter 2.3, we evaluated the annual rate of non-drug treatments in ASD children in the 
USA. The study design was a cross-sectional web-based survey of over 5,122 caregivers. 
Caregivers reported that almost all children (96%) received a non-drug treatment in the 
past 12 months, with speech and language therapy (SLT; 71%), occupational therapy (OT; 
60%) and behavioural therapy (56%) being the most common. SLT and OT were more 
often provided in school while behavioural therapy and psychological interventions were 
more frequently provided outside school. Psychological therapy and a catch-all category 
of “other” therapies (such as academic support, recreational and/or animal-based therapy) 
were the only types of treatment to increase with age.
In a similar survey study in 18 countries in Europe by Salomone et al 9, a high rate of any 
non-drug treatment use was observed too (91%). Only 75% of children received these 
services in the UK however, and authors suggested the variation by country may reflect 
that some respondents did not report treatments that were provided in schools. An 
alternative explanation for lower non-drug use in the UK could be difficulties seeking 
support or unclear referral pathways in the UK healthcare system, similar to those 
outlined above for drug treatments too. Additionally, Applied Behaviour Analysis (ABA) 
is an approach to behavioural therapy used far more regularly in the USA than Europe 46. 
Suggested reasons for this include a lack of consensus on its effectiveness, differences in 
numbers of trained practitioners and cultural differences regarding the appropriateness 
of techniques used 47.
The main hypothesis tests in Chapter 2.3 regarded associations between geography 
and insurance types on the uptake of non-drug treatments. We found no significant 
differences in levels of treatment use between private and Medicaid insurances, which 
is contrary to historical evidence of higher healthcare use in Medicaid 48,49. Following the 
recent introduction of many state-level insurance mandates, requiring private insurance 
companies to cover ASD services by law, other studies have found significant increases 
in outpatient service expenditure for privately insured ASD patients 48,50. Regarding 
geography, a significantly higher proportion of children in metropolitan areas versus non-
metropolitan areas received SLT (72% vs 65%) and behavioural therapy (57% vs 46%). The 
most widely reported barrier to care in rural areas was a lack of available local services.
The vast majority of caregivers commonly reported themselves as being the main 
coordinator of care, yet only 30% accessed a caregiver education program. The median 
intensity of child-directed treatment was 6 hours per week, despite some authors 
recommending at least 25 hours per week to achieve optimal outcomes 51.
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The aim of Chapter 3 was to explore possible unintended effects of commonly used drug 
treatments in ASD children.
In Chapter 3.1, we found no association between serious cardiovascular (SCV) events 
and the prescription of stimulants or atomoxetine: so-called “ADHD medications”. From 
a cohort of 326,221 ASD children identified in USA claims data, we compared 48 patients 
who experienced a SCV event with 480 randomly selected age and sex matched control 
patients who had not experienced an event. Only 13% of the cases were currently exposed 
to ADHD medications versus 22% of controls, meaning that ADHD medication appeared 
to play no significant role in which patients would experience a SCV event (odds ratio and 
95% confidence interval (OR): 0.49 (0.20–1.20)).
There were other differences between the cases and controls however. Perhaps most 
striking was that 19% of the children with a SCV event had underlying congenital heart 
conditions compared to only 2% of the controls. This compares to around 1% in the wider 
general population 52. Due to the way we extracted this information from the database, 
it is evident that the underlying conditions were known at least 30 days prior to the SCV 
event. An open question therefore is why some children with underlying heart conditions 
were exposed to ADHD medication, despite previous recommendations 53–56 and warnings 
on package inserts 57–60 to not use these medications in patients with structural cardiac 
abnormalities.
In a sensitivity analysis, we excluded cases and matched controls with such underlying 
risk factors, but still found no association between SCV events and ADHD medication 
exposure. With hindsight, a more meaningful analysis might have actually been to exclude 
patients without the underlying risk factors. This would have helped to elucidate if ADHD 
medication actually compounded the risk of SCV events in this vulnerable group of 
patients, or if the risk was mainly down the underlying heart conditions alone. Such a 
research question is an example of what would not be ethical to test in a randomised 
study, but where retrospective “real life” clinical practice data can be used instead. In 
a series of other sensitivity analyses, we controlled for underlying risk factors using 
other methodologies. One of the methods used was novel and is discussed later in the 
methodological considerations section of this chapter. In all analyses, our findings stayed the 
same. There were no associations found between SCV events and ADHD medications.
Supporting the above findings, we also found no association between SCV events and 
ADHD medication in a larger, parallel group of children with ADHD. The results were 
largely constant with previous observational studies from literature in the wider child and 
adolescent population 55,61,62, but add considerable value given the recency of data and the 
large number of patients identified. ASD and ADHD patients combined, we studied 234 
SCV events versus 81 events in the largest previous study with comparable outcomes 62.
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The overall incidence rate of SCV events was extremely low but comparable to other 
studies 61,62. Our estimates per 100,000 person-years were 5.6 in the ASD cohort and 
3.1 in the ADHD cohort. These are consistent with the rates observed in other cohorts 
primarily comprised of ADHD children and adolescents in claims databases (2.8 to 3.1 
per 100,000 61,62).
In Chapter 3.2, the aim was to compare the risk of bone fractures in children with ASD 
who were exposed to either risperidone or aripiprazole. Using claims data from the USA, 
we retrospectively identified 3,312 patients exposed to each medication, and found that 
over the whole duration of available follow-up there was a 40% lower risk of fracture 
in the risperidone group (hazard ratio and 95% confidence interval (HR): 0.60 (0.44-
0.83)). Risks were comparable between groups for the first 180 days on treatment, but 
significantly higher in the aripiprazole group thereafter. Extremity fractures drove most 
of the increased risk. Results were stable regardless of patient gender, but risk differences 
widened further for children aged 10 years or younger.
These results cast doubt on previously proposed mechanisms by which antipsychotics 
might affect bone health. Firstly, drug-induced hyperprolactinemia has been proposed as a 
possible mechanism leading to fractures 63,64. Yet, of the drugs we studied, only risperidone 
increases prolactin levels while aripiprazole actually decreases prolactin levels 65,66 and 
it was with aripiprazole that we observed increased fracture risk. Secondly, it does not 
appear that increased somnolence or drowsiness increased the risk either, as these 
adverse effects have also previously been reported more often under treatment with 
risperidone 67,68 than aripiprazole 69,70.
Clearly, more work is needed to understand other mechanisms and risk factors that may 
have contributed to our findings. A potential weakness of our study was that median 
follow-up was only around 10 months (interquartile range: 4 to 12 months) in both 
treatment groups. On the other hand, this duration must be reflective of real world clinical 
practice, and the reasons for discontinuation were comparable between groups (as far as 
can be ascertained from claims data).
Autism Impact Measure
The goal of Chapter 4 was to test the validity of the Autism Impact Measure (AIM) in 
children. We did this by inviting over 5,000 parents and caregivers of children with ASD 
to complete the AIM online, via the SPARK online research initiative 71. We confirmed 
previous findings 72 that the questionnaire has good psychometric properties, and covers 
five distinct symptom domains (Communication, Social Reciprocity, Repetitive Behavior, 
Atypical Behavior, and Peer Interaction) as well as the option to study a “total” score 
and/or the “frequency” or “impact” of symptoms only. We also showed the AIM has high 
internal and external validity, and can discriminate between “known-groups” of children 
with different symptom severity. This means that the AIM can be reliably used to study 
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different aspects of ASD development over time, and/or to assess the effectiveness of 
different treatments too. We estimated clinically important responder (CIR) thresholds, 
which will help with future study design and clinical interpretation of the results.
Another novel aspect was that we demonstrated the AIM can be administered 
electronically, with similar validity on mobile and computer devices, taking an average of 
just over 7 minutes to complete. This is clearly an advantage of caregiver symptom report 
over other available tools that require trained personal and a much longer duration to 
administer. In ASD, direct patient reported outcomes would be more difficult to obtain. 
This is due to a range of verbal abilities and the general difficulties autistic children face, 
including communication and identifying and expressing feelings 73. The age range in which 
we validated the AIM was 3-17 years.
Methodological considerations
As with any type of research, it is important to reflect critically on methodological 
limitations encountered in this thesis. By their nature, epidemiological studies may be 
prone to different kinds of bias, which can produce erroneous results or conclusions. 
Bias should be restricted wherever possible and at a minimum be properly acknowledged 
so that results can be taken in context. Bias in epidemiological studies can generally be 
grouped into three types: information bias, selection bias and confounding 74,75. We will 
discuss specific issues related to these three types of bias below.
Information bias
Information bias occurs when data is incorrectly specified in a database. Here we discuss 
the accuracy of identifying eligible patients for study, as well as the definition of key 
exposure and outcome variables. The most profound issue would be if we suspected a 
differential pattern of information bias among different groups being compared.
Identification of ASD
Perhaps the most important aspect of any study is the correct identification of eligible 
patients. Widely used standard diagnostic criteria for autism are found in the Diagnostic 
and Statistical Manual of Mental Disorders (DSM), which is periodically updated by the 
American Psychiatric Association (APA). However, throughout secondary data use studies 
in this thesis, we needed to use different coding systems in order identify patients.
Since 2013, the DSM-V 76 has been the most recently published version, and is the first 
version to replace previously established subtypes of autism with the single term “autism 
spectrum disorder”. The DSM-IV, first published in 1994 and revised in 2000 77, included 
a broad category of “pervasive developmental disorder” (PPD). This included subtypes of 
autism including autistic disorder (the “classical” subtype); Asperger syndrome (so-called 
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“high-functioning” autism) 78,79; childhood disintegrative disorder (least common; where 
development regresses after typical early childhood 80); and pervasive developmental 
disorder, not otherwise specified (PDD-NOS). The change from DSM-IV to DSM-V 
was meant to make autism diagnoses more consistent and better reflect that there are 
currently no known biological differences to separate these different subtypes 81. There 
was expected to be no significant changes concerning the diagnosed prevalence of autism 
in real-life practice 82.
Our data sources do not provide data on the comprehensiveness of the underlying 
diagnostic process, which may differ between healthcare systems or clinics. To arrive at 
a clinical diagnosis of ASD in clinical practice, this usually requires a thorough evaluation 
of core and associated symptoms by a developmental paediatrician, psychiatrist, 
neuropsychologist or other ASD specialist. Aims of the evaluation typically include 
establishing if symptoms align with published diagnostic criteria, whether psychiatric 
comorbidities are present, and the specific neurodevelopmental profile 83. We do not 
have information on which diagnostic tools were used, such as the Autism Diagnostic 
Observation Schedule (ADOS) 84, the Autism Diagnostic Interview-Revised (ADI-R) 85 
or the Childhood Autism Rating Scale (CARS) 86.
In the USA, in insurance claims databases, physicians and facilities complete billing forms 
using a nationally modified version of the International Classification of Diseases coding 
system (ICD-CM). Version 9 (ICD-9-CM) was used until September 2015, when it was 
replaced by version 10 (ICD-10-CM). Both systems are similar to the DSM-IV, and present 
subtypes of PPD rather than the all-encompassing autism spectrum disorder. The main 
difference between ICD-9-CM and ICD-10-CM is that ICD-10-CM includes Asperger 
syndrome. As insurance forms are used for reimbursement purposes rather than a precise 
documentation of medical history, a single recorded ICD code does not always denote 
a clinical diagnosis. It could instead represent any reason for consultation on this topic 
including, for example, a patient complaint or diagnostic testing.
Fortunately, a previous validation study by Burke et al 87 evaluated how often patients 
with ICD-9-CM codes for autism in insurance claims also had recorded evidence of 
autism in their medical charts. The study was set between 2001 and 2009. Investigators 
identified 432 patients from a commercial USA insurance database using ICD-9-CM 
codes (299.0x, 299.8x and 299.9x). An expert clinician reviewer with training on ASD 
chart abstraction for national prevalence estimates then confirmed if retrieved medical 
charts for the patient also contained evidence of ASD. There were two levels of certainty 
defined from the charts: either a description “highly indicative” of a DSM-IV diagnosis 
(level 1 criteria), or wider evidence of behavioural, social or communication deficits in 
the charts, consistent with the DSM-IV, but not enough to meet level 1 criteria (level 2). 
The study found that requiring two or more ICD-9-CM codes achieved a level 1 positive 
predictive value (PPV) of 61% and a level 2 PPV of 87%. These were much higher than 
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when requiring just one ICD-9-CM diagnosis code (43% and 74%). Hence, requiring two 
ICD codes formed the basis of the algorithm we used to identify ASD patients from claims 
databases throughout this thesis. The exception was Chapter 3.2 in which only one ICD 
code for ASD was required, because patients were also required to have a dispense of 
risperidone or aripiprazole, which itself is likely a confirmation of ASD.
While the Burke et al validation study was for ICD-9-CM, we assumed their applicability 
for ICD-10-CM too, which came into effect for billing purposes in September 2015. ICD-
10-CM codes used were similar to ICD-9-CM in that they corresponded to autism/autistic 
disorder (F84.0), and other/unspecified PPD (F84.8 and F84.9). The difference in ICD-
10-CM is that it also included Asperger’s syndrome (F84.5) which was not present in 
ICD-9-CM. Differences in ICD versions would not have affected Chapter 2.1, which was 
set in calendar year 2014 and prior to ICD-10-CM adoption. However, Chapter 3.1 was 
set between 2000 and 2016, and Chapter 3.2 was set between 2013 and 2018, which 
spanned the version change. Both studies were comparative in nature and calendar date 
was used as a matching variable in both. Therefore, any differences in diagnostic criteria 
over time were accounted for in comparative analyses. Naturally, further validation studies 
for ICD-10-CM should be welcomed in the future. ICD-11 will be the first version to refer 
to the autism spectrum but this is not expected for release until 2022 and its adoption in 
USA insurance data will likely be even later.
Of note, we also excluded patients with an ICD code for Rett’s syndrome or who were 
under the age of 2 to 3 years in order to reflect diagnostic uncertainties 2,4,87. Additionally, 
as per the validation study by Burke et al, we did not include ICD codes for childhood 
disintegrative disorder (CDD), which authors described as clinically distinct from the other 
ASD. This means that patients who would have previously met such criteria were not 
represented in our MarketScan studies. This likely has little impact on the external validity 
of our studies as a whole however, as CDD accounted for only around one in every 60 to 
175 cases of autism, under the old DSM-IV definitions 80.
Since the mid-1990s, the UK CPRD database has used the Read code system for 
documentation of clinical symptoms and diagnoses. As electronic medical records are used 
to document more precise medical history and symptoms than claims data, two previous 
validation studies showed that requiring just one Read code for autism in the CPRD 
database carries a high PPV (over 90%) 88,89. The first study by Fombonne et al 88,90, which 
evaluated 318 Read code-identified children born between 1973 and 1997, found a 93% 
PPV by making a detailed comparison between medical charts and the DSM-IV criteria. 
The most recent study, by Hagberg and Jick 89 demonstrated that a reduced list of Read 
codes carried a 92% PPV versus medical charts between 1990 and 2014. This is probably 
because the most common Read codes in their study (autism, autistic disorder and 
Asperger syndrome) also identified most patients in the study by Fombonne et al. However, 
Hagberg and Jick also included the term autism spectrum disorder, which Fromebone et al 
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did not. Around 25% of the patients in the Hagberg and Jick study were diagnosed after 
2013, coinciding with when the concept of the autism spectrum was introduced in DSM-V. 
In their study, authors demonstrated that use of the Asperger syndrome code decreased 
from approximately 40% of patients born in 1995 (the year after the DSM-IV was first 
published) to around 10% of patients born in 2005, and to only 2% of patients born after 
2010. In Chapter 2.2, we used the codes produced by Fombonne et al but also included 
the Read code for autism spectrum disorder, hence creating the most comprehensive 
list, while being reassured that the PPV remained high. We also excluded patients with 
Rett’s syndrome codes in the CPRD study, but the code list included CDD, unlike the 
MarketScan studies. The Read code system, historically used for clinical terminology in 
the UK, is currently undergoing a transition to the SNOMED system 91. Hence, further 
validation of the SNOMED codes will also be needed in the future.
High PPVs in both MarketScan claims data and the CPRD means we can be confident most 
patients identified in our studies are true cases. However, it is much harder to know the 
sensitivity of the code lists used. Perhaps some eligible patients with ASD were excluded 
incorrectly from our studies. Probably more patients in the USA were excluded than 
patients in the UK, due to the requirement of two codes in the USA databases. Potentially 
this is another reason why a higher proportion of patients in the USA received treatments, 
as milder cases with just one ASD code may not have been included. The extent of this 
misclassification is very difficult to assess given the data available.
Unfortunately, in both CPRD and MarketScan databases, it is not possible to ascertain 
information on the severity or specific symptoms of patients. None of the validation 
studies mentioned above benchmarked against established clinical diagnostic instruments 
92. Finally, none of the validation studies included an adult population. This means that the 
accuracy by which adult patients were included in our studies is less clear. This affects 
Chapter 2.1 and Chapter 2.2 only. Only by the DSM-III, first published in 1980, was autism 
first recognised as a distinct disorder to schizophrenia 93. That said, contemporary medical 
records, which were used in our studies (all studies used codes entered between 2000 
and 2018), will probably reflect contemporary diagnostic criteria regardless of a patients 
initial diagnosis.
In the SPARK cohort (Chapter 2.3 and Chapter 4.1), the caregiver-report of ASD diagnosis 
is assumed highly valid as per other previous online studies (e.g. the Interactive Autism 
Network) 71. Recruitment for many of the patients in SPARK was also in collaboration 
with clinical sites to increase chances that participants had a valid diagnosis. As fielding of 
our survey was in the DSM-V era, the majority of caregivers reported autism spectrum 
disorder as the main diagnostic label (74%). The DSM-V grouping is supposed to emphasise 
similarities between ASD patients rather than differences, as well as make diagnosis easier 
46. However, this does make it more difficult to study subgroups, and assess the external 
validity our findings compared to previous studies.
545324-L-bw-Houghton
Processed on: 28-12-2020 PDF page: 197
197
General discussion
Overall, for the studies in this thesis based on SPARK, we have a better characterisation 
of patients such as caregiver reported age at diagnosis, severity of symptoms and 
verbal ability. The possible limitation for the SPARK database is its representativeness 
of the wider ASD population, given that this is a survey-sample. The topic of survey 
representativeness is discussed in detail later in this chapter. For the drug utilisation 
studies, detailed patient characteristics or even the certainty of a true ASD diagnosis is not 
available in the MarketScan or CPRD data. Nonetheless, given the above, we have around 
an 87% PPV in MarketScan data and a 92-93% PPV in CPRD. Furthermore, as these 
cohorts are extracted from population-based data, they are likely more representative 
of the whole autism spectrum. Unfortunately, we cannot study subgroups in these data, 
and severity of symptoms could be an important missing confounder for the comparative 
studies. Confounding is also discussed later in the current chapter.
Exposure data
Other key variables to ascertain correctly are the exposures of interest. In MarketScan 
claims and CPRD data, exposure data simply reflect if prescriptions have been dispensed 
or issued, respectively. It is not possible to know if patients actually took the medication 
as prescribed.
Identification of “new users” of risperidone and aripiprazole in Chapter 3.2 was only 
possible via an algorithm, requiring at least one year of prior continual enrolment in the 
MarketScan database without any record of antipsychotic prescription. There was perhaps 
slightly more chance of incorrectly specifying patients in the aripiprazole group as new 
users, given the age at index in this unmatched group was 11.3 years opposed to 9.3 years 
for risperidone. On the other hand, the mean prior enrolment in the database without 
treatment was around 3 years in both treatment arms, so the chances of misspecification 
were small and differences between groups would be negligible.
A general concern regarding the CPRD data used in Chapter 2.2 could be that it that it 
only covers the primary care setting. Indeed NICE guidelines for ASD generally suggest 
referral to specialist care before prescription of psychotropic drugs, and especially for 
children 10,11. Nevertheless, the level of underreporting is likely to be small. This is because 
specialists generally determine which medication is appropriate, but ask the GP to actually 
write the prescription 94. Additionally, even when prescriptions are started outside of 
primary care, the nature of the GP “gatekeeper” system in the UK means that repeat 
prescriptions will normally be managed in primary care, and an account of what happened 
in secondary or tertiary care will be sent back to the GP for record keeping. The CPRD 
database will also cover patients permanently living in long-term residential facilities, so 
long as they are not classified as hospitals 94. Since 2019, Public Health England have used 
another primary care database (The Health Improvement Network: THIN) which partly 
overlaps with CPRD, to monitor the success of its national program on the reduction of 
psychotropic drug use in people with ASD or a learning disability 95.
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In insurance claims data, multiple diagnosis codes can be recorded on each billing form. The 
MarketScan database contains up to five diagnosis codes from inpatient and outpatient 
physician forms (usually the CMS 1500 form) and up to nine diagnosis codes from facility 
forms (usually the UB04 form). In the event of an inpatient stay, a primary diagnosis field 
is also populated, which usually corresponds with the principal discharge code 96.
When identifying serious cardiovascular (SCV) events in Chapter 3.1, we initially searched 
for relevant ICD codes in all of the diagnosis fields. This naïve approach resulted in us 
estimating incidence rates around 30 times higher than rates previously reported 
61,62 and prompted a more careful look at validation studies that linked claims data to 
confirmed SCV events in electronic medical records. Literature reviews show that by 
only considering cases with ICD codes in the primary diagnosis field from an inpatient 
visit, can achieve a PPV of at least 85% in the majority cases 97–101. According to studies 
which reported it, this also keeps sensitivity relatively high 99,100. Application of these more 
stringent criteria in our study resulted in SCV event rates completely aligned with those 
previously reported.
This highlights the importance of such validation studies for accurately identifying 
diagnoses in claims data. A limitation of the MarketScan claims data that cannot be 
overcome however, is that deaths outside of hospital are not recorded. As a small 
proportion of sudden SCV events may have led to death without a hospital visit, these 
events would likely have been missed in our study. Missing death information is unlikely 
to have had an impact on Chapter 3.2, as we censored patients in the Cox model when 
they left the database regardless of the reason (which is undocumented). Mortality rate 
in this group of young patients is expected to be very low.
Claims data have also been shown to have high PPV for identifying fractures 102–105. 
However, literature is lacking to confirm this specifically in children, and differences in 
accuracy exist by fracture site 104,105. For the study Chapter 3.2, we should be reassured in 
the accuracy of identifying true fractures, as over 90% of the diagnosis codes we identified 
were recorded in the first diagnosis field on billing forms. Additionally, the incidence rates 
were broadly similar to those studied the general child population and in other types of 
databases 106. Importantly, for comparative purposes, there is no obvious reason why 
fractures would be recorded differently between patients exposed to risperidone or 
aripiprazole.
Recall bias
Recall bias refers to a situation in which a respondent incorrectly recalls what happened in 
the past. A strength of data from EMR or claims databases is that information is collected 
routinely, and usually during or shortly after consultation with the patient, so recall bias 
is not an issue. In contrast, recall bias can be problematic in surveys.
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During the SPARK survey conducted in Chapter 2.3, caregivers were asked to recall which 
treatments and services their child had received in the past year. Most of the non-drug 
treatments were reported as still ongoing (61-89% depending on type of treatment) and 
perhaps there is more difficulty recalling services received further in the past. Due to 
the close involvement of caregivers in coordinating care however 107, we expect them to 
recall this information well overall. There is no obvious reason why recall bias would be 
different based on geography or insurance status.
We also surveyed caregivers from the SPARK platform in Chapter 4.1. The AIM 
questionnaire only asks caregivers to recall their dependants’ symptoms over the past 
two weeks, so recall bias seems less of a concern. A two week recall period also offers the 
option of more frequent and independent measurements to be collected over time.
Selection bias
Selection bias occurs when a sample selected for a study are not representative of the 
underlying population, or when there are systematic reasons that determine why patients 
are more or less likely selected into different comparison groups. In such scenarios, 
results may not be generalisable, or biased estimates may be produced when comparing 
groups.
Survey representativeness
Perhaps the most obvious and intuitive example of selection bias, is when respondents 
of a survey are not representative of the wider population which were intended to be 
studied. This concept is applicable to studies in this thesis that surveyed participants from 
the SPARK online ASD platform (Chapter 2.3 and Chapter 4.1).
Regarding parental education levels, we had around twice as many respondents that 
completed a graduate degree than in the general USA adult population (64% vs 33%108). 
The most commonly reported family income in our study was between $50,000 and 
$75,000 in 2017, which coincided with the median USA household income of $61,423 
in the same year 109. However this is still likely slightly higher than a typical family with an 
autistic child due to work productivity loss 110,111. Those with higher income and education 
are perhaps more likely to be aware of and secure access to treatments for their children, 
via either advocacy or out-of-pocket payments 9,112.
An additional inclusion criterion for our survey was that participants needed to understand 
English. This presumably excluded 9% of people in the USA who speak English “less than 
well” according to the 2009-2013 US Annual Community Survey 113. More of the children 
in our survey were of White/non-Hispanic race than in the general ASD population (69% 
vs 53%) but were similar in terms of age at diagnosis, sex and caregiver-reported use of 
medications for ASD 114.
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The online format of the survey would have removed any potential barrier to participation 
in terms of travel time to research sites. Additionally, in the USA, only 3% of adults aged 
30-49 years (the majority age range of caregiver respondents) do not use the internet 115 
so this should have widened the opportunity to take part. Any small residual differences 
in internet availability between rural and metropolitan areas would likely have negligible 
impact on our findings. The study actually had participants from all 50 states, plus 
overseas territories. Despite some clear limitations, the size and diversity of our sample 
is unprecedented for this kind of study, as is the SPARK cohort in general 71. With regard 
to selection by parental education, the results in our study can still be compared to work 
carried out by Salomone et al 9 in Europe which also had high rates of graduate level 
education among caregiver respondents (63% vs 64%).
Biases in case-control studies
In a case-control study, we have two opportunities to introduce selection bias: first, when 
picking the cases, and then when selecting the controls. Here we explore these concepts 
in the context of Chapter 3.1.
First, we selected cases who experienced a serious cardiovascular event (SCV). The intent 
was to see if these patients were more commonly prescribed ADHD medication than 
controls in the time leading up to the event. Another characteristic common to many of 
these patients however was the presence of other underlying cardiovascular comorbidities 
(19% had underlying a congenital heart condition). As the ADHD medications of interest 
carry class wide SCV warnings 57–60, the expectation is that patients with underlying 
cardiovascular risk are actually less likely to receive treatment. This “reverse causality” 
could have paradoxically given rise to what looks like a protective effect of ADHD 
medications on SCV events (the point estimate for odds ratio was 0.49). In fact, this type 
of bias does not only influence selection of cases in case-control studies 116, but is called 
confounding by (contra-) indication and impacts cohort studies too 117.
The controls were sampled according to the incidence density sampling technique 118. 
This means that at the time of the cases’ event, all patients in the cohort yet to experience 
the event (“at-risk”) had an equal chance of being selected as a control. This is important 
step to not introduce bias. While the probability is small, this method means is possible 
for some cases to also be a considered a control for another case, using data prior to their 
own outcome of interest.
To make cases and controls more comparable, we matched on age, sex and insurance type. 
This accounts for the some of the confounding factors, however, we still needed to adjust 
for other factors at the analysis stage. A common issue when deriving covariates in case-
control studies is the inclusion of information that happened post exposure, potentially 
on the causal pathway between exposure and outcome and therefore introducing bias 
119,120. We tried to account for this in our covariate derivations, by ignoring data during 
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a 30-day lead-in period prior to the event. For example, this means that if a patient had 
a cardiology visit in the last 30 days prior to event, then we ignored it when deriving 
the cardiology visit covariate. This is because there is a good chance the cardiology visit 
happened after the exposure, and may be causally related to exposure itself. Justification 
for 30 days was based on the belief that the most likely exposure effect would be acute 
121. It is an assumption however, and must be acknowledged.
For these reasons and others, there are strong critics of the case-control design, and self-
controlled designs have been suggested as an alternative approach 120. Self-controlled 
designs have an inbuilt advantage of controlling for within subject characteristics during 
periods of exposure and non-exposure. Disadvantages however include that results 
are only representative of patients who experience an event. Exposure time after an 
event is also counted 122, and this is likely to introduce a different kind of bias because 
experiencing serious or chronic adverse effects will likely make future use of the same 
treatment less likely 123. In an ironic example, a study that tried to expose the flaws of 
case-control designs, included exposure time after the event of ulcerative colitis onset (a 
chronic disease) 120. Breaking up post-event time into periods of high and low exposure 
windows has been suggested, but the approach still only makes sense with acute, non-
severe outcomes and transient exposures 122. Cohort studies are another option but they 
require repeated assessments of exposure status, and potentially covariates, over time. 
This makes cohort studies less operationally convenient for testing assumptions about 
the proximity of exposure to the outcome of interest 119. For example we also performed 
analyses based on exposure in the previous 90 days prior to the SCV event and an “ever 
exposed” analysis, without needing to redefine which patient to include in the analyses 
or re-derive any other variables.
A final type of bias to consider in the case-control design is immeasurable time bias. This 
time-related bias occurs in scenarios where it would be impossible to observe exposures 
during the pre-event exposure window 124. For example, if the event of interest led to 
cases being in hospital during the days prior to the event, then outpatient prescriptions 
to the patient would not be possible. This type of bias would be related to the contra-
indication bias mentioned above for Chapter 3.1, as cases with poorest underlying health 
would be more likely hospitalised prior to the event. In our study design however, such 
hospitalisations would not be directly related to SCV events as we used the first SCV 
inpatient hospitalisation record to denote the event date. Additionally, the proposed 
mechanism for ADHD medications leading to SCV events means that admission to 
hospital would be very shortly after an exposure.
Ultimately, there are some clear limitations in Chapter 3.1, but measures were taken to 
limit them as much as possible, and sensitivity analyses testing different assumptions all 
provided consistent results. In a future analysis, it would be interesting to empirically check 
for evidence of reverse causality by assessing negative control exposures on the same 
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selected cases and controls 120,125. Additionally, a future study aiming to replicate findings 
using a cohort study approach would be a good experiment too. Both study designs should 
produce the same estimates in theory 119.
Biases in cohort studies
The objective of Chapter 3.2 was to compare the safety of two drugs head-to-head over 
time. The head-to-head approach of two active treatments made it possible to emulate 
certain aspects of a controlled “target trial” 126. This is because an index date (start of 
follow-up time) could be easily defined in both groups as the time of new treatment 
initiation. This is called a new-user design 127. A clearly defined index date not only provides 
a clear start of follow-up, but also facilitates easy application of eligibility criteria at this 
specific point in time. This is similar in principal to clinical trials, where all patients who 
meet explicit eligibility criteria at baseline are included as part of the intention-to-treat 
(ITT) analysis, regardless of their later compliance with the treatment regimen 128.
Other time-related effects, still possibly related to treatment, such as differential loss 
to follow-up or discontinuation of treatment can also be easily observed in this design. 
In our study, we noticed that patients in both the aripiprazole and risperidone groups 
were followed for similar amounts of time, and had similar reasons for leaving the cohort. 
Hence, there was no obvious differential loss to follow-up, other than in the differential 
rate of fractures. In other studies where reasons for loss to follow-up are related to the 
outcomes of interest, this can cause spurious results 129. In such cases, competing risk 
time to event models can be applied 130. Examples of competing risks include receiving 
a kidney transplant when studying time to death for patients with kidney disease 131 or 
finding a new stable partner when studying HIV infection rates among sex workers 132. In 
our study, a potential competing risk for bone fracture could be death due to accidents, 
which is not possible to evaluate in our database, as death is not well recorded. It likely has 
little impact on our results however, given that mortality in this young cohort is expected 
to be extremely rare. Another potential competing risk would be switching to the opposite 
treatment of interest (i.e. from aripiprazole to risperidone or vice versa). However, we 
know that the proportion of patients switching was similar in both treatment arms so this 
unlikely resulted in a biased comparison.
In other study designs, where assignment of an index date for patients is less clear, time 
related biases are usually harder to identify. It is especially difficult to assign an appropriate 
index date to patients who receive no treatment; hence, a comparison of treatment 
versus no exposure needs careful attention. In selecting the follow-up period for such 
studies, immortal time – defined as a studied period in which the outcome of interest 
could not have occurred – should be avoided 133. A classic example of this is a study that 
counted follow-up time from a given calendar date rather than beginning of a treatment 
regimen 134. The study compared the number of drug prescriptions received over time 
with an outcome of future hospitalisation. However, for patients who went on to receive 
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treatment, the time between start of follow-up and first prescription is immortal as no 
hospitalisation could occur in this time. This artificially lowered the rate of hospitalisations 
in the exposed group 133.
Another way in which immortal time may be introduced is based on exposure hierarchy 133. 
In such circumstances, patients ever exposed during the observation period are compared 
to patients never exposed during the whole observation period. If patients are then 
excluded from the ever-exposed group based on a prior event, then these events are not 
properly counted towards the non-exposed time. This phenomenon is clearest when the 
event of interest is death. For example, in a CPRD study, the rate of death was compared 
between patients exposed to a combination of inhaled corticosteroids and long-acting 
beta-agonists versus patients exposed to a bronchodilator 135. Some patients included 
in the combination therapy group had previously been exposed to a bronchodilator. If 
patients had died in the bronchodilator exposure period, they could not ever have been 
included in the combination therapy group 133.
To reiterate, these immortal time issues will not have influenced Chapter 3.2 in its current 
state due to the new-user design and comparison of two cohorts with clearly defined index 
dates. In the future however, if extensions are made to study the effects of cumulative 
dose, or washout periods in which risk remains altered after treatment, then these 
exposures need to be accounted for carefully. For example, patients need to survive a 
period of current exposure in order to reach a period of previous exposure. Similarly, high 
cumulative doses will only be experienced after event free periods at lower doses. Time 
dependant Cox models have been suggested 133 and demonstrated 136 to correctly adjust 
for these time varying exposures. In the more complicated case that important covariates 
also vary over time and are dependent on prior exposure, then g-estimation or marginal 
structural models (MSM) are recommended 137, as they take such conditional probabilities 
into account 138,139. This would likely be the case in a study of fractures in ASD given the 
frequent use of other psychotropic drugs in this population.
In our experience, such models can quickly become extremely complex, both to define 
and interpret. If the main aim is to simply study effects of antipsychotic exposure versus 
no pharmacological drug exposure, then an alternative approach could be to define a 
reference group as new users of behavioural therapy. This solves the problem of defining 
an index date for a non-pharmacological exposure group, and arguably provides a more 
similar comparator group too, as patients are starting some form of treatment over 
no treatment at all. Naturally, other reasons for initiating non-drug therapy first over 
antipsychotic therapy would need to be considered. This then becomes a problem of bias 
by confounding rather than bias by selection.
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Confounding refers to a process in which exposures and outcomes of interest are 
both influenced by a third “confounder” variable. Confounding is a serious problem in 
epidemiological research as it may result in finding spurious (not causal) estimates of 
association between exposures and outcomes if not properly addressed 140. Without 
adjustment for confounders, effect estimates may be distorted in size or even reversed 
141. As discussed previously, some types of confounding can be introduced unintentionally 
at the study design phase. Commonly however, other confounding factors are impossible 
to eradicate at the design phase, as they are true reflections of real life situations and 
clinical practice. Identification of confounding variables typically requires disease area 
knowledge. Below we discuss specific methods used to adjust for confounding in the 
analysis stage of studies.
Directed acyclic graphs
Directed acyclic graphs (DAGs) are pictorial representations of assumed processes that 
gave rise to observed data. In epidemiology, they can be used to decide which minimum 
set of variables need to be adjusted for in analyses order to eliminate confounding and 
estimate unbiased associations between exposures and outcomes 142. Contrary to 
common practice, it is not always desirable to simply adjust for all available variables, and 
doing so can actually introduce more bias in some circumstances 143,144.
In Chapter 2.3, we used a DAG to consider the relationships among all variables assumed 
to influence the association between type of insurance coverage (private or Medicaid) 
and receiving treatment, or between geography (level of urbanisation) and receiving 
treatment. We graphically displayed the DAG and identified the minimal adjustment sets 
using free software 145. We also confirmed the minimal adjustment sets using graphical 
criteria of the backdoor test for sufficiency 142,146. While the full DAG is available in 
Chapter 2.3 (supplement S.2.3.1), key assumptions we made about important variables 
are displayed in Figure 5.1 and discussed below.
The first key variable in Figure 5.1 is household income. Household income clearly 
confounds the relationship between insurance type and treatment: that is, it clearly 
influences them both. Firstly, low earners qualify for Medicaid, while high earners will 
not. Secondly, a greater proportion of high earners would be able to pay for access to 
treatment directly (“out-of-pocket”). While income is likely influenced by geography 
– perhaps concerning the type of jobs available in the local area - it is less clear that a 
causal relationship exists in the other direction. Hence, income does not confound the 
relationship between geography and treatment.
Similar to household income, high levels of education strongly aids parents to seek out 
and advocate for their child’s access to ASD services 9, but as we assumed no relationship 
between parent education and geography, then parent education does not confound the 
545324-L-bw-Houghton
Processed on: 28-12-2020 PDF page: 205
205
General discussion
relationship between geography and treatment either. We assumed there is likely an effect 
of parent education on insurance, however this is “through” the effect on income (also a 
proxy for job), and is unlikely to influence insurance type directly.
Figure 5.1: Simplified causal diagram for key variables influencing non-drug treatment useFigure . : Simplified c us l diagram for key variables i fluencing non-drug treat
 
Insurance type = private or Medicaid; Geography = rural or urban location.  
Full diagram available in Chapter 2.3 (supplement S.2.3.1). 
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The assumptions underlying this DAG led to the choice of variables that we simultaneously 
controlled for in Chapter 2.3. Naturally, these assumptions might be challenged, but we 
believe that this clear and open approach is part of good scientific practice, allowing 
replicability of findings and proper scrutiny in peer review. Other advantages to defining 
an a priori set of variables for statistical adjustment is that it can also aid study design (e.g. 
selecting the right dataset), increase statistical efficiency (only need to adjust for minimum 
set) 147 and ensure control of type I error rates (through reduction of multiple testing with 
various adjustment sets).
Sometimes confounding can be so strong in a dataset, that statistical adjustment is not 
appropriate. For example, in our dataset, at the lower and upper strata of household 
income, children were almost exclusively enrolled into Medicaid (<$20,000) or in private 
insurance provided by employer (>$99,000). We therefore restricted our analysis only to 
those families with an annual income between $20,000 and $99,999. Clearly, this means 
that results can only be interpreted in this more limited, middle-income group, but the 
approach was most appropriate in this context.
5
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The fundamental reason that randomised control trials (RCTs) remain the gold standard 
method for evaluating treatment effects, is randomisation. Randomisation means that 
each person enrolled in a study has an equal chance of being assigned to each exposure 
group, independent of any other factors. By design therefore, all factors - including those 
that could influence outcomes - are balanced equally between treatment groups and 
confounding is not possible 148,149.
In observational studies, various factors could play a role in reasons why people receive 
different treatments. Hence, when these factors are confounders, statistical adjustment 
is usually needed in order to remove their effect and estimate the “true” treatment effect. 
One commonly used method is the propensity score (PS). The basic idea of the PS method 
is to evaluate the probability of assignment to a given treatment as a function of observed 
patient characteristics 150, and incorporate these estimates into subsequent analysis. 
Different methods for estimating the PS have been suggested. Most commonly, logistic 
regression is used, but other methods involving decision trees and other machine learning 
methods are also used 151,152.
Once PSs have been estimated for different patients, they are typically (not exclusively) 
incorporated into analyses using one of two methods: matching or weighting. Matching 
involves comparing patients who have similar propensity scores (i.e. had similar probability 
of receiving the same treatment), but that actually received different treatments. This in 
essence achieves a “pseudo-randomised” subset of the entire available dataset, filtered 
on the most comparable patients. It is the method we used in Chapter 3.2 to compare 
risperidone and aripiprazole for fracture risk. Weighting on the other hand, can use data 
from all patients, but uses the propensity score as a way to assign more or less contribution 
of their information to the analysis. These weights are sometimes referred to as inverse 
probability weights (IPW). Weights can be assigned such that resultant weighted groups 
are more representative of a specific exposure group (thus estimating the average 
treatment effect in the exposed population: ATT); or, such that both groups are more 
representative of the overall source population (estimating the average treatment effect: 
ATE) 153. In Chapter 2.3, we used the ATE weighting approach to compare if access to non-
drug ASD treatments were more associated with private or Medicaid insurances. This 
seemed most appropriate, as policy makers are initially most likely interested to know if, 
on average, access to treatment is currently comparable across both types of insurance. 
This is opposed to the ATT, which would have estimated the possible effect of expanding 
Medicaid eligibility to all patients who are currently privately insured (or expanding private 
insurance, depending how we set the model up).
Propensity score weighting in case-control studies
Propensity score approaches are less commonly used in case-control studies. The main 
reason is that controls are typically sampled in some pre-defined ratio to the number of 
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cases and hence the probability of being a case or control is fixed by design. As probabilities 
are fixed, the notion of estimating the true probability of being a case or a control only 
using information from the sample of cases and controls is flawed.
With that said, we employed a novel method in the case-control study in Chapter 3.1, 
with some theoretical motivation from propensity score inverse probability weighting. 
To justify the choice of this method, first we must bear in mind the end goal of propensity 
score techniques is to achieve covariate balance between comparison groups 148. The 
propensity score is simply a means to arrive at such a junction. As such, an ideal method 
would be able to estimate weights that balance groups directly, without first estimating 
propensity scores. Fortunately, gradient boosted models (a type of machine learning 
method) are able to do just that 154. Another advantage of using this approach is that 
many covariates can be controlled for without having to consider the functional form 
of their relationships to each other and to group assignment 154. To our knowledge, this 
application of the boosted derived weighting scores is new in case-control studies.
Naturally, like with any new approach, it will be important to provide more reassurance 
on its validity before encouraging widespread use in other studies. A statistical proof that 
provides a full set of all assumptions would arguably be the best way to do this, at least 
from a theoretical point of view. In reality however, strict assumptions in such proofs 
rarely hold true when working with observational data, so empirical evidence that the 
method works will also be highly beneficial. Some of this was already achieved in Chapter 
3.1. For example, the boosted-weights method produced results wholly consistent 
with the conditional logistic regression models, which is a more established method for 
covariate adjustment. Our results were also consistent with the majority of other studies 
that previously addressed a similar research question, including those which did not use 
a case-control study design. Moving forwards, more replication of results from other 
historical studies should also be undertaken. These should include a variety of disease 
areas and previous study designs. Additionally, evidence that that method correctly 
identifies relationships in simulated data would also provide a very credible argument. 
A combination of the above approaches should be carried out in order to generate a 
consensus that the new method is robust.
As the rationale for case-control studies in large administrate databases is declining 120, 
acceptance of this method would most likely have biggest incremental impact outside of 
this setting.
General comments on confounding
In all comparative studies in this thesis, we propensity score adjusted for a large number of 
potential confounders and/or carefully selected a confounder set based on DAG theory. 
Fundamentally however, propensity scores (or any other adjustment method) cannot 
account for confounders unmeasured in the dataset 148. Likewise, DAGs may reassure 
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us that adjustment sets are correctly specified given assumptions, but they do require us 
to make assumptions in the first place. Hence, even with careful design and analysis, we 
should always be aware of potential residual confounding in all observational studies.
Recently, the concept of e-values have been introduced to the epidemiological literature 
155. An e-value denotes the minimum strength of a cofounder variable that would be 
needed to alter the observed association between exposures and outcomes 155,156. 
Using free online software 156,157, we calculated the minimum strength of an unmeasured 
confounder needed to alter the conclusions of Chapter 3.2 (i.e. to bring the upper bound 
of the confidence interval for the hazards ratio for fractures above 1). In this circumstance, 
the unmeasured confounder would need to alter both the choice of antipsychotic 
(aripiprazole or risperidone) and the risk of bone fractures by 1.7 times or more in order 
to change our conclusion. Hence, we can be confident even a small amount of residual 
confounding would not have changed our study conclusions. A general limitation of 
e-values is its underlying assumption that only unmeasured confounding may explain 
distorted findings in an observational study, thereby ignoring types of information or 
selection bias.
Instrumental variables have been proposed as a way to mimic “natural randomisation” via 
exploitation of natural phenomenon 158,159 and negative controls are a technique that can 
help to identify unmeasured confounding in observational data 125. Where feasible, both 
techniques could be used in the future to verify or dispute some of the inferences made 
in this thesis. These issues of confounding are not relevant in sufficiently powered RCTs 
due to the “magic of randomisation” 149.
Overall implications and recommendations
The results of Chapter 2 provided a comprehensive insight into real-world treatment 
utilisation patterns in ASD. We extended previous literature in this area by studying the 
adult ASD population as well as children, estimating treatment use outside the USA, 
assessing non-drug treatment use, and updating prior information by around 10 years 
compared to the other most recent studies. Our cohorts were mainly population-based, 
broadly representative, covered private and Medicaid insurances in the USA and were 
larger than any other previous studies. Overall, the levels of treatment utilisation were 
substantial: both for drug and non-drug services. Reflective of disease heterogeneity, 
this included a wide variety of treatments for core and non-core ASD symptoms, as well 
as associated psychiatric comorbidities, which were highly prevalent. This knowledge on 
treatment utilisation can be useful for ASD researchers planning or interpreting results of 
new studies, and for healthcare systems planning training and resourcing for ASD services 
in the coming years.
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Additionally, we studied factors associated with treatment use, in order to understand if 
certain groups of patients had more challenges in accessing appropriate treatments than 
others. Patients in the USA and UK were more likely to receive treatment in the presence 
of other psychiatric comorbidities, but this did not explain all of their use. In the USA for 
example, children in foster care were more likely to receive treatments. A recent policy 
experiment in Texas showed that multi-team screening interventions significantly reduced 
inappropriate (off-label) medication use in foster care children 160 and hence similar 
programs should be considered elsewhere. Also in the USA, White patients were more 
likely to receive drug treatment than Black or Hispanic patients were. Historical racial or 
ethnic disparities in early ASD diagnosis rates have been narrowing in recent years 161 
but more should be done to continue this trend. We did not assess race differences in 
the UK studies. Additionally, further research should be done to understand other social-
cultural reasons for racial differences in uptake and discontinuation rates of treatments, 
and address them where necessary. Recent widening of ASD private insurance mandates 
in the USA seems to have had little effect on addressing racial differences in treatment 
access 162. However, expansion of the Medicaid Home and Community Based Services 
(HCBS) waiver – allowing patients to receive services in their own home or community 
– has shown greater potential 163.
Specifically concerning non-drug treatments in the USA, we found no significant 
association between insurance type and the uptake of services. Our results therefore may 
indicate that private insurance ASD mandates have had an effect on levelling-up historical 
differences in access to ASD services between private and Medicaid insured patients. A 
study that specifically addressed this issue found expenditure on ASD outpatient services 
almost doubled among large, employer-sponsored plans following the introduction of 
the insurance mandate in Pennsylvania 164. A specific limitation of our study is that we 
assessed associations on a USA-wide level, despite that Medicaid eligibility criteria and 
the scope of private insurance mandates vary by state 165. Point estimates also mainly 
favoured Medicaid despite not being statistically significant. Further analysis on the state 
level should therefore be explored. This could partly be achieved in our own dataset, given 
that we had representation from all 50 states, plus overseas territories. However, we did 
not collect information prior to the introduction of mandates. Insurance claims data would 
offer an alternative approach, but with less detail on specific treatments received.
Another major finding, was that autistic children in non-metropolitan (rural) areas received 
fewer non-drug treatments and for fewer hours per week than peers in metropolitan 
areas. These included treatments that are more commonly provided inside and outside 
of school. Corresponding with this finding, more caregivers in rural communities 
reported a lack of locally available services as the biggest barrier to care. Telehealth has 
been suggested as one possible avenue to overcome the barriers of accessing specialist 
support in rural areas 166. Indeed, online cognitive behaviour therapy has been shown 
effective in non-autistic children with anxiety 167 and sleep disorders 168, but these online 
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services clearly would not be appropriate for all children with ASD. Naturally, parents and 
caregivers already commonly provide around the clock support for children with ASD, 
yet specific training to equip caregivers as interventionists has also been encouraged 107. 
Training courses delivered online for parents may be more feasible, and initial research 
in this area has been promising 169,170. Further research should also focus on the impact of 
such interventions on parent resources and stress levels, its possible impact on siblings 
107,171 and how training can be tailored to meet various cultural views on parenting style 
172. Other general limitations of our survey of non-drug treatment was that it attracted 
responses from an above-averagely educated parent group, and that treatment utilisation 
in adults with ASD were not studied. These limitations should also be addressed in future 
studies.
Although studies in Chapter 2 were not designed for direct comparison to one another, 
an unmissable difference was that pharmacological treatment use is around twice as high 
in the USA than in the UK. Perhaps contributing to this was possible underreporting of 
prescriptions made directly from secondary or tertiary care in Chapter 2.2. While 
the impact on our findings are likely minimal, they cannot be fully quantified without 
supplemental information from these settings. A linkage study between the CPRD and the 
Mental Health Dataset (MHDS) could provide this opportunity 173. Additionally, patients 
were identified for studies using different coding systems and algorithms as discussed 
in the methodological considerations section of this chapter. Further validation of both 
the MarketScan and CPRD data for positive identification of ASD according to the most 
recent diagnostic criteria (DSM-V) and in adults is needed. Opportunities may lie in the 
linkage of these data to prospective cohort studies, for example the linkage of CPRD data 
to the Adult Autism Spectrum Cohort 174.
Other potential reasons for differences in country prescription rates were laid out in the 
summary of findings in context section of this chapter. Briefly, differences in regulatory drug 
approvals likely explain some variation, but other factors such as differences in clinical 
guidelines, attitudes towards receiving drug treatment and differences in healthcare 
systems deserve further exploration. Healthcare insurance coverage in the USA has 
been discussed above. Specific concerns relating to the GP “gatekeeper” system in the 
UK are starting to be properly acknowledged and addressed too. For example, a 2016 
government-commissioned report included recommendations to build a primary care 
autism register and to offer annual GP health checks for all autistic people 175. A similar 
program is already in place that covers people aged 14 years or over with a learning 
disability 176. Pilot programs will extend this over the coming years to additionally cover 
all people with autism as part of the NHS Long Term Plan 177. The rationale is that these 
consultations will prompt proactive healthcare planning for ASD services, as well 
an opportunity to discuss other healthcare needs 175. GPs should also be trained and 
reminded to make “reasonable adjustments” to accommodate the needs of autistic patients 
such as communicating in simplified language or scheduling appointments at the end of 
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the day to avoid unnecessary sensory overload in busy waiting rooms 176. On a similar note 
in May 2020, the Royal College of GPs (RCGP) and Autism Alliance UK published joint 
guidance on how to make the environment at GP practices more autism-friendly 178. This 
is part of the RCGPs wider work on providing additional ASD training for GP staff, and 
tips for GPs and autistic patients on how to benefit most from consultations 178,179. Such 
initiatives should be welcomed in order to make sure that all ASD patients and caregivers 
are comfortable seeking support when needed, and are reassured in their doctors ability 
to help them access appropriate available care.
While Chapter 2 of this thesis offered broad insights into system-wide treatment patterns, 
future choices about if to initiate specific treatments will always be made on an individual 
level. These choices should be based on all available information about an interventions 
potential risks and benefits. To contribute some available information regarding risks, 
Chapter 3 provided evaluations on potential side effects of commonly used treatments 
in ASD. We complimented this in Chapter 4 by assessing the suitability of a new outcome 
measure for quantifying potential benefits of different interventions.
Results of Chapter 3.1 demonstrated no association between SCV events and prior 
treatment with ADHD medications. Additionally, the incidence rate of such events was 
extremely low. These results should reassure physicians, patients and parents that for 
the vast majority of autistic children, these outcomes are highly improbable and not 
systematically linked to ADHD treatment. Children with serious underlying cardiac 
abnormalities were however at increased risk. Further observational studies should 
consider focusing on this subgroup, and evaluate if risk is independent of - or compounded 
by - ADHD medication in this specific group of vulnerable patients. Until the evidence is 
clear, physicians should continue to note class-wide warnings and make careful cardiac 
evaluations in such patients before a decision to prescribe these medications 57–60.
Results of Chapter 3.2 demonstrated that over long periods of exposure in childhood, 
risperidone was associated with a 40% reduction in bone fractures compared to 
aripiprazole. Differences between treatments in children aged 2-10 years were most 
pronounced. These results are contrary to a theory 63 linking antipsychotic-induced 
hyperprolactinemia with reduced bone mineral density and fractures, mainly in elderly 
populations 180,181. Further validation studies in ASD children should therefore be carried 
out, and they should adjust for other potential confounding factors that were unavailable 
in our study. These include diet, BMI, physical activity and ASD severity 182,183. Due to 
mechanistic uncertainties, future studies should ideally ascertain causes of the fracture 
too. Finally, future studies should assess dose effects, including the initial dose and 
changes over time (current and cumulative dose). Until more is understood about these 
mechanisms and patients most at risk, patients and physicians should continue to use 
aripiprazole as usual but be aware of this signal.
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The final major contribution of this thesis was the validation assessment of the Autism 
Impact Measure (AIM). Given the variety of available interventions already being used, 
plus those in development, having reliable and accurate ways to compare treatment 
benefits is of critical importance for decision making. Fortunately, we found that the AIM 
has good psychometric properties, and allows the report of core ASD symptoms including 
communication deficits, difficulties with social interactions and repetitive behaviours. It 
could therefore be a candidate endpoint for future clinical trials. As the AIM has other 
distinctive benefits of being caregiver-relevant, quick and inexpensive to administer 
remotely, then it should also be considered as suitable tool for real world monitoring of 
ASD symptoms too. Through such a mechanism, the evaluation of different therapeutic 
approaches beyond the duration and setting of clinical trials can inform treatment 
guidelines on a group level. It could also allow rapid feedback direct for effectively finding 
optimal treatment strategies on the individual level 184. While we validated the AIM in 
children aged 3-17 years, further adaptation would likely be needed in order to facilitate 
its use in adults, given the phrasing of certain questions like “playing” with peers or “toys”. 
Additionally, there may be benefit in assessing if the AIM is more or less valid in any specific 
subgroups, such as those stratified by age, verbal ability or intellectual disability.
While our study was the first to estimate thresholds of clinically important changes of the 
AIM, a weakness was that these estimates were only based on cross-sectional data. As 
we collected information via the SPARK online platform however, this offered a unique 
opportunity to re-survey the same caregivers for longitudinal data. Invitations for a 
second survey of these caregivers were sent in autumn 2018, approximately one year 
after the first survey. New findings related to clinically meaningful thresholds of AIM, 
and associations between changes in AIM scores, baseline treatment use, and caregiver 
reported burden are expected to be published soon 185. The fact the SPARK platform as a 
whole has recruited 60,000 individuals with ASD and their families since forming in 2016 
186,187 is testament to the incredible engagement and willingness of the ASD community 
to contribute to further research. All data from our studies in the SPARK cohort will be 
made available for linkage via the SPARK platform. The opportunity for future studies 
in the platform, either prospective or retrospective in nature, should not be missed.
Final conclusions
This thesis demonstrates that the treatment landscape in ASD is varied with many drug 
and non-drug treatment options commonly used. The likelihood of accessing and receiving 
these treatments is dependent on more than just health status, and is also associated 
with increased age, country of residence, female gender (in the UK), and urbanisation of 
residence, fee-for-service healthcare plans, race, and foster care status (in the USA). We 
showed that serious cardiovascular events were not associated with ADHD medication 
for most children with ASD. Compared to risperidone, long-term aripiprazole use in ASD 
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was associated with increased risk of fractures, especially for children under age 10 years. 
Finally, the Autism Impact Measure (AIM) offers a valid, quick and inexpensive method 
for caregivers to report their child’s severity of core autism symptoms.
In the coming years, as the treatment landscape in ASD continues to evolve, epidemiology 
and real world databases (both primary and secondary data use) will continue to 
compliment clinical trials in helping to understand real life experiences of how people 
with ASD access and use treatments, as well as the risks and benefits of doing so.
5
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This thesis explored utilisation and outcomes of treatment in autism spectrum disorder 
(ASD). ASD is a lifelong neurodevelopmental disorder, characterised by core symptoms 
of communication deficits, difficulties with social interaction, and restricted and repetitive 
behaviours. Associated symptoms of autism include obsessions, self-injury, irritability, 
aggression, and under-reactivity to sensory stimuli. Psychiatric and neurological 
conditions such as attention deficit/hyperactivity disorder (ADHD), anxiety, depression, 
epilepsy and bipolar disorder are also more commonly diagnosed in children and adults 
with autism than in the general population. ASD is typically diagnosed at age 3-4 years in 
developed countries. Approximately, three to four times as many boys are diagnosed than 
girls. Up to 1 in 54 children and 1 in 45 adults are diagnosed with ASD in the USA today.
Chapter 1: Introduction, objectives and data
Chapter 1 set out the background to this thesis, by characterising the current ASD 
treatment landscape and some important knowledge gaps.
The purposes of treatment in ASD should be to minimise core and associated ASD 
impairments, to maximise daily living skills for independence, and to relieve the impact 
of problem behaviours.
There are currently no pharmacological treatment options for the core symptoms of ASD. 
In the USA however, the atypical antipsychotics risperidone and aripiprazole are approved 
for associated symptoms of irritability and aggression in children and adolescents. These 
drugs been recommended in clinical guidelines for treatment of aggression or self-
injurious behaviours, in order to facilitate daily living, or to allow better adherence to 
non-drug therapies, but typically only when behavioural interventions have not been 
successful. These drugs do not have a marketing authorisation in ASD in Europe, yet 
the United Kingdom National Institute for Health and Care Excellence (NICE) also 
recommends antipsychotic medications for children with behavioural challenges when 
non-drug treatments have not helped: so long as these drugs are started by a paediatrician 
or psychiatrist.
Generally, it is acknowledged that other classes of psychotropic drugs (e.g. antidepressants, 
anticonvulsants) may be required to manage common psychiatric comorbidities in 
ASD. A recent systematic review reported median psychotropic drug use estimates of 
42% in children and 62% in adults in ASD. The systematic review also pointed to some 
clear gaps in the literature however. Firstly, the vast majority of studies only focused 
on North America and used data from over a decade ago. There are limited studies in 
the adult population and studies generally do not have non-ASD comparator groups to 
contextualise results.
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Drugs used for the treatment of ADHD, such as stimulants and atomoxetine are used 
frequently in ASD (around 14-19% in children). These drugs have consistently shown 
medication-induced increases in blood pressure and heart rate, which coupled with 
case reports, has raised concerns over the potential increased risk of more serious 
cardiovascular (SCV) events such as stroke, myocardial infarction, and cardiac 
arrhythmias. Limited observational studies on this topic have produced inconsistent 
results. Furthermore, this has not been studied in children with ASD.
Children with ASD also commonly use antipsychotic medication (around 17%). 
Antipsychotics have been associated with increased bone fracture risk in elderly dementia 
patients, yet the mechanisms leading to increased risks is not clear. For example, it may 
be due to an increased risk of accidents or falling, or due to a negative impact on bone 
mineral density. The relationship between antipsychotics and fracture risk has not been 
well studied in children. However, as risperidone and aripiprazole are commonly used in 
ASD and have slightly different pharmacological profiles, this setting can offer a unique 
opportunity to understand possible mechanisms and inform relevant clinical decisions 
about which treatment to prescribe.
The mainstay of currently recommended treatments for ASD are non-pharmacological 
in nature, and include behavioural and social-communication based therapies. In a study 
across 18 European countries, 91% of children with ASD received at least one type of 
non-drug intervention by age 7 years. Historical uptake of non-drug treatments is also 
high in the USA, with up to 77% current use. However, there are concerns that children in 
more rural settings have access to fewer services. Additionally, healthcare expenditures 
have previously been higher for ASD children with public versus private health insurance, 
suggesting public insurance may be an advantage for accessing services.
While a number of diagnostic instruments are available to aid a professional diagnosis 
of ASD, there is little consensus on the most appropriate tools for measuring effects of 
treatment. Patient or caregiver-reported assessments can offer a quick and cheap option 
to collect patient symptoms. They may also be administered remotely, for example on a 
computer or mobile phone. Hence, provided they are validated, they can offer a more 
sustainable opportunity to evaluate treatment effectiveness over longer periods, and 
outside controlled clinical trial settings.
This thesis comprised a collection of studies to address various abovementioned 
knowledge gaps regarding the utilisation and outcomes of treatment in ASD. The 
objectives were grouped into the following three categories: treatment utilisation patterns, 
treatment safety, and validation of a new caregiver-reported measure of ASD symptom 
severity. These categories correspond to Chapters 2 to 4 of the thesis respectively.
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We used three main sources of real world data throughout the thesis. The first was the 
MarketScan insurance database which covers de-identified patient-level health data from 
private (“commercial”) and publically (Medicaid) insured populations in the USA. The data 
covers all billed episodes of care, regardless of the setting. The second database was the 
Clinical Practice Research Datalink (CPRD) electronic medical record database from the 
UK. Data is recorded in the primary care setting, although due to the nature of the general 
practitioner (GP) “gatekeeper” system in the UK, prescriptions should be managed (or at 
least documented) by the GP even if they started in secondary or tertiary care. The third 
database was collected via a primary data collection survey study, nested in the Simons 
Foundation Powering Autism Research for Knowledge (SPARK) platform. SPARK is an 
online, USA-based research initiative for individuals with ASD and their family members.
Chapter 2: Treatment utilisation in ASD
Chapter 2 focused on the production of up to date estimates of drug and non-drug 
treatment utilisation in ASD, as well as predictors of use.
Chapter 2.1 was a retrospective, cross-sectional cohort study based in USA MarketScan 
claims in calendar year 2014. Among 46,943 commercial- and 46,696 Medicaid-insured 
patients we found substantial annual proportions of psychotropic drug use (64% and 69% 
respectively). These proportions increased rapidly throughout childhood from 11-25% 
in the 3-4 years age group to 76-80% in the 12-17 years age group. In adulthood, the 
proportions roughly plateaued (78-81%). All age groups combined, the most commonly 
used treatments (commercial-Medicaid) were stimulants (30-32%), antipsychotics 
(25-35%), antidepressants (33-29%) and hypotensive agents (20-31%). The rate of 
polypharmacy (two or more treatments concurrently for 30 days) was also high and 
increased with age (35-44% for all age groups combined, but already 24-36% by age 5-11 
years). Medications were most frequently prescribed in conjunction with the indicated 
psychiatric condition, although over 30% of participants received medication in the 
absence of a coded psychiatric condition other than ASD. Beyond age and comorbidities, 
we also found that fee-for-service insurance plans, foster care and White race were 
associated with higher treatment rates.
Chapter 2.2 was a retrospective, cross-sectional cohort study based in the UK CPRD 
database in calendar year 2015. Among 10,856 patients, 32% used a psychotropic 
drug. This is around half the annual proportion observed in the USA, but substantial 
nonetheless. Also unlike in the USA, treatment rates increased gradually throughout 
childhood and adulthood years, with small increases in prevalence rate at each increasing 
age group (11% at age 3-4 years, 26% at age 12-17 years and 44% in adulthood). All 
age groups combined, the most commonly used treatments were anxiolytics/sedatives/
hypnotics (14%), antidepressants (13%) and antipsychotics (8%). Hypotensive agents 
were used by less than 1% of patients. The rate of polypharmacy was 10% overall, and 
also increased gradually with age. Presence of psychiatric comorbidities was associated 
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with treatment use, but similar to the USA, some patents (14%) received psychotropic 
medication despite having no record of corresponding psychiatric comorbidities. Beyond 
age and comorbidities, females were more likely to be treated than males. In age, sex, 
and region matched comparative analysis, we found that psychotropic treatment use, 
polypharmacy, and healthcare resource use were all substantially higher in ASD than in 
the general population. However, odds for these outcomes were roughly halved in ASD 
versus an ADHD-matched cohort. This was primarily driven by the higher frequency of 
stimulant prescriptions in ADHD (35%) versus ASD (7%).
Chapter 2.3 was a survey study of parents and caregivers of children aged 3-17 years with 
ASD. The survey was embedded as part of the SPARK platform. We received responses 
from 5,122 caregivers (45% of invited) on questions regarding their child’s use, setting 
and barriers to care for different non-drug treatment types over the past year (roughly 
September 2016 to September 2017). Overall, 96% of children received at least one type 
of non-drug treatment, with the most common being speech and language therapy (SLT; 
71%), occupational therapy (OT; 60%) and behavioural therapy (56%). Around 30% of 
caregivers attended caregiver-training courses. The median intensity of all child-directed 
treatments combined was 6 hours per week, with behavioural therapy being the most 
intense (4 hours per week). All treatments were more commonly given in individual rather 
than group sessions. SLT and OT were more often provided in school, while behavioural 
therapy and psychological interventions were more frequently provided outside school. 
Controlling for other factors, behavioural therapy and SLT were significantly more frequent 
and more intense in metropolitan (urban) than in nonmetropolitan (rural) areas (odds 
ratios and 95% confidence intervals (OR) were 1.54 (1.30-1.83) for behavioural therapy, 
and 1.41 (1.17-1.69) for SLT). There were no consistently significant associations between 
non-drug treatment use and type of insurance coverage (commercial or Medicaid).
Chapter 3: Safety evaluation of treatments in children
Chapter 3 explored safety concerns of two commonly used drug classes in children with ASD.
Chapter 3.1 consisted of two case-control studies, nested within respective cohorts 
of ADHD and ASD children aged 3-18 years. In these groups, we evaluated the 
relationship between serious cardiovascular (SCV) events and current use of ADHD 
medications. ADHD medications were atomoxetine and stimulants (such as amphetamine, 
methylphenidate, lisdexamfetamine). We defined cases by a composite SCV outcome of 
stroke, myocardial infarction, or serious cardiac arrhythmia, and for each case, we matched 
ten controls on age, sex, and insurance type. We used the MarketScan commercial (years 
2000-2016) and Medicaid (years 2012-2016) data. We identified 2,240,774 children 
for the ADHD cohort and 326,221 children for the ASD cohort. Overall, incidence rates 
of SCV events was extremely low: 3.1 per 100,000 patient years in the ADHD cohort 
and 5.6 per 100,000 patient years in the ASD cohort. For ADHD, 33.9% of cases (63 
of 186) versus 32.2% of controls (598 of 1,860) were exposed, which yielded an OR of 
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1.08 (0.78-1.49). For ASD, 12.5% of cases (6 of 48) versus 22.1% of controls (106 of 
480) were exposed (OR 0.49 (0.20-1.20)). Covariate-adjusted results and results for 
individual outcomes and other exposure definitions were also consistent with no increased 
risk of SCV events. In short, we found no evidence of increased SCV risk in children and 
adolescents with ADHD or ASD exposed to ADHD medications.
Chapter 3.2 was a propensity score matched cohort study to compare the risk of fracture 
among children aged 2-18 years with ASD using either risperidone or aripiprazole. We 
identified 3,312 new users of each drug from the MarketScan Medicaid data between 
years 2013 and 2018. The main exposure was continued use of aripiprazole or risperidone 
over time. Over the full duration of follow-up (median 10 months in both cohorts), 
incidence rates of any fracture per 1,000 patient-years were 23.2 for risperidone and 
38.4 for aripiprazole. The hazard ratio and 95% confidence interval (HR) was 0.60 (0.44-
0.83). Risks were similar between cohorts throughout the first 180 days on treatment, 
but significantly higher in the aripiprazole group thereafter. Extremity fractures drove 
most of the increased risk, with the biggest differences in lower leg and ankle fractures. 
Differences widened for children aged 10 years or younger (HR 0.47 (0.30-0.74)). In short, 
compared to aripiprazole, risperidone was associated with 40% lower risk of fracture.
Chapter 4: Validation of caregiver reported ASD severity
Chapter 4 was dedicated to the psychometric validation of the Autism Impact Measure 
(AIM): a new caregiver reported assessment for the severity of ASD symptoms in children. 
The AIM was completed online by 5,001 caregivers from the SPARK cohort during 
September and October 2017, and the study sample are a subset of those caregivers 
surveyed in Chapter 2.3. Children were aged 3-17 years. This study demonstrated the 
AIM’s ability to discriminate between “known-groups” of children with different symptom 
severity, estimated thresholds for clinically important responses and confirmed internal 
and external validity of the measure. We also confirmed meaningful and distinct domains 
of the AIM including ASD core symptoms of communication deficits, difficulties with social 
interactions and repetitive behaviours. Importantly, this study showed the AIM is a valid 
tool, which can be quickly completed in a remote setting by caregivers on computer and 
mobile devices (median time: 7 minutes).
Chapter 5: General discussion
Chapter 5 provided a summary and critical reflection on the main body of the thesis. It 
included a lengthy summary of the main findings placed into a broader context, a critical 
evaluation of epidemiological methods used and considerations for future research and 
implications. Please see the relevant section of this thesis for further details.
Conclusion
This thesis demonstrates that the treatment landscape in ASD is varied with many drug 
and non-drug treatment options commonly used. The likelihood of accessing and receiving 
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these treatments is dependent on more than just health status, and is also associated 
with increased age, country of residence, female gender (in the UK), and urbanisation of 
residence, fee-for-service healthcare plans, race, and foster care status (in the USA). We 
showed that serious cardiovascular events were not associated with ADHD medication 
for most children with ASD. Compared to risperidone, long-term aripiprazole use in ASD 
was associated with increased risk of fractures, especially for children under age 10 years. 
Finally, the Autism Impact Measure (AIM) offers a valid, quick and inexpensive method 
for caregivers to report their child’s severity of core autism symptoms.
In the coming years, as the treatment landscape in ASD continues to evolve, epidemiology 
and real world databases (both primary and secondary data use) will continue to 
compliment clinical trials in helping to understand real life experiences of how people 
with ASD access and use treatments, as well as the risks and benefits of doing so.
A
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Valorisation refers to the process of transferring purely scientific knowledge gained 
in academic studies into value for broader societal purposes. Results of this thesis are 
discussed in this context in this appendix.
Healthcare problem
Autism is a neurodevelopmental condition which can have a tremendous impact on the 
affected person as well as other members of the family. Around 2% of people in the USA 
are diagnosed with autism today and it is known to affect people of all geographies and 
ethnic, cultural and racial backgrounds. The main symptoms are difficulties with verbal 
and non-verbal communication, difficulties understanding social or emotional cues, and 
the desire to carry out simple and repetitive tasks. Other common difficulties — faced by 
some, but not all people with autism — include attention deficits, depressive thoughts, 
anxiety, sleep problems, irritable and aggressive behaviours, and obsessions, among 
others. The wide variety of symptoms in autism is what prompted Dr Stephen Shore – a 
special education professor with autism - to say, “If you’ve met one person with autism, 
you’ve [only] met one person with autism.” In other words, autism effects different people 
in different ways. This also the reason for the coining of the term autism “spectrum” 
disorder, or ASD for short.
Today, there are no drugs to treat autism’s core symptoms. Instead, the majority of 
recommended treatments are based on individualised behavioral or social-developmental 
therapies. There are however concerns that not all children with autism have the same 
access to such therapies. For example, in the USA, there have been historical concerns 
that children in rural areas, or on private healthcare plans, find it harder to access these 
treatments.
The fact that most recommended treatments are non-drug based, does not mean that 
people with autism do not take drugs as well. In fact, prior to the start of this thesis, 
estimates were that around 42% of autistic children and 62% of autistic adults use 
psychotropic drugs (drugs that effect the brain). These numbers are mainly based on data 
from North America however, and the studies on adults did not include many people.
With the widespread use of psychotropic medications in ASD comes concerns about 
potential safety effects, especially in children. For example, stimulants and atomoxetine 
(used to manage attention deficits), are known to increase blood pressure and heart 
rate, which in turn has raised concerns about the possible increased risk of more serious 
cardiovascular events such as stroke, heart attacks, or severe irregular heartbeats. 
Antipsychotics (used to manage behavioral difficulties in ASD) have previously been 
associated with increased bone fracture risk in elderly dementia patients, but it is unclear 
if this is also the case in children with autism.
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In terms of testing new treatments for autism, there is little agreement on how to measure 
which treatments are most effective. Measures used in clinical trials are often time-
consuming and expensive. It is often meaningful to understand how effective treatments 
are in “real-life” settings too, so cheaper and more sustainable ways to measure autism 
severity are needed. Given that parents of children with autism are often the main 
organisers and advocates for their child’s treatment plan, a questionnaire of autism 
severity that can be completed by caregivers would be especially meaningful.
Main findings and implications of this thesis
This thesis comprised a collection of studies to address various problems and unanswered 
questions related to the use and outcomes of treatments in ASD, as mentioned above. All 
studies were based on either data from “real-life” settings using data that already existed in 
electronic medical records or insurance claims data, or by surveying caregivers of children 
with ASD.
The first set of results in this thesis examined levels of drug and non-drug treatment 
use in people with ASD. Having reliable treatment utilisation estimates is important 
for a variety of reasons. They can be used to quantify disease burden, inform health-
economic and cost-benefit assessments of treatments, inform healthcare resource and 
training plans, measure the scale of certain risks (e.g. adverse events) and to aid planning 
for further research (such as defining eligibility criteria and interpreting results of new 
clinical trials). Other uses include identifying deviations from treatment guidelines or 
spotting differences in treatment approaches between countries, regions or healthcare 
plans, which can lead to additional understanding of underlying causes of deviations from 
guidelines, or if one healthcare system can learn from the other.
In this thesis, we found that drug treatment use is more prevalent in the USA (around 
60% for children and 80% for adults) than in the UK (24% for children and 44% for 
adults). Differences in regulatory drug approvals likely explain some of the variation, but 
other factors such as differences in clinical guidelines, attitudes towards receiving drug 
treatment and differences in healthcare systems all deserve further exploration (which 
we began to do in Chapter 5). In time, results of our drug utilisation studies may provide 
important “baseline” data by which to assess the effectiveness of new policies aimed at 
either increasing or decreasing use of these drugs in the future. For example, since 2016 
in the UK, a national program to stop “over medication” of all psychotropic drugs to people 
with ASD or intellectual disabilities, has been supported by NHS England. Additionally, our 
findings about other factors associated with increased treatment use, such as foster care 
and White race in the USA, and female gender in the UK should become the target of other 
future policy changes, to ensure equitable access to appropriate treatments for all.
For non-drug treatments, caregivers in the USA reported that almost all children (96%) 
received a non-drug treatment during a one-year period. We found no significant 
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differences in levels of treatment use between private and Medicaid (public) insurances, 
which is contrary to historical evidence of higher healthcare use in Medicaid, and supports 
the notion that recently introduced private insurance mandates have been effective at 
correcting historical advantages for accessing treatments via public plans. This evidence 
could be used to advocate for the introduction of similar mandates in other disease areas. 
Regarding geography, a significantly higher proportion of children in metropolitan areas 
versus non-metropolitan areas received SLT (72% vs 65%) and behavioural therapy (57% 
vs 46%). The most widely reported barrier to care in rural areas was a lack of available local 
services. Services like telehealth should be considered to address this gap in the future.
The second set of results in this thesis regarded safety concerns, as outlined above. Firstly, 
in two large case-control studies of children with ASD and attention deficit/hyperactivity 
disorder, we found no association between serious cardiovascular events and the current 
use of stimulants or atomoxetine. This finding should reassure the vast majority of 
physicians and parents, as well as a large number of patients who take these medications 
(around 14-19% children use one of these drugs annually). Further observational studies 
should focus on the subgroup of children with serious underlying cardiac abnormalities 
who were at increased risk however, and evaluate if their risk is independent of, or 
compounded by these medications. Until the evidence is clear, physicians should continue 
to note class-wide warnings and make careful cardiac evaluations in this vulnerable subset 
of patients prior to prescribing these medications.
Secondly, for fractures, we found a 40% lower risk of fracture for risperidone-exposed 
children compared to aripiprazole-exposed children. Risks were comparable between 
groups for the first 180 days on treatment, but significantly higher in the aripiprazole 
group thereafter, and even more pronounced for children less than 10 years old. If 
further studies corroborate our findings then this could deliver unique insights into the 
mechanisms by which antipsychotics have an impact on bone health, and eventually 
have impact in prescribing patterns in other disease beyond ASD too (for example, 
in schizophrenia and dementia). Nonetheless, until more is understood about these 
mechanisms and patients most at risk, patients and physicians should continue to use 
aripiprazole as usual but be aware of this signal. The information is certainly important 
and very clinically relevant, given that around 17% of autistic children use of these 
antipsychotics per year in the USA.
A final major contribution of this thesis was the validation of the Autism Impact Measure 
(AIM) as a reliable tool for measuring the severity of core autism symptoms. Given the 
variety of available interventions already being used by people with autism, plus new 
treatments in development, having reliable and accurate ways to compare treatment 
benefits is of critical importance for future decision making. This includes weighing up 
the benefits and risks of new treatments, by regulatory authorities, payers and providers 
of healthcare, and patients themselves.
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As the AIM has distinctive benefits of being caregiver-relevant, quick and inexpensive to 
administer remotely, then it should be considered as tool for the real world monitoring of 
ASD symptoms, as well as in clinical trials. Through such a mechanism, the evaluation of 
different therapeutic approaches can inform treatment guidelines at a group level. It could 
potentially also allow rapid and direct feedback for effectively finding optimal treatment 
strategies on the individual level.
For the studies of non-drug treatment utilisation and validation of the AIM, we surveyed 
parents of children with ASD in the USA, via the Simons Foundation Powering Autism 
Research for Knowledge (SPARK) platform. SPARK is an online, USA-based research 
initiative for individuals with ASD and their family members. An intended and valuable 
benefit of conducting research via the SPARK online platform is that this offers a unique 
opportunity to engage the autism community directly in research, and to receive feedback 
on its relevance to them. Of the more than 5,000 caregivers surveyed, our research topic 
received an average rating of 4.8 out of 5 stars for its importance to them and their family. 
Once SPARK participant said, “I wanted to thank you for doing this study. We moved to 
a different state and we found vastly different therapies and available providers. This is 
a real problem for families.”
The fact the SPARK platform as a whole has recruited 60,000 individuals with ASD 
and their families since forming in 2016 is testament to the incredible engagement and 
willingness of the ASD community to contribute to further research. All data from our 
studies in the SPARK cohort will be made available for linkage via the SPARK platform. 
The opportunity for future studies in the platform, either prospective or retrospective 
in nature, should not be missed.
A
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MarketScan is a registered trademark of Truven Health Analytics Inc., an IBM Company.
The Clinical Practice Research Datalink (CPRD) data referred to throughout this thesis 
is the CPRD GOLD database. For information on other CPRD databases visit https://
www.cprd.com/. CPRD is jointly sponsored by the Medicines and Healthcare products 
Regulatory Agency and the National Institute for Health Research, as part of the 
Department of Health and Social Care in the United Kingdom.
The Simons Foundation Powering Autism Research for Knowledge (SPARK) platform is 
sponsored and operated by Simons Foundation Autism Research Initiative (SFARI).
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